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The BBB is a biological firewall that carefully regulates the cerebral microenvironment by 
acting as a physical, metabolic and transport barrier to molecules bound for the brain. This 
selectively permeable interface was modelled in this thesis using the recently established 
immortalised human cerebral microvascular endothelial cell line (hCMEC/D3) to investigate 
interactions with endogenously and exogenously derived molecules of clinical significance. 
The endogenous molecules in question are the cationic amino acids (CAA) L-arginine, the 
precursor for nitric oxide (NO), and asymmetric dimethylarginine (ADMA), an endogenously 
derived analogue of L-arginine that acts as a potent inhibitor of NO production. As well as 
being an important vasodilator, NO has regulatory roles in the brain and on the BBB itself. 
Transport mechanisms utilised by L-arginine are known, but are not fully understood for ADMA 
– particularly so at the BBB. This is of clinical significance giving the emerging role of ADMA in 
many brain and cerebrovascular diseases. Understanding these transport mechanisms and 
other interactions of ADMA with the BBB is therefore very important for the study of disease 
emergence, detection and progression. We discovered in the hCMEC/D3s that high 
concentrations of ADMA could induce endothelial dysfunction in a BBB permeability model, 
leading to an increase in paracellular permeability to the paracellular marker FITC-dextran 
(40kDa). We also illustrated interactions of ADMA with a variety transport proteins, basing the 
study design on our observed L-arginine interactions. The CAA transport system y+ was heavily 
implicated for both molecules through the use of established inhibitors. Furthermore, the 
expression of CAT-1, the best known protein from this group was confirmed in the 
hCMEC/D3s. We also found evidence of an efflux transport system for ADMA (but not L-
arginine), implicating the neutral and CAA transporter ATB0,+. The protein expression of ATB0,+ 
was also confirmed in the cells. Intracellular ADMA was even shown to induce trans-
stimulation of extracellular L-arginine, providing evidence for a role of ADMA in the 'L-arginine 
paradox', a phenomenon observed in vivo that administered L-arginine can alleviate the 
effects of NO reduction (such as vasoconstriction), despite there being 20-30 times the amount 
of L-arginine present to saturate the NO producing enzyme. 
In summary, our endogenous molecule findings from this thesis identify the likely transport 
mechanisms used by ADMA and implicate ADMA in endothelial dysfunction as well as the ‘L-
arginine paradox’. These data are not only important with regards to the brain, but apply to 
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other microvascular endothelia such as those found in peripheral cardiovascular system, 
where ADMA remains a major area of investigation. 
The exogenous molecules studied during this PhD are drugs currently used to treat the 
second-stage of human African Trypanosomiasis (HAT). HAT is a neglected parasitic disease 
that continues to persist in sub-Saharan Africa. It is fatal if untreated. Recently, it has been 
described that eflornithine and nifurtimox combination therapy (NECT), improves the efficacy 
of both drugs compared to their monotherapy, although why this happens remains unclear. 
We hypothesised that it may be due to improved CNS delivery, although we failed to show 
improvements in accumulation of either eflornithine or nifurtimox with NECT or when the 
individual drugs were in combinations with the other anti-HAT drugs. Interestingly, the 
combination of eflornithine and pentamidine caused a decrease in eflornithine accumulation, 
implicating an unidentified pentamidine-sensitive transport system – possibly an adenosine-
sensitive influx transporter.  The cellular influx transport mechanisms used by eflornithine has 
been suggested to be those used by CAA due to the structural similarity of eflornithine with 
the CAA ornithine and so this was studied. We revealed in the hCMEC/D3s that eflornithine 
had degrees of sensitivity to a variety of transport mechanisms, in which system y+ appears to 
be the principal influx mechanism. Similar anti-HAT drug combination therapy studies with 
nifurtimox were performed and also illustrated a significant interaction with pentamidine; 
although conversely to eflornithine we demonstrated an increase in nifurtimox accumulation 
as a result of nifurtimox-pentamidine combination. Previous in situ observations by our group 
suggested nifurtimox was a substrate for efflux transport systems at the BBB that are separate 
from P-gp and this too was investigated, identifying the well known drug efflux pump BCRP as 
the principal nifurtimox efflux transporter.  
With regards to exogenous molecules, we provide evidence of CAA influx mechanisms for 
the anti-HAT drug eflornithine and an efflux system for nifurtimox, principally involving BCRP. 
We also found that NECT and combination therapy of eflornithine or nifurtimox with the other 
anti-HAT drugs did not improve eflornithine or nifurtimox accumulation when compared to 
controls – except when pentamidine was combined with nifurtimox. This finding suggests that 
nifurtimox-pentamidine combination may improve efficacy of nifurtimox in the field. 
Collectively, these data further demonstrate of the suitability of the hCMEC/D3 cell line as a 
powerful tool for human in vitro BBB investigation across a range of study areas. 
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Chapter 1. Introduction 
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1.1. The need for brain barriers 
As the central component to the nervous system in vertebrates and most invertebrates, the 
brain is the most complex organ in the body. It processes a huge array of information and 
controls activities all over the body, and as such is very metabolically active.  Due to the brains 
limited ability to store energy a constant supply is essential, most of which comes in the form 
of glucose which is converted to adenosine-triphosphate (ATP) to maintain neuronal function 
(Liu et al., 2009). Despite being only 2% of the body mass, the human brain metabolises about 
50% of total body glucose and receives 15% of cardiac output under basal conditions (Fehm et 
al., 2006).  
On top of needing a high amount of energy, the brain also requires a carefully controlled 
microenvironment for proper functioning of sensitive neuronal and brain processes. This 
homeostasis can only be achieved by separating the central nervous system (CNS) from the 
milieu of the periphery and carefully regulating the molecular traffic between the two 
interfaces. Furthermore, the CNS and peripheral separation interfaces must also be effective 
enough to block the entry of pathological agents and microorganisms in to the brain. Thus a 
variety of selectively permeable barriers have evolved at different areas of the CNS-blood 
interfaces. These barriers are the blood-cerebrospinal fluid barrier (BCSFB), blood-retinal 
barrier (BRB), blood-nerve barrier, blood-labyrinth barrier and the focus of this thesis, the 
blood-brain barrier (BBB) (please see (Neuwelt et al., 2011) for further descriptions of these 
barriers). 
The resultant separation of the CNS from the periphery is done to the extent that the brain 
is virtually isolated from the peripheral immune system under normal healthy conditions. This 
immune-privileged status held by the brain is not entirely accurate however as we now know a 
small number of peripheral surveillance immune cells are able to scan just inside the CNS, 
interacting with the highly sensitive microglial cells which constantly scan the CNS for potential 
infectious agents. The interactions between immune cells and pathological agents are 
extremely rapid in the CNS to reduce the potential damage both an infection and  immune 
reaction could have on the highly sensitive brain tissue (see (Engelhardt and Coisne, 2011) for 
a recent review).   
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1.2. Cirumventricular organs 
The BCSFB, formed by epithelial cells between the choroid plexus (CP) blood vessels and 
cerebrospinal fluid and the second largest CNS-blood interface barrier, plays important roles in 
regulating the brains molecular traffic, such as ascorbic acid transport (Spector, 2009). The CP 
belongs to specialized brain regions collectively called the cirumventricular organs (CVOs). The 
CVOs form an interacting network of organs which have leaky barriers allowing neurons to 
detect substances such as peptide hormones across the tissue and blood, but are separated 
from the rest of the brain by the BCSFB and the BBB (Abbott et al., 2006). The other CVOS fall 
into two categories – sensitive organs or secretory organs – depending on their functions. The 
sensitive organs are the vascular organ of the lamina terminalis, the subfornical organ, and the 
area postrema and are involved in fluid regulation and peptide detection, with the latter 
involved in vomit control following detection of noxious substances (Duvernoy and Risold, 
2007). The secretory organs are the neurohypophysis, which secrete hormones made in the 
hypothalamus, and the pineal gland which produces hormones such as melatonin (Ganong, 
2000). The reader is directed to (Siso et al., 2010) for an overview of the CVOs, which are not 
the focus of this thesis. Please also see (Redzic, 2011) for a recent detailed overview of the 
BCFSB. 
1.3. Historical observations 
The existence of a BBB was first empirically observed by the German Nobel laureate Paul 
Ehrlich in the late 1890s. He designed a series of experiments to compare the oxygen 
consumptions of various organs by using intravital dyes, the colours of which change with their 
redox state. He noted that some of the dyes following injection into peripheral veins, arteries 
or subcutaneously, poorly stained the brain and CNS tissues despite heavily staining other 
organs. Ehrlich and others incorrectly concluded from these early observations that the dyes 
had organ-specific affinities (Banks, 2008).   
Further experimental work by Ehrlich’s student, Edwin Goldman, and Max Lewandowski 
shed light on this phenomenon. They injected brains directly with dyes and observed that the 
brain was stained heavily, but the peripheral tissues were unstained. As a result they came up 
with a new theory that the brain must hold back certain molecules and coined the term 
‘Bluthirnschranke’ (‘blood-brain barrier’ in German), but the location of actual barrier eluded 
these early BBB pioneers. The crude light microscopy techniques of the time failed to show any 
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difference between brain and peripheral vasculatures. As a result, the concept of the BBB 
didn’t gain widespread acceptance until scanning electron microscopes and systemic injection 
of horseradish peroxidise were used to visualize the BBB in the 1960s (Bechmann et al., 2007). 
These techniques started to reveal a complex arrangement of different cell types around the 
BBB and that a complex network of tight junctions (TJs) also existed between the cells. It is a 
combination of these features that give the brain vasculature their greater physical barrier 
properties over their peripheral equivalents.  
Thus it became clear that the BBB proper is localised at the cerebral capillary endothelium 
and acts as a biological firewall, carefully regulating the flow of molecular traffic whilst 
simultaneously blocking microbial entry to the brain. 
1.4. Components of the blood-brain barrier 
The features of the barrier exist due to a group of interacting cellular components that are 
not only crucial for the development of the structure, but also crucial for its continued activity. 
1.4.1. The Neurovascular unit 
A single layer of brain microvascular endothelial cells (BMECs) of the BBB, together with the 
surrounding basal lamina, neighbouring pericytes, and the endfeet of glial cells called 
astrocytes (which cover >98% of the BBB vascular wall) are the integral components of a 
structure called the neurovascular unit (NVU, see figure 1.1 a) (Abbott et al., 2006, Neuwelt et 
al., 2011). The NVU encompasses all components of the BBB, maintaining structural integrity 
and allowing a link between neuronal activity and the oxygen and nutrient supply from the 
blood. It also helps to regulate BBB permeability through modulation of cellular substrate 
specific membrane transporters, transcytotic vesicles, and BMEC paracellular permeability 
(Neuwelt et al., 2011).  
The NVU even regulates the blood flow to the BBB by interacting with surrounding smooth 
muscle cells upstream of the BBB (Saunders et al., 2008). Endothelial vasoactive substances 
such as nitric oxide (NO) (discussed later in section 1.9) are released from brain endothelial 
cells (BECs) by agonists that activate specific receptors on the cell surface, or by changes in 
shear stress produced by alternations in the rate of blood flow. Gap junctions (GJs) between 
adjacent BECs, connect the cytoplasm of cells together and so permit intracellular responses to 
be transmitted between BECs, invoking a large chemo-responses which are converted by 
smooth muscle cells and pericytes into changes in vascular diameter (Iadecola, 2004). These 
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signals constrict or relax smooth muscle cells by inducing changes in concentrations of 
intracellular Ca2+ and altering the phosphorylation state of light chain myosin. These processes 
result in regulation of blood flow to the brain microvasculature, crucial to homeostasis of the 
cerebral microenvironment (Iadecola, 2004, Hawkins and Davis, 2005, Abbott et al., 2006). 
Please see (Attwell et al., 2010) for a recent detailed review of the control components of the 
NVU have on brain blood flow. 
Studies are revealing the true dynamic role the NVU plays in using its specialised cell groups 
and complex signalling processes to both serve and protect the brains interests. See (Abbott et 
al., 2006, Neuwelt et al., 2011) for in-depth reviews of the NVU.  
1.4.2. BBB endothelium 
Compared to peripheral capillary endothelium, BMECs have reduced non-specific 
endocytosis and transcytosis to hydrophobic molecules, meaning they can almost only cross 
the BBB via the selective transport proteins or by specialised receptor mediated transcytosis 
events (figure 1.1 b) (Abbott et al., 2006, Abbott et al., 2010).  BMECs of the BBB also have 
more ATP-producing mitochondria than peripheral endothelium to power the energy 
dependent transport mechanisms (e.g. ABC-transporters) that are abundant at the BBB 
(Oldendorf and Brown, 1975, Oldendorf et al., 1976).  
As well as these features, BMECs have the most complex cell-cell junction components of 
all the endothelium in the body that almost completely block the paracellular flow of 
molecules, sealing the cells together; essentially forming a continuous single-cell-wide 
membrane. These junctional components are discussed in section 1.6. 
1.4.3. Astrocytes 
Astrocytes are glial cells and one of the most numerous cell classes in the CNS. They have a 
wide variety of roles in the brain including maintenance of ion homeostasis of the extracellular 
space, neurotransmitter uptake and processing, and pH regulation (Sofroniew and Vinters, 
2010). In the context of the BBB, astrocytes interact with BMECs and pericytes to form the 
tube-like structures of capillaries in vitro and are believed to play key roles in gliovascular 
signalling by inducing perivascular release of vasoactive agents (Ramsauer et al., 2002). Due to 
their physical association with the BBB endothelium, astrocyte end-feet have long been 
associated with proper BBB functioning (Davson and Oldendorf, 1967, Abbott, 2002, Abbott et 
al., 2006). There is much evidence from in vitro studies that astrocytes upregulate BBB features 
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such as TJs, drug metabolising enzyme expression and transport protein polarisation (Dehouck 
et al., 1990, Haseloff et al., 2005).  
Despite the importance of astrocytes in maintaining the BBB, the precise mechanisms by 
which this is achieved remain poorly understood. The temporal correlation between astrocyte 
differentiation and maturation of the BBB during early development also suggests functional 
roles for astrocytes in the early establishment as well as regulation of the BBB, and it is 
believed that Wnt signalling pathways are involved (Liebner et al., 2011).  
1.4.4. Pericytes 
The role of pericytes in the maintenance and induction of the BBB has, until recently, been 
poorly understood. Pericytes are contractile cells that abluminally surround endothelial cells, 
sharing the extracellular matrix layer known as the basal lamina. They are found in high 
amounts at the BRB and the BBB (Frank et al., 1987, Shepro and Morel, 1993) and were 
originally believed to only support the vascular endothelium, helping to regulate local blood 
flow (Balabanov and Dore-Duffy, 1998). This belief was supported by the discovery that 
pericytes contain receptors for a variety of vasoactive mediators such as angiotensin II (Healy 
and Wilk, 1993) and vasopressin (van Zwieten et al., 1988).  
However, by using viable pericyte-deficient murine models it was discovered that pericytes 
actually help regulate BBB permeability through modulation of transcytosis, which resulted in 
permeability of the BBB to normally impenetrable immunoglobulins (Armulik et al., 2010). It 
has also recently emerged that pericytes have integral roles in maintaining astrocyte end-feet 
polarisation around the cerebral microvasculature and also regulating BBB-specific gene 
expression (Armulik et al., 2011).  
As with astrocytes, pericytes have also been implicated in BBB development during 
embryogenesis. Data analysing genetically modified mice deficient for pericyte formation 
(mice with null and hypomorphic alleles of Pdgfrb) revealed that pericyte distribution during 
BBB development directly determined BBB permeability in vivo (Daneman et al., 2010). In their 
paper, Daneman et al., also demonstrated that pericytes regulated BBB specific features such 
as complex TJ formation in vitro, increasing the transendothelial electrical resistance (TEER – a 
measurement of ionic paracellular flow) 4-fold in co-culture with BMECs when compared to 
BMEC culture alone. The authors also discovered that astrocytes do not extend processes to 
contact the early BBB until the first postnatal week, meaning that if astrocytes were 
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responsible for BBB formation, these would not be acquired until after birth. Their findings 
provided compelling evidence that pericytes in fact are more crucial than astrocytes during 
BBB development by strengthening the TJs, reducing transcytosis and inhibiting leukocyte 
adhesion molecule expression in endothelial cells, to help them maintain a BBB phenotype into 
adulthood, where astrocytes then play roles in maintaining and regulating BBB function 
(Daneman et al., 2010). 
1.5. Functions of the blood-brain barrier 
With a surface area of 12 to 18 m2 per average adult human brain, the largest CNS-blood 
interface by far is the BBB and therefore it plays the predominant role in regulating the 
cerebral microenvironment (Abbott et al., 2010).  
The BBB supplies the brain with nutrients whilst allowing efflux of brain waste into the 
blood. It also protects the brain from ionic composition fluctuations that occur after metabolic 
events or exercise which could disturb synaptic and axonal signalling events in the brain 
(Abbott et al., 2006). The BBB separates peripheral and CNS pools of neurotransmitters and 
other neuroactive molecules, stopping interference between the two systems (Bernacki et al., 
2008, Abbott et al., 2010).  
The collective influence of the NVU has not only allowed the BBB to evolve a highly 
specialised phenotype, but it continues to regulate and maintain the BBB’s crucial physical, 
metabolic and transport barrier functions (see figure 1.1 b for overview schematic). 
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Figure 1.1. The neurovascular unit (NVU) and the blood-brain barrier (BBB). a| The NVU 
constituents are the basal lamina, pericytes, astrocyte end-feet, and perivascular neurons 
(Interneuron) that all interact with the mitochondria-rich cerebromicrovascular endothelial 
cells giving them unique properties over the peripheral endothelium. This forms the BBB. b| 
The phenotype of the BBB gives it three barrier functions; a physical barrier formed by the 
tight junctions (TJ) and adherens junctions (AJ) eliminating paracellular flow of molecules (see 
section 1.4.1), a metabolic barrier consisting of drug metabolising enzymes such as 
cytochrome P450s (P450s) and a transcellular substrate specific transport barrier that 
regulates the traffic of polar molecules through the transmembrane proteins such as ATP-
binding cassette (ABC) transporters  P-glycoprotein (P-gp) and multi-drug resistance associated 
proteins (MRPs), amino-acid transporters (AAT) and glucose transporters. Some larger 
molecules such as peptides and antibodies can cross the BBB by compartmentalisation via 
receptor mediated transcytosis (e.g. insulin) or non-specific absorptive-mediated transcytosis. 
Figure based on (Cecchelli et al., 2007).  
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1.6. Physical barrier 
As a type of continuous capillary system, the BMECs of the BBB are sealed together by a 
combination of junctional complexes, which collectively form a physical barrier to the brain. 
The junctional complexes are GJs, adherens junctions (AJs) and TJs. 
1.6.1. Gap junctions 
The cytoplasm connecting GJs (mentioned previously in 1.4.1) promote signalling and 
molecular exchange between adjacent cells (of molecules up to 1kDa in molecular weight) and 
can also be responsible for perpetuating adverse conditions and disease (Eugenin et al., 2011). 
However, GJs do little in the way of maintaining structural integrity (Nagasawa et al., 2006).  
1.6.2. Adherens junctions 
AJs are formed by a variety of different molecules that interplay with TJs to form a dynamic 
barrier that regulates specific functional properties. They therefore indirectly contribute to the 
physical barrier of the BMECs. Through AJs, cellular adhesion is mediated by transmembrane 
proteins which promote homophilic interactions and form a paracellular zipper-like structure 
along the cell border (Dejana, 2004). Through the transmembrane adhesion protein vascular 
endothelial cadherin (VE-cadherin), AJs are believed to connected to the cell actin cytoskeleton 
via α- and β- catenins, which stabilises the junction (Niessen, 2007), although the precise 
components involved are unclear.   
AJs are crucial for proper TJ formation and blocking aspects of their arrangement can inhibit 
correct organisation of TJs. This was demonstrated recently when AJ transmembrane adhesion 
protein vascular endothelial cadherin (VE-cadherin) was shown to mediate regulation of TJ 
protein claudin-5, modulating permeability in vitro (Taddei et al., 2008).   
1.6.3. Tight junctions 
Whereas the compositional organisation of AJs is ubiquitous along the vasculature, TJ 
composition varies greatly depending on the location and role of the endothelium. In areas 
such as post-capillary venules where rapid interchanges between blood and tissue are 
required, TJs are poorly organised and permeable, but in the BMECs they are the most 
complex and restrictive of the body, conferring the physical barrier properties to the BBB 
(Dejana, 2004, Niessen, 2007). Such is the effectiveness of the restriction, even the paracellular 
movement of small ions such an Cl- and Na+ are significantly restricted, giving the BMECs a 
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TEER measurement of >1000 ohm.cm2 in vivo, compared to the 20 ohm.cm2 of peripheral 
equivalents (Abbott et al., 2006).   
 
Figure 1.2. Adherens junction and tight junction organisation. a| At adherens junctions, cell 
adhesion is promoted by VE-cadherin which closely associates with the actin cytoskeleton. 
Through its extracellular domain, VE-cadherin is complexed with vascular endothelial protein 
tyrosine phosphatase (VE-PTP) and so is involved in endothelial proliferation and 
differentiation signalling processes. At tight junctions, cell adhesion is maintained by claudins, 
occludin, junction adhesion molecules (JAMs) and endothelial cell selective adhesion molecule 
(ESAM). Nectin is involved in the organisation of both adherens junctions and tight junctions. 
b| A transmission electron microscopy image of a small blood vessel containing a monocyte, 
complete with a visible endothelial junction (arrow). Cells partially overlap at the point of 
junctional formation (insert). Diagram adapted from (Dejana, 2004). 
 
Claudins are the main constituents the TJ backbone and bind homotypically to other 
claudins on adjacent cells. This produces the primary seal of the junction (Huber et al., 2001, 
Bernacki et al., 2008). Some claudins expressed in the TJs of the BBB endothelium are very 
rarely found in the peripheral endothelium and attribute to the tightness of the BBB TJs 
(Wolburg et al., 2009). These include claudin-1, -3, -5 and -12, although due to cross-reactivity 
of antibodies, there is some controversy as to which claudins are more specific to the BMECs 
of the BBB (Lippoldt et al., 2000, Wolburg et al., 2003). There are currently 24 members of the 
claudin family (Erickson et al., 2007) which share their overall organisation of four 
transmembrane domains with two extracellular loops with another transmembrane protein 
called occludin.  
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Although it was the first TJ protein found at the BBB (Furuse et al., 1993), the precise 
function of occludin in TJs is not yet fully understood but it has been shown to regulate the 
physical barrier and have a signalling role (Dejana, 2004, Niessen, 2007). Although occludin is 
not required for the formation of TJs, it may be necessary to regulate barrier properties 
(Wolburg et al., 2009). What is clear is that it is the combined presence of claudins and 
occludins that give TJs their proper function.  
Other transmembrane proteins such as members of the junctional adhesion molecule 
(JAM) family and the endothelial cell selective adhesion molecule (ESAM) play contributing 
roles the cell-cell adhesion by interacting with one another and with cytoplasmic proteins such 
as zonula occludens (ZOs) which link with the cellular actin skeleton (Bazzoni, 2003). ZOs are 
junctional components able to associate with many transmembrane proteins as well as other 
ZOs to form effective scaffolding structures. JAMs also play roles in monocyte migration 
through the BBB during inflammation and immune responses (Palmeri et al., 2000).  
The complexity of the BMEC TJs come down to the not only the transmembrane adhesion 
protein components, but where they are associated in the membrane and how they are 
regulated by the microenvironment.  Freeze-fracture electron microscopy, the method of 
choice when investigating TJ morphology, has allowed comparisons to be made between the 
component complexity of different TJs of different cell types and locations (Wolburg et al., 
2009). The two fracture faces (the interior view of membranes exposed by freeze fracturing) 
are termed the P-face and E-face (the fractured membrane halves adjacent to the Protoplasm 
and Extracellular space respectively (Robenek and Severs, 2008). TJs from brain and non-brain 
endothelial cells show that their components are not only different but they associate with 
different areas of the membrane. In BMECs, the TJ molecules associate with both membranes 
equally (or slightly more to the P-face) whereas in non-brain endothelium, the TJ components 
almost completely associate with the E-face alone (Wolburg et al., 2009). Interestingly, freeze-
fracture analysis of in vitro BBB endothelium gives a TJ component association of non-brain 
endothelium, suggesting the quality of the barrier offered by the TJ is under the control of the 
brain microenvironment and NVU (Wolburg et al., 2009). 
Furthermore, tight junctions are also a crucial factor in development of luminal-abluminal 
cell polarity (Dejana, 2004, Schneeberger and Lynch, 2004). Mutual exclusion during cellular 
membrane formation between two evolutionarily conserved protein complexes, Crumbs (CRB) 
 INTERACTIONS OF ENDOGENOUS AND EXOGENOUS MOLECULES WITH 




and partitioning defective (Par) complexes, expressed at TJs allows establishment and 
maintenance of luminal and abluminal polarity of epithelial and endothelial cells, (covered is 
great detail in (Shin et al., 2006)). The establishment of cell polarity also requires growth and 
motility inhibition at cell confluency (in vitro and in vivo) in which both AJ and TJ components 
are implicated alongside growth factors such as vascular endothelial growth factor (VEGF) 
(Dejana, 2004).  
1.7. The metabolic barrier 
Metabolism is a crucial process in the body where molecules such as amino acids, lipids and 
carbohydrates are constructed (anabolised) or destructed (catabolised) to allow proper cellular 
function. Drug metabolism is the pharmacological and toxicological inactivation and 
elimination of toxic compounds, including drugs and xenobiotics, which could have adverse 
effects on the body. It is an essential factor in overall drug disposition to body regions and the 
rate of which it occurs has a huge impact on the action and intensity of pharmacological agents  
(Strazielle and Ghersi-Egea, 2005).  
Although drug metabolism is essentially a hepatic responsibility, it also occurs (to a lesser 
extent) in the brain. Metabolizing enzymes at the BBB act as a ‘metabolic barrier’ for the CNS. 
These metabolic processes act to filter unwanted blood-derived compounds and change the 
bioavailability of drugs to the brain. Both phase I enzymes (such as epoxide hydrolyses and 
cytochrome P450s, see figure 1.1 b) and phase II enzymes, (e.g. UDP-glucuronosyltransferase, 
glutathione S-transferase or sulfotransferase), have been identified in human and rodent BBBs 
(Strazielle and Ghersi-Egea, 2005). Although not ‘classical’ drug-metabolizing enzymes, purine 
and pyrimidine metabolizing enzymes may also play a role in the delivery of nucleoside 
derivatives to the CNS. High specific activities of purine nucleoside phosphorylase and 
adenosine deaminase have been measured in bovine brain endothelial cells (Johnson and 
Anderson, 1996).  
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1.8. Transport barrier 
With the paracellular route to the brain virtually unavailable to water-soluble compounds in 
a healthy BBB system, a variety of transcellular and transport-mediated pathways remain the 
only means for entry (see figure 1.3). The majority of these pathways are substrate specific 
and give the BBB its selectable ‘gate’ properties. Small non-polar gaseous molecules such as O2 
are able to freely diffuse through the lipid membranes, and this route is also an entry point for 
other small lipophilic agents such as ethanol (Abbott et al., 2006). The levels of non-specific 
endocytosis (i.e. pinocytosis) are low in cerebral endothelia due to a lack of vesicles, compared 
to peripheral endothelium, but receptor mediated transport and substrate specific transporter 
proteins (transporters) are prominent at the BBB and most hydrophilic substrates have to use 
these to cross the brain endothelium (Hawkins and Egleton, 2008).   
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Figure 1.3. Molecular pathways across the blood-brain barrier. a| Some small lipid-soluble 
molecules are able to passively diffuse across the large membrane surface area of the BBB 
endothelium. These include drugs such as barbiturates and alcohols. b|  ATP-binding cassette 
(ABC) transport pumps such as p-glycoprotein (P-gp), breast cancer resistance protein (BCRP) 
and multi-drug resistance associated proteins (MRPs), actively efflux some of these lipid-
soluble molecules against their concentration gradient, out of the brain endothelium into the 
blood. Most are luminally (blood) located, but some are found at the abluminal (brain) side. c| 
A huge variety of substrate specific transport proteins are expressed on both the luminal and 
abluminal membranes of the BBB. The vast majority of these are solute carrier (SLCs) which 
are either passive or secondarily active which transport essential polar molecules including 
amino acids and glucose. This can be done using unidirectional pumps into the CNS (1), by an 
exchange of one substrate for another or be driven by ionic gradients (transport using this 
method is bidirectional depending on electrochemical gradients) (2), unidirectional out of the 
CNS (3) or bidirectional pumps which depend on substrate concentration gradient (4). d| 
Under healthy conditions, the tight junctions (TJ) and adherens junctions (AJ) of the BBB 
severely restrict paracellular movement of hydrophilic molecules so only a small percentage 
can cross this route. Some immune cells and pharmacological agents are able modulate the TJs 
to partially or fully open the paracellular route for entry to the brain. e| Receptor mediated 
transcytosis and endocytosis allows large proteins such as insulin to bind to a specific receptor 
and cross the BBB. f| Cationic (+) molecules can attract to the anionic (-) membrane or 
glycocalyx, internalise and cross the BBB by adsorptive mediated endocytosis and transcytosis. 
Both of these transcytosis/endocytosis methods involve vesicular pathways through the BBB 
cells. Figure redrawn based on figures from (Abbott et al., 2006, Abbott et al., 2010). 
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1.8.1. Endocytosis at the BBB 
Most solutes with large molecular weights such as proteins and peptides are only able to 
cross the healthy BBB whole via endocytotic mechanisms which internalises them forming 
vesicles and then traffics them across the BBB endothelium via transcytosis (Abbott et al., 
2010). There are at least two forms of endocytotic events for these molecules at the BBB, 
depending on their properties; clathrin-dependent endocytosis (CDE) or clathrin-independent 
endocytosis (CIE). Clathrin is a protein with structural properties that has crucial roles in 
shaping and lining cellular vesicles with a variety of specialised accessory proteins (Mousavi et 
al., 2004). BMECs are characterised by a high density of clathrin-coated pits (Simionescu et al., 
1988) and so CDE is believed to be the more prominent method of endocytosis at the BBB. It is 
also interesting to note that clathrin-coated pits have been found more abundantly at the 
luminal membrane in rat BMECs, indicating a unidirectional blood-brain pathway (Simionescu 
et al., 1988). 
CIE often involves lipid-rafts, highly ordered lipid microdomains in the lipid bilayer of 
eukaryote plasma membranes that are involved in endocytosis (Kirkham and Parton, 2005). 
One abundant type of lipid raft involved in CIE is caveolae, formed by complexes of integral 
membrane proteins called caveolins which bind to other transmembrane proteins, inducing 
their endocytosis upon stimulus. Therefore, caveolae internalisation is a highly regulable 
process and has been shown to be a key mediator of claudin-5 and occludin internalisation 
following chemokine stimulus, that alter TJ integrity during pro-inflammatory events (Kirkham 
and Parton, 2005, Stamatovic et al., 2009). However, there are less caveolae at the BBB in 
comparison to peripheral endothelium, suggesting that this form of endocytosis is less 
accessible to molecules than the abundant clathrin-coated pits (Herve et al., 2008). One form 
of CIE – macropinocytosis – has been demonstrated to be the method of BBB entry used by 
HIV-1 when ICAM-1 molecules line the macropinosome as it invaginates (Liu et al., 2002). 
1.8.2. Transcytosis at the BBB 
As well as two major forms of endocytosis, there are two methods of transcytosis at the 
BBB. These are receptor-mediated transcytosis (RMT) and adsorptive mediated transcytosis 
(AMT, see figure 1.3 for schematic). RMT involves the binding of a molecules ligand to its 
specific receptor on the cell surface, before internalisation of the receptor and subsequent 
transcytosis via vesicular transport pathways (Jones and Shusta, 2007). This transport method 
has been well demonstrated with the iron binding glycoprotein transferrin at the blood-brain 
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barrier in vitro and in vivo (Roberts et al., 1993, Descamps et al., 1996). RMT often involves the 
presence of receptors in clathrin-coated pits, which are either expressed in the pits before or 
after ligand binding, although caveolae can also have specific receptor expression (Herve et al., 
2008).  
AMT is believed to be non-specific, and without the influence of receptors, and in most 
cases requires the molecule to have a net positive charge which will bind to negative charges 
on the cell membrane or glycocalyx which can be absorbed and internalised as a vesicle before 
transcytosis (Jones and Shusta, 2007). It is important to note that the transcytosis trafficking 
pathways through the cells used by cationic substrates are not well defined. AMT has also 
recently been suggested to be the method of BBB traversal used by the bacterium species 
Cronobacter in vitro, with the authors demonstrating presence of the bacterium inside 
vacuoles in primary human BMVECs and below the filters following transcytotic events (Giri et 
al., 2012). 
For thorough reviews of endocytosis and transcytosis across the BBB see (Herve et al., 
2008, Smith and Gumbleton, 2006). 
1.8.3. Transport proteins 
The continuous membrane of BMECs, essentially formed by the physical barrier of the BBB, 
allows polar molecules unable to cross the membrane to utilise a huge variety of transporters. 
The polarised structure of the BBB, created by the physical barrier, creates a situation where 
substrate concentration gradients can exist between brain and blood which is exploited by the 
transporters to regulate the brain’s molecular traffic. These transport processes can be 
facilitated or active transport mechanisms (see figure 1.4). Certain transporters move polar 
substrates down their concentration gradient from high to low in an energy-independent 
process termed facilitated diffusion, using carrier proteins. It is thought that these carrier 
proteins undergo conformational changes to transfer bound substrate across the membrane 
down their concentration gradient (Alberts et al., 1994).    
Ions such as Na+ use gated transmembrane channel proteins that open and close to rapidly 
regulate ion and substrate flow and intracellular concentration, along concentration gradients. 
In active transport, energy expenditure is required to move solutes from one side of the 
membrane to the other against concentration gradients. This form of transport can be divided 
into secondary and primary. Primary active transport require the hydrolysis of ATP at the 
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nucleotide binding domains of the transport proteins themselves to release energy for 
substrate transport (Leslie et al., 2005). Secondary active transport however uses the 
electrochemical gradient of ions to power solute exchange through antiport proteins 
(exchangers) where the driving ion and solute move in opposite directions, or symport 
proteins (a.k.a. cotransporters) where the driving ion and solute move in the same direction 
(Alberts et al., 1994).  
 
Figure 1.4. Membrane transport processes. Only a limited number of solutes can cross cell 
membranes without the aid of transport proteins (simple and passive diffusion). The great 
majority of biologically relevant solutes must use membrane transport proteins thorough 
passive or active transport mechanisms to cross cell membranes. Passive transporters are 
either channel-mediated proteins for passive diffusion, or carrier-mediated for facilitated 
diffusion. Active transport can be divided into secondary or primary. Secondary requires ion 
electrochemical gradient exchange with solutes for movement with or against concentration 
gradients and can be either symport or antiport. Primary active transport requires the 
hydrolysis of adenosine triphosphate (ATP) to adenosine diphosphate (ADP) and inorganic 
phosphate (Pi) to move substrates against concentration gradients. Big arrows depict 
movement of substrate against concentration gradients (low to high) and small arrows depict 
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1.8.4. ABC transporters 
Protecting the brain and CNS from potentially harmful substances are a superfamily of 
transport proteins known as ABC transporters, most of which export their substrates from 
BMECs of the BBB into the blood (Begley, 2004). These active transport systems hydrolyse ATP 
to adenosine diphosphate (ADP) and inorganic phosphate (Pi) to induce conformational 
changes in their transmembrane domains. This allows transport of their substrates which vary 
from lipids and drug solutes to toxins and steroids (Begley, 2004). Because of their roles in 
exporting therapeutic drugs from cells, several members of the 48-member ABC-transporter 
superfamily are collectively known as multidrug resistance (MDR) proteins and these have a 
huge impact on the distribution of drugs into the CNS (Leslie et al., 2005).  
The best-known representative of the MDR ABC transporters and the first shown at the 
human BBB is P-glycoprotein (P-gp) (also known as MDR1 in humans and mdr1a and mrd1b in 
mice) which is coded by the gene ABCB1 in humans and abcb1a and abcb1b in mice (Cordon-
Cardo et al., 1989, Begley, 2004). MDR1 in humans appears to fulfil the functions of the rodent 
mdr1a and mrd1b, as MDR2 codes for another type of P-gp transporter (mdr2 in rodents), 
which does not appear to play roles in drug export or multi-drug resistance (Demeule et al., 
2002, Begley, 2004). P-gp is expressed on the luminal membrane at the BBB in humans and 
rodents, expelling products back into the circulation restricting their penetration into the brain 
(Eyal et al., 2009).  
P-gp transports a huge array of substrates, particularly those that are lipophilic, uncharged 
or weakly basic, (although some acidic compounds can also be transported (Varatharajan and 
Thomas, 2009) and this large substrate range has made it difficult to design specific inhibitors. 
Included in these substrates are therapeutic drugs and so P-gp remains a major obstacle for 
CNS drug delivery. Studies have shown in mice that brain permeation of drugs (that were 
known substrates of P-gp) increased 100-fold when mdr1a was knocked out compared to wild-
type (wt) controls, but that the increase had consequences for the toxicity of the drugs 
(Schinkel and Jonker, 2003).  
P-gp has been demonstrated to have two substrate binding sites, which are divided 
between two almost symmetrical halves (domains) of the protein (see figure 1.5) (Bruggemann 
et al., 1989). When expressed at the cell membrane the protein folds to bring the two halves in 
close proximity (dimerisation), with the substrate binding site acting as one unit (Begley, 
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2004). When transporting, the single unit utilises two ATP molecules for a single transport 
cycle, one inducing a conformational change in the transporter which expels the substrate, and 
the other bringing the transporter back to its original shape (Begley, 2004). Despite the 
importance of P-gp and the large amount of literature directed toward its study, the precise 
dimerising mechanisms have yet to be elucidated. 
 
Figure 1.5. The putative structure of P-gp. P-gp has 12 transmembrane regions (I-XII) spanning 
the cell membrane. The drug-binding regions are associated with transmembrane domains V 
and VI and XI and XII, and are highlighted here by broken red circles. The black arrows point to 
glycosylation sites. The two intracellular ATP-binding domains (known as nucleotide-binding 
domains) are shown and the molecule is known to be divided into two near-symmetrical 
halves by a linker protein (curving line). Figure adapted from (Begley, 2004). 
 
Another major MDR ABC transporter family are the multidrug resistance-associated 
proteins (MRPs). There are 9 members to this family, coded for by the genes ABCC1-9 in 
humans (Bernacki et al., 2008). Of the 9 members, MRP-4, 5, 8 and 9 have a ‘short’ structure 
consisting of 12 transmembrane regions between 2 domains, with 2 membrane spanning 
domains attached to a nucleotide (ATP) binding domain (NBD), similar to P-gp (Chen and 
Tiwari, 2011). The remaining 5 MRPs (MRP-1 to 5) are known as the ‘long’ structure MRPs and 
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have a third domain giving them 17 transmembrane spanning regions (see figure 1.6), 
although the function of this extra domain remains elusive. Despite the structural similarities 
between P-gp and MRPs, it is believed that MRPs do not dimerise or associate with other 
membrane proteins to function as efflux transporters (Begley, 2004).  
  MRPs predominantly transport organic anions but in addition transport neutral organic 
compounds and some require the presence of co-factors such as glutathione to mediate 
transport (Deeley et al., 2006). Many of their substrates overlap with P-gp, making it difficult to 
distinguish functionally between the two ABC transporter families, although it is known the 
MRPs have a preference for organic anions and drugs that are conjugated to glutathione, 
sulphate or glucuronate by enzymatic activity in the CNS  (Minn et al., 2002).  
Their expression at the BBB has been confirmed in several species, with MRP1, 2, 3, and 5 
confirmed in human BMECs, with MRP1 and 2 believed to play major roles in protecting the 
brain and CVOs from xenobiotics and the associated toxicity (Borst et al., 2000, Begley, 2004, 
Bernacki et al., 2008). 
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Figure 1.6. Structure of ‘long’ and ‘short’ MRPs. ‘Long’ MRPs (MRP1, 2, 3, 6 and 7) have 17 
transmembrane regions grouped into 3 domains. The extra domain (on the top left of MRP1) 
compared to the P-gp-like core is known as transmembrane domain 0 (TMD0) and is joined the 
core by linker protein L0. The ‘short’ or truncated MRPs (MRP4, 5, 8 and 9) are shorter with 
only 12 transmembrane regions divided between two domains, in a similar arrangement to P-
gp. The purpose of the extra domain on the ‘long’ MRPs is not clear. NBD - nucleotide binding 
domain. From (Begley, 2004). 
 
Breast cancer resistance protein (BCRP), coded by the ABCG2 gene in humans is the second 
most prominent MDR ABC transporter expressed at the BBB following P-gp, with a similar 
substrate specificity (Begley, 2004, Tai et al., 2009b) and luminal expression profile, indicating 
its importance in efflux of xenobiotics from the brain and BBB (Cooray et al., 2002). As the 
name suggests, BCRP confers cancer cells drug resistance by expelling chemotherapy drugs 
including doxorubicin and daunorubicin (Doyle et al., 1998). It has also been demonstrated 
BCRP expression increases 3-fold at the BBB in mdr1a -/- mice, which demonstrates a P-gp 
compensatory role for the transporter in rodents (Cisternino et al., 2004). 
Unlike P-gp and MRPs, BCRP has only 1 domain consisting of 6 transmembrane regions with 
a single NBD, and is believed to function as a homodimer (Bernacki et al., 2008) (see figure 
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1.7). This dimerisation of BCRP proteins represents an attractive target for pharmacological 
intervention in cancer treatment (Ni et al., 2010).   
         
Figure 1.7. Putative structure of BCRP. BCRP consists of a single domain with a NBD and 6 
transmembrane regions. It has been demonstrated to function as an efflux transporter in a 
homodimer. Taken from (Leslie et al., 2005). 
 
ABC transporters are not expressed exclusively at the BBB; many are widely expressed 
throughout the NVU and nervous system (and many other tissues). The focus of the thesis 
however is on the BBB, and so for an overview of transporter expression in the NVU see 
(Neuwelt et al., 2011).  
1.8.5. Solute carriers 
The vast majority of facilitated diffusion carrier proteins and secondary active transporters 
expressed by all cells constitute the solute carrier transport group (SLC transporters, see figure 
1.3). SLCs can be divided into 46 recognised families with a combined membership of over 380 
different proteins in humans, making the SLC group of transporters the second biggest after G 
protein-coupled receptors (Hoglund et al., 2011).  
At the BBB, SLC transporters can be expressed in either a polarised manor – at luminal or 
abluminal membranes – or at both membranes (Abbott, 2002, Bernacki et al., 2008, Abbott et 
al., 2010). Their widespread distribution at the BBB along with the fact that their expression is 
partly regulated by components of the NVU (Abbott et al., 2006) highlights their importance as 
nutrient suppliers to the brain.  
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One well studied nutrient transport system at the BBB is the SLC2 family, which consists of 
13 transporters – GLUT1-12 and HMIT – which facilitate the transport of glucose and lactate to 
the brain (Simpson et al., 2007). GLUT1 is the major isoform expressed at the BBB, accounting 
for up to 90% of BBB glucose transport (Pardridge et al., 1990). GLUT1 has been found at both 
luminal and abluminal membranes of BMECs, as well as intracellularly (Harik et al., 1990, 
Farrell and Pardridge, 1991). It has been hypothesised that the intracellular pool of GLUT1 may 
upregulate GLUT1 membrane expression to replenish depleted supplies to glucose during 
conditions of increased demand such as during hypoglycaemia (Simpson et al., 1999). 
The organic anion transporter (OAT) family and the organic anion-transporting polypeptide 
(OATP) family are SLC transporters with broad substrate specificities. OATs make up the SLC22 
family and transport organic anions against chemical and ion gradients (VanWert et al., 2010). 
OAT1 and OAT3 are believed to have important substrate transporting roles at the BBB as 
suggested by murine and porcine models (Sauer et al., 2010, Miyajima et al., 2011).  
OATPs are sodium-independent, multi-specific anion exchangers (i.e. they exchange a drug 
for another ion or molecule), some of which are expressed at both luminal and abluminal 
membranes (Figure 4). OATP-mediated transport can be bidirectional, depending on local 
substrate concentration gradients. Among OATP family members, three transporters have 
been identified at the human BBB. OATP1A2 and OATP2B1 are localized at the luminal 
membrane of brain endothelial cells and the thyroid hormone transporter, OATP1C1 has also 
been identified in the human brain endothelium , but its precise localization has yet to be 
identified (Eyal et al., 2009).  
Due to the huge varieties of SLC transporters at the BBB, an abundant wealth of knowledge 
about their roles in physiology and homeostasis of the brain is well published in the scientific 
literature. This knowledge has also been exploited pharmacologically. SLCs can be targeted by 
transport inhibitors, which block their function, but also by drugs that mimic endogenous 
substrates in order to improve delivery to the brain for the treatment of many diseases and 
adverse conditions. An example of this is with L-DOPA, the precursor to the neurotransmitter 
dopamine, used in the treatment of Parkinson’s disease. Patients with Parkinson’s disease are 
deficient in dopamine which in its active form is unable to cross the BBB. L-DOPA, however, is 
transported across the BBB into the brain by system L transporter large neutral amino acid 
transporter 1 (LAT1) (Kageyama et al., 2000).  
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For further descriptions of SLC transporters, the reader is directed to the general review by 
(Hediger et al., 2004). For the purposes of this thesis, I shall concentrate on amino acid 
transporters, which will be discussed extensively in the following section (1.9).  
 INTERACTIONS OF ENDOGENOUS AND EXOGENOUS MOLECULES WITH 




1.9. Endogenous molecule interactions at the BBB – amino acids 
The human brain has evolved complex cognitive capacity and it can be argued that feeding 
habits are directly linked to the development of civilisation as people’s choice of what-to and 
what-not-to eat are heavily influenced by religion, society and culture (Gomez-Pinilla, 2008). 
This complexity in brain function attributes to a high metabolic rate and so the brain must be 
continually supplied with nutrients. One crucial group of nutrients required by the brain (and 
all other organs) in constant supply are amino acids (AAs), which are central to biochemistry 
for metabolism and protein synthesis purposes.  
There are 22 ‘standard’ amino acids that are incorporated into proteins and polypeptides in 
the human body, 20 of which are coded for by the universal genetic code. However, 9 of these 
cannot be created in humans and so are known as ‘essential’ amino acids that must be taken 
in the form of food and are transported to tissues and organs throughout the body via the 
circulatory system along with other AAs synthesised elsewhere in the body (Campbell and 
Reece, 2002). The BBB contains a huge variety of AA specific transporters that traffic AAs in 
and out of the brain. Some of these circulating AAs, such as tryptophan and L-DOPA, are 
precursors for neurotransmitters such as serotonin and the already discussed dopamine (in 
section 1.8.5) (Pardridge, 1998, Kageyama et al., 2000).  
BBB AA transport plays critical roles in the regulation of several pathways of brain AA 
metabolism. This is because the rate-limiting enzymes involved in the cerebral biosynthesis of 
serotonin, dopamine and other neurotransmitters are not saturated by normal concentrations 
of precursor amino acid substrates in brain cells (Pardridge, 1998). Therefore, the availability 
of AAs within brain cells is proportional to biosynthesis through these rate-limiting steps, and 
this AA availability is determined by BBB transport (Pardridge, 1977). Brain protein synthesis is 
also inhibited by supraphysiological concentrations of amino acids and therefore altered amino 
acid availability in the brain can result in proportionate decreases in cerebral protein synthesis 
(Pardridge, 1977, Pardridge, 1998). These roles played by AA availability in brain functioning 
highlight the importance of AA transport mechanisms at the BBB.  
A variety of different SLC transport systems exist at either or both the luminal and 
abluminal membranes of the BBB and transport neutral AAs (NAA), anionic AAs (AAA) and 
cationic AAs (CAA) in and out of the brain. These AA transporters can be functionally classified 
as either Na+-dependent or independent. This thesis will cover the CAA transport systems and 
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the reader’s attention is turned to (Mann et al., 2003) and (Hawkins et al., 2006) for reviews of 
the other AA transport systems. 
1.9.1. Cationic amino acids 
Out of the 22 ‘standard’ AAs, 3 are positively charged; Arginine, Lysine and Histidine (see 
figure 1.8). Of these 3, only Arginine and Lysine carry a positive charge at the physiological pH 




Figure 1.8. The 3 standard cationic amino acids and their structures. Only Lysine and Arginine 
carry their positive charge at pH 7.4 (+) Figure taken from Dan Cojocari, University Health 
Network, University of Toronto with permission. 
 
1.9.2. CAA transporters 
CAAs are transported in and out of cells by two families: the broad-scope amino acid 
transporter (BAT) family transport and the cationic amino acid transporter (CAT) family. 
Transport systems b0,+, y+L and B0,+ are collectively known as the BATs and system y+ 
transporters are known as CATs (see table 1) (Closs et al., 2004). Another transport system 
which does not belong to either the CAT or BAT families, b+, has also been shown to exhibit 
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CAA transport although so far this system has only be found in mouse blastocysts and so isn’t 
discussed here (Van Winkle and Campione, 1990).  
1.9.3. Broad-scope amino acid transporters 
Although they aren’t the principle CAA transporters, the BATs are able to transport CAAs in 
a Na+-independent manner (except for system B0,+ which requires Na+) but also retain affinity 
for NAAs (Mann et al., 2003).  
System b0,+ has two covalently-linked heavy and light chain protein subunits called rBAT and 
b0,+AT which are coded by the genes SLC7A9 and SLC3A1 in humans respectively, and associate 
to form a heterodimeric transporter which exhibit affinities for CAAs and L-cystine as well as 
NAA  (Wagner et al., 2001, Verrey et al., 2004). b0,+AT has been found in the gut with rBAT, 
which has been found in the mouse brain (Dahlin et al., 2009). Their messenger ribonucleic 
acid (mRNA) expression has been demonstrated in a human in vitro model of the BBB (Carl et 
al., 2010). 
System y+L has 2 proteins called y+LAT1 and y+LAT2 which are coded by SLC7A6 & SLC7A7 in 
humans, and were first identified in the early 1990s (Deves et al., 1992). Both proteins 
associate with a ubiquitous transmembrane protein called 4F2hc (also called CD98 coded by 
human gene SLC3A2) to form heterodimeric structures which exhibit y+L activity in the ionic-
dependent transport of CAAs and NAAs (Torrents et al., 1998, Mann et al., 2003). 4F2hc also 
forms the light subunit of LAT1 and this combined with the fact that the transporters exhibit 
greater affinity to NAA compared to system y+ gives it the name y+L (Torrents et al., 1998). 
Distinguishing functionally between systems y+ and y+L is somewhat difficult due to their 
affinities for CAAs and the lack of a specific inhibitor for y+L. However, it has been 
demonstrated that flux of L-lysine through system y+L can be inhibited by L-leucine (NAA) in 
the presence of Na+, whereas the same experiment through system y+ causes no effect 
(Estevez et al., 1998, Rotmann et al., 2007). Expression patterns between y+LAT1 and y+LAT2 
differ, with the former found in kidney and lung epithelia, and the latter found in the brain, 
heart, small intestine and testis (Broer et al., 2000). The mRNA expression of both y+LAT1 and 
y+LAT2 has also been demonstrated in a human in vitro model of the BBB (Carl et al., 2010). 
System B0,+ (not to be confused with system b0,+) was discovered in a murine blastocysts in 
vitro following experiments studying alanine transport where it was discovered that L-lysine 
and 2-amino-2-norbornanecarboxylic acid (BCH) were competitive inhibitors (Van Winkle et 
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al., 1985). System B0,+ comprises one protein member known as ATB0,+ which is coded by  
SLC6A14 in humans, transports a wide variety of CAAs and NAAs in a Na+-dependent manner 
(Deves and Boyd, 1998, Sloan et al., 2003) and has been hypothesised to be the principle β-
alanine SLC protein (Anderson et al., 2008). It is expressed heavily in the gut and also the 
hippocampus in the murine and bovine models (Sloan and Mager, 1999). As the 14th member 
of SLC6, ATB0,+ shares homology with the other members, some of which are important 
neurotransmitter transporters in the brain (Mann et al., 2003, Anderson et al., 2008). 
Interestingly, ATB0,+ has been found at the bovine BBB in vitro with polarised expression 
(Sanchez del Pino et al., 1995, Czeredys et al., 2008). ATB0,+ has also been shown to transport 
the intracellular fatty acid transport compound L-cartinine in another bovine model of the BBB, 
which is known to accumulate in the brain, although in this assay, transport was found to 
occur at both luminal and abluminal membranes (Berezowski et al., 2004). Despite these 
interesting observations, the expression and role of ATB0,+ at the human BBB has been poorly 
studied.  
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1.9.4. Cationic amino acid transporter (CATs) 
System y+ transporters are the only family of transporters that are specific for CAAs (Deves 
and Boyd, 1998), although they are able to weakly transport NAAs in the presence of Na+ 
(White, 1985).  It is also the principle transport system for CAAs in endothelial cells (Baydoun 
et al., 1994, Closs et al., 1997a, Hawkins et al., 2006). This is also no exception at the BBB 
where they are expressed at both luminal and abluminal membranes of the BMECs of mice 
(O'Kane et al., 2006, Hawkins et al., 2006). The system was first described in the 1960s in vitro 
(Christensen and Antonioli, 1969, Christensen and Handlogten, 1969, Christensen et al., 1969) 
but not named until the early 1980s (White et al., 1982, White and Christensen, 1982). System 
y+ transports CAAs, particularly the L isomeric forms L-arginine, L-ornithine and l-lysine in a 
bidirectional manner dependent on substrate concentration in the µM range and membrane 
potential (Verrey et al., 2004). Another characteristic of system y+ is stimulation of transport by 
substrate on the opposite side of the membrane, so called ‘trans-stimulation’, the sensitivity of 
which varies between members of the transport system (Closs et al., 2006). There are 4 
members to the family, aptly named CAT-1, CAT-2, CAT-3 and CAT-4, which are coded by the 
human genes SCL7A1–4 respectively and distinguished functionally by their affinity to 
protonated histidine (Closs et al., 2006).  
CAT-1, with an almost ubiquitous expression (except for the liver), was one of the first 
amino acid transporters to be identified and cloned in mice (Kim et al., 1991) with its 
expression level in tissue regulated by a wide variety of stimuli including hormones, nutrients 
and cell proliferation (Hatzoglou et al., 2004). It is highly sensitive to trans-stimulation and in 
the rat brain, mRNA for CAT-1 is expressed >40 times in the BBB compared to the rest of the 
brain tissue (Stoll et al., 1993). CAT-1 appears to be the major system y+ transporter and 
deletion of mCAT-1 in mice in lethal, with pups dying 1 day after birth. Under targeted 
mutagenesis, mCAT1 gene mutation also produces pubs that are 25% smaller than normal 
littermates and decreased red blood cells and haemoglobin levels, suggesting crucial roles for 
the transporter in haematopoiesis and growth control during mouse development (Perkins et 
al., 1997). It is believed CAT-3 compensates to some extent for CAT-1 gene deletion to allow 
the developing mice to make it to birth as its expression increases in CAT-1 knockout cell lines 
(Nicholson et al., 1998). CAT-1, along with the other CAT proteins, is sensitive to inhibition by 
L-homoarginine and N-ehylmaleimide (Stoll et al., 1993, Deves and Boyd, 1998). The 
localisation of CAT-1 puts it in physical contact with endothelial nitric oxide synthase (eNOS) - 
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an enzyme that catalyses the reaction of L-arginine to L-citrulline and NO in endothelium - at 
caveolae the plasma membrane, signifying the importance of the transporter in the production 
of NO (McDonald et al., 1997, Mann et al., 2003, Li et al., 2005).  
Human CAT-2 is found as two splice variants known as CAT-2A and CAT-2B which differ 
from one another by 42 amino acids (Closs et al., 1997a). CAT-2B has higher affinity for CAAs 
than CAT-2A and exhibits similar substrate specificity to CAT-1 although is less sensitive to 
trans-stimulation (Closs et al., 1997b, Vekony et al., 2001). Conversely, CAT-2A is almost 
completely insensitive to trans-stimulation (Closs et al., 1993). CAT-2A is predominantly 
expressed in the liver whereas CAT-2B, referred to as the inducible CAT isoform, is often only 
located in inflammatory cells following cytokine or lipopolysaccharide treatment and is often 
induced with inducible/immune nitric oxide synthase (iNOS) (Hatzoglou et al., 2004). CAT-3, 
expressed strongly in the thymus and brain of humans, exhibits strong affinity for CAAs and is 
somewhat sensitive to trans-stimulation, although not as sensitive as CAT-1 (Vekony et al., 
2001). CAT-4 is expressed in the brain, testes and placenta of humans, although no CAA 
transport role has been attributed to it and its physiological significance is unknown 
(Sperandeo et al., 1998, Wolf et al., 2002). 
Human CATs expressed in Xenopus laevis oocytes exhibit a Michaelis half-saturation 
constant (Km) for L-arginine of 70-250µM for CAT-1, 2-5mM for CAT-2A, 38-380µM for CAT-2B, 
and 40-450µM for CAT-3, with similar values for L-ornithine and L-lysine (Closs et al., 1993, 
Kavanaugh et al., 1994, Closs et al., 1997a, Closs et al., 1997b). L-histidine is a poor substrate 
for all members of system y+ at physiological pH, but good at pH 5.5 when protonated, except 
for CAT-3 which does not recognise histidine in any form (Kim et al., 1991). In rat in situ brain 
perfusion models, CATs have been reported to have a Km of 30-100µM for L-arginine, 70-
100µM for L-lysine and 109µM for L-ornithine (Mann et al., 2003). Data from human brain 
endothelium varies, but falls within the latter concentrations. These transport kinetic data 
illustrate the differences between the CATs themselves as well as differences between species 
and models. It has also been shown that CAT activity is voltage dependent and maximum influx 
rate (Vmax) is increased with membrane hyperpolarisation induced by vasoactive substances 
such as bradykinin (Nilius and Droogmans, 2001).  
The predicted structure of CATs based on numerous data show 14 transmembrane domains 
with intracellular N-and C-terminals (figure 1.9 below) (Closs et al., 2006). The third 
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extracellular domain serves as a binding site for murine leukaemia viruses, a finding which 
attributed its position to be extracellular (Kim et al., 1991, Albritton et al., 1993). This loop is 
heavily N-glycosylated and shows great variability between species, although doesn’t appear 
to hold transport functions (Kim and Cunningham, 1993). It has also been established that 
CATs exhibit few polymorphisms, which suggests slight alterations in protein sequence are not 
tolerated for proper functioning (Closs et al., 2006).  
 
Figure 1.9. The putative structure of CATs 1-3 (4 is unknown). CATs have 14 transmembrane 
domains (yellow cylinders), intracellular N- and C-termini (NH2 and COOH) and are glycosylated 
at positions which vary between species. The region highlighted in red confers differences in 
transport function between the CATs. Black arrows indicate known glycosylation sites. Black 
triangles indicate areas crucial for substrate recognition and transport function. Adapted from 
(Verrey et al., 2004) and (Closs et al., 2006). 
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The CAA L-arginine is classified as a ‘conditionally essential’ or ‘semi-essential’ amino acid 
on the grounds that it can be synthesised in sufficient quantity in adults, but in developing 
animals and adults suffering certain disease or trauma it is obtained from the diet to 
supplement endogenous synthesis (Barbul, 1986). However, as not all tissues in the healthy 
adult contain the necessary enzymes for the de novo synthesis of L-arginine, careful regulation 
of its supply in relation to its consumption is crucial, and is maintained by a balance between 
intracellular metabolism and membrane transport (Wiesinger, 2001). Endogenous L-arginine 
synthesis involves the mitochondria-based enzymes ornithine carbamoyltransferase and 
carbamoylphosphate synthetase I which are involved in the urea cycle and heavily expressed in 
liver hepatocytes, but not found in the CNS (Morris, 1992). In addition to the more widely 
expressed arginosuccinate synthase enzymes which catalyse the recycling of L-citrulline to L-
arginine and are important for NO production. Deficiency in this specific process can have 
severe consequences for patients – which includes progressive hepatic disease and continued 
intellectual impairment – highlighting the importance of endogenous L-arginine production 
(Erez et al., 2011).  
The role of L-arginine in the body is dependent on the cell-type and the desired end-
product. Besides a role in the urea cycle (see (Morris, 2002) for a thorough review), L-arginine 
participates in creatine, L-ornithine, and L-glutamate synthesis and is the precursor for 
polyamines, proline and spermidine (see (Grillo and Colombatto, 2004) and the references 
within).  
Arguably, the most important role of L-arginine is that it is the primary substrate for all 
isoforms of nitric oxide synthase (NOS) enzymes (including endothelial NOS (eNOS), neuronal 
nitric oxide synthase (nNOS) and inducible nitric oxide synthase (iNOS), which are classified by 
their tissue and cell distribution and expression) and hence involved in the production of NO, 
as briefly mentioned in previous sections of this thesis. The enzymes, which share an 
approximate 50% sequence homology and function as homodimers, catalyse the NADPH and 
O2-dependent oxidation of L-arginine to L-citrulline and NO (Vallance and Leiper, 2002) (see 
figure 1.10 below).  
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Figure 1.10. L-arginine metabolism by NOS. NOS enzymes form homodimers and bind the 
cofactors haem, flavin mononucleotide (FMN), flavin adenine dinucleotide (FAD) and 
tetrahydrobiopterin (BH4) for enzymatic activity. Each NOS dimer also coordinates a single zinc 
(Zn) atom. On binding calmodulin (CAL), the active enzymes catalyse the oxidation of L-
arginine to L-citrulline and NO using NADPH and O2 as co-substrates. Adapted from (Vallance 
and Leiper, 2002). 
 
1.9.6. Nitric oxide – action and targets 
The importance of NO in physiology was epitomised when it was named ‘molecule of the 
year’ by the journal Science in 1992  (Culotta and Koshland, 1992).  NO is a gaseous free radical 
signalling molecule in the respiratory, gastrointestinal, genitourinary, cardiovascular and 
nervous systems, and disordered NO generation is implicated in a wide range of diseases 
(Alderton et al., 2001, Vallance and Leiper, 2002). In the respiratory system, NO improves 
pulmonary vascular integrity, improving arterial oxygenation which is related to its effect on 
blood-flow distribution in the lungs (Giacoia, 1995). NO plays similar roles in the gut such as 
regulation of blood supply and helping maintenance of gut epithelial integrity, but it also 
exhibits protective effects by inhibiting gastric acid secretion (Lanas, 2008, Stanek et al., 2008). 
In the genitourinary system too, NO is implicated in a wide variety of roles including penile 
erection, localised renal blood flow and tubular function (Burnett, 1995). In the cardiovascular 
system, eNOS generates NO to vasodilate the vasculature which maintains it in a relaxed state 
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to promote blood flow, inhibit platelet and immune cell adhesion, and to inhibit smooth-
muscle cell replication (Strijdom et al., 2009). The many effects of NO on the cardiovascular 
system are reviewed in detail in (Loscalzo and Welch, 1995). 
It is believed NO reacts with four main cellular targets: thiols, metals, molecular oxygen and 
reactive oxygen species (ROS) (such as superoxide (O2-)) and that NO signalling is dependent 
on the redox state of the cell. This allows the highly reactive NO can be involved with 
numerous signalling pathways, and probably explains why NO can have both physiological and 
pathophysiological influences on the body (Vallance and Leiper, 2002).  
NO signalling often occurs via interaction with the soluble lysase enzyme guanylyl cyclase 
(sGC), stimulating its activity which results in the production of the secondary messenger 3’,5’-
cyclic guanosine monophosphate (cGMP) from guanosine triphosphate (GTP) (Burnett, 1995) 
which induces downstream activation of protein kinases and subsequent downstream 
signalling events resulting in smooth-muscle relaxation and a variety of other physiological 
processes (Guix et al., 2005). This type of signalling has been shown to occur in rat BBB cells 
(Janigro et al., 1994). NO signalling can also happen through cyclooxygenase, Akt kinase, and 
by S‑nitrosylation of pathway components, in which it binds to thiol groups of proteins and 
non-protein molecules to regulate cell signalling components (Guix et al., 2005, Calabrese et 
al., 2007). 
1.9.7. NO, the brain, and the BBB 
NO can act on both the peripheral nervous system (PNS) and CNS. In the PNS, NO produced 
from nNOS is important in the relaxation of vascular and non-vascular smooth muscle and a 
variety of other locally-acting processes (see (Vallance and Leiper, 2002)). In both the PNS and 
the CNS, NO is also able to act as a secondary neurotransmitter via cGMP mechanisms, which 
was first shown in a landmark paper demonstrating that NO was produced as a result of N-
methyl-D-aspartate (NMDA) receptor stimulation by glutamate (Garthwaite et al., 1988). This 
process was subsequently described at several brain regions including the hippocampus and 
hypothalamus, which showed that via a retrograde mechanism NO is also able to inversely 
stimulate glutamate release which is crucial in memory function of the brain (Guix et al., 2005). 
NO has also been implicated in the release of other types of neurotransmitters including 
serotonin (Lorrain and Hull, 1993) and noradrenalin (Feldman and Weidenfeld, 2004) as well as 
in neuronal survival and neuronal protection (Calabrese et al., 2007).  
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In the cerebrovasculature, NO comes from eNOS in BMECs and BECs (Moncada et al., 
1991), and nNOS from brain neurons (Bhardwaj et al., 2000) or autonomic nitrergic nerves 
(Toda and Okamura, 2003) which controls cerebral blood flow, vascular tone, vascular 
resistance, and vascular growth, which have direct effects on local blood flow at the BBB (Toda 
et al., 2009). At the BBB, NO appears to have functional and protective roles as well as 
deleterious effects depending on its source and the state of brain and cerebrovascular health. 
As well as acting upstream of smooth-muscle cells to induce vasodilation, NO from eNOS 
which is highly expressed at caveolae of BMECs via palmitoylation with caveolin proteins, 
appears to be involved in regulating transendothelial permeability during endocytotic and 
transcytotic events (Thiel and Audus, 2001).  This was demonstrated by  (Schnitzer et al., 1996) 
in situ and in vitro with rat models who showed the hydrolysis of GTP by NO activated cGMP 
was crucial in the fission of caveolae away from the plasma membrane. NO was shown in an in 
vitro rat co-culture model (astrocytes and BMECs) to scavenge ROS during hypoxia and 
reoxygenation events, protecting the BBB at a functional and molecular level (Utepbergenov et 
al., 1998). NO, has also been shown in patch-clamp electrophysiology work, to party regulate 
BMEC membrane hyperpolarisation in vitro by regulating inward ionic currents (Janigro et al., 
1994). 
As well as its important physiological roles, NO is implicated in several cerebrovascular and 
brain pathologies. Neurodegenerative diseases such as Parkinson’s disease (PD), Alzheimer’s 
disease (AD) and Huntington’s disease (HD) and cerebrovascular diseases such as ischemia and 
stroke, all exhibit a varying degree of oxidative stress, producing free radicals which can form 
ONOO- – a powerful oxidant that modifies lipids and proteins by nitration (see (Guix et al., 
2005) –- upon reaction with NO. The source of this NO is believed to be iNOS, the inducible 
form of NOS which is only expressed during a pro-inflammatory response, which is a hallmark 
of neurodegenerative disease (Thiel and Audus, 2001). In mouse BBB cells in vitro, NO has 
been shown to increase permeability by interactions with TJ proteins (although a mechanism 
wasn’t demonstrated) and inhibit P-gp efflux of a well characterised P-gp substrate 
rhoadamine 123, which was believed to be a result of an ATP production decrease due to the 
inhibition of glycolytic enzymes (Yamauchi et al., 2007). NO alongside ONOO- can function as 
downstream effectors of tissue plasminogen activator (tPA, a serine protease involved in 
blood-clot metabolism) mediated excitotoxicity, which results in neuronal cell death and BBB 
breakdown in vivo (Parathath et al., 2006). However, it is important to point out that ONOO- 
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also has conflicting data regarding its toxicity and has been demonstrated to convey a 
neuroprotective role against NO-mediated apoptosis (Garcia-Nogales et al., 2003).   
The source of NO and the health state of the brain may explain conflicting data pointing to 
positive and negative roles of NO in brain and cerebrovascular pathologies, and this provides 
compelling reason to further understand the mechanisms and physiology of NO, to assist 
therapeutic intervention. 
1.9.8. Asymmetric dimethylarginine 
The first described competitive NOS inhibitors were L-arginine analogues: NG-monomethyl-
L-arginine (L-NMMA), NG-nitro-L-arginine (L-NNA) and its methyl ester (L-NAME), and N-
iminoethyl-L-ornithine (L-NIO) (Rees et al., 1990). Around the same time, another related L-
arginine analogue with perhaps more clinical relevance was discovered (figure 1.11). This 
molecule, NG,NG-dimethylarginine or asymmetric dimethylarginine (ADMA) (isolated in 1987 
(Ogawa et al., 1987a)) was first demonstrated to inhibit NOS activity (Vallance et al., 1992b, 
Vallance et al., 1992a). Since these early data, there have been over 1500 peer-reviewed 
publications relating to ‘asymmetric dimethylarginine’ with the number increasing annually 
(NCBI PubMed searches December 2011).  
ADMA potently inhibits all NOS isoforms in a competitive manner by competing with L-
arginine for the NOS binding site (Siroen et al., 2006) with reported inhibition constants (Ki) of 
0.4µmol/L for nNOS (Kielstein et al., 2007), 0.9µmol/L for eNOS (Anderssohn et al., 2010) and 
3.9µmol/L for iNOS (Tsikas et al., 2000).  
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Figure 1.11. The chemical structures of L-arginine and ADMA. Despite their similarity, L-
arginine is the primary substrate for all forms of NOS, whereas ADMA is a potent inhibitor for 
all forms of NOS. Picture adapted from (Boger, 2003). 
 
1.9.9. Production of ADMA 
ADMA, along with L-NMMA and the closely related symmetric dimethylarginine (SDMA, 
which does not inhibit NOS but is a marker of renal failure (Kielstein et al., 2006b) are 
endogenously produced as a result of proteolysis of methylated arginine residues on proteins 
by a group of enzymes referred to as protein-arginine methyltransferases (PRMTs) (Leiper and 
Vallance, 1999, Pope et al., 2009). These methylarginines are continuously produced 
intracellularly by PRMTs during normal protein turnover, with the primary protein source 
being nucleolar proteins (Leiper and Vallance, 1999, Zoccali, 2006b). PRMTs methylate the 
guanidino group of arginine residues on proteins (Rawal et al., 1995), which are then 
hydrolysed, forming the methylarginines (Zoccali et al., 2007).  
There are currently 11 PRMTs in mammals, 9 of which exhibit PRMT activity and are divided 
into type groups depending on their catalytic capabilities (Krause et al., 2007). Type I PRMTs 
catalyse the production of ADMA, type II PRMTs, SDMA, and both types catalyse L-NMMA 
production (Bedford and Richard, 2005). The methylation of protein-arginine residues is a 
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wide-spread post-translational method of protein modification involved in a wide variety of 
cell functions which include subcellular protein localisation, protein-protein interactions and 
signal transduction (see (McBride and Silver, 2001) for a detailed review). With no other 
synthetic route of production identified, methylarginines only appear in the cytosol as a result 
of PRMT methylation and protein degradation, meaning their presence is governed by protein 
turnover, clearance and PRMT activity (Leiper and Nandi, 2011). Although ADMA is produced 
throughout in the body, the concentrations do vary in tissues, with the cardiovascular system 
and lungs major sources of ADMA due to their high expression of type I PRMTs (Bulau et al., 
2007).  
1.9.10. ADMA metabolism and clearance 
From the 300µmol of ADMA produced daily in the human body, almost 80% is metabolised 
intracellularly and the remaining 20% is eliminated from the body by the renal route (Achan et 
al., 2003, Zoccali, 2006b). This metabolism was first demonstrated to be mediated by a group 
of intracellular enzymes called NG,NG-dimethylarginine dimethylaminohydrolases (DDAH) in 
1987 (Ogawa et al., 1987a, Ogawa et al., 1987b), confirming the theory that a metabolic 
pathway must exist for ADMA following the observation that the amount of SDMA in urine was 
30-fold higher than ADMA in rabbits (McDermott, 1976). DDAH activity has also been 
demonstrated against L-NMMA, but not SDMA which is almost completely cleared from the 
body through renal excretion (Richir et al., 2008).  
DDAH is expressed as two isoforms (DDAH-1 and DDAH-2), both of which are responsible 
for ADMA catabolised at varying sites in the body (Leiper et al., 1999) although which isoform 
is the most responsible is not known (Pope et al., 2009). The isoforms display a 62% AA 
sequence homology (Tran et al., 2003) and both catalyse the reaction of ADMA to L-citrulline 
and dimethylamine (Palm et al., 2007). DDAH-1 is widely expressed, especially in the kidney 
and liver – which are the major sites of ADMA metabolism (Nijveldt et al., 2003, Nijveldt et al., 
2004) – but also (to a lesser extent) in the brain, pancreas, and aorta (Palm et al., 2007). It has 
also been shown to be expressed in the vascular endothelium (Konishi et al., 2007). The high 
expression of DDAH-1 in the kidney and liver has lead to it being referred to as the ‘guardian of 
circulating ADMA’ (Palm et al., 2007). The expression of DDAH-1 is generally thought to be 
associated with tissues where nNOS expression is high, and the two enzymes have been 
demonstrated to co-localise (Leiper et al., 1999, Pope et al., 2009). Using purified recombinant 
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human DDAH-1 it has been demonstrated that DDAH-1 exhibits a Km of 68.7µM and Vmax of 
356nmol/mg/min for ADMA (Forbes et al., 2008). 
The DDAH-2 isoform is expressed predominantly in tissues associated with eNOS and has 
been shown to be complexed with eNOS in endothelial cells (Palm et al., 2007). DDAH-2 
exhibits a 5.1-fold greater expression of mRNA over DDAH-1 (Wang et al., 2007) and 
overexpression of DDAH-2 and not DDAH-1 has been shown to reverse impaired NO 
production in endothelial cells (Lu et al., 2007). These observations nominate DDAH-2 as the 
predominant DDAH isoform in the vascular endothelium. It is highly expressed in the heart and 
also in immune tissues such as the thymus, lymph nodes and immune cells expressing iNOS 
(Tran et al., 2000). Recombinant human DDAH-2 has been shown to have a Km of 16µM and 
Vmax of 4.8nmol/mg/min for ADMA, demonstrating a kinetic rate 70 times less than DDAH-1 
(Pope et al., 2009).  This work is also supported by the observation that decreasing DDAH 
expression using small interfering ribonucleic acids (siRNA) against DDAH-1 in rats caused a 
50% increase in plasma ADMA levels, but no change in plasma levels was observed with DDAH-
2 down regulation, (although there was a 40% decrease in endothelium-dependent relaxation 
by 40%) (Wang et al., 2007). These observations suggest DDAH-1 could be the principle ADMA 
catabolising enzyme in the body. 
It is worth mentioning that a separate ADMA and methylarginine catabolic pathway has 
been shown involving an enzyme called alanine-glycoxylate aminotransferase (Rodionov et al., 
2010). This separate pathway however is believed to metabolise less than 20% of the total 80% 
of ADMA which is ultimately catabolised, meaning DDAHs play the major ADMA catabolic roles 
(Leiper and Nandi, 2011). Another important observation to report is that DDAHs can also 
exert effects independently of the ADMA-NOS pathway. This was recently demonstrated that 
DDAH2 can upregulate expression of VEGF through Sp1 transcription factor promoter 
activation in vitro, although evidence so far suggests this role is of less importance compared 
to its ADMA-NOS pathway role (Hasegawa et al., 2006, Leiper and Vallance, 2006). 
The importance of DDAH in ADMA metabolism was calculated using estimates of daily 
protein methylation content and protein turnover in human plasma and urine from (Vallance 
et al., 1992a), which revealed that if ADMA metabolism did not occur there would be a 5µmol 
per L increase in plasma ADMA per day (Achan et al., 2003). This value greatly exceeds the Ki 
values for all forms of NOS and would cause dramatic inhibition of NOS production and 
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signalling throughout the body. This highlights the importance of the ADMA-DDAH-NOS 
pathway (summarised in figure 1.12) and how imbalances could lead to adverse conditions.
 
Figure 1.12. The ADMA-DDAH-NOS pathway. Nitric oxide (NO) synthesis is catalysed by three 
isoforms of nitric oxide synthase (NOS), neuronal NOS (nNOS), endothelial NOS (eNOS) and 
inducible/immune NOS (iNOS), which have varying tissue distributions. L-arginine residues 
incorporated into proteins can be methylated by protein arginine methyltransferases during 
normal protein turnover and degradation processes. Proteolysis of these arginine-methylated 
proteins release methylarginines into the cytosol. Two of these methylarginines, asymmetric 
dimethylarginine (ADMA) and NG-monomethyl-L-arginine (L-NMMA) are potent competitive 
inhibitors of all forms of NOS. Both ADMA and L-NMMA are removed from the body through 
catabolism by dimethylarginine dimethylaminohydrolases (DDAH), and to a lesser extent, renal 
excretion. DDAH enzymes can induce physiological effects via NOS-independent pathways 
such as regulation of vascular endothelial growth factor (VEGF). EDRF, endothelium-derived 
relaxing factor; SMC, smooth muscle cell. Figure adapted from (Leiper and Nandi, 2011). 
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1.9.11. ADMA and the ‘L-arginine paradox’ 
As the precursor for NO, L-arginine is crucial for normal NO production in physiology. It has 
also been widely used as a supplement to alleviate the effects of NO impairment in 
cardiovascular associated conditions such as hypercholesterolemia (Creager et al., 1992) and 
coronary artery disease (Yin et al., 2005). L-arginine induces widespread vasodilation in these 
conditions, improving blood-flow and endothelial dysfunction which is often associated with 
impaired NO production (Bode-Boger et al., 2007).  
On closer inspection, when one observes eNOS enzyme kinetics combined with 
physiological concentrations of L-arginine, the observations are extremely puzzling. eNOS 
function should by fully saturated by both normal plasma and intracellular concentrations of L-
arginine (Palm et al., 2007) (which are around 60-100µM in human plasma and range from 
100-800µM in endothelial cells), as the enzyme has an L-arginine Km of 2.9µM (Miner et al., 
2004, Boger, 2007). Therefore, there should be more than sufficient amounts of L-arginine 
already present in patients – yet L-arginine increases NO production when supplemented. This 
curiosity has been named the ‘L-arginine paradox’ and there are two main theories that could 
explain the phenomenon. 
One theory is that NOS activity is dependent on transport of extracellular L-arginine into 
the cell of – which has quick access to eNOS due to the close association of CAT-1 and eNOS – 
and is supported by observations in vitro showing eNOS activation in relation to increased L-
arginine transport (Ogonowski et al., 2000, Miner et al., 2004). However, in vivo data is 
currently lacking. For this theory to work, it would be required that the intracellular L-arginine 
concentrations were compartmentalised away from eNOS, which could also explain why 
intracellular concentrations are significantly higher than extracellular concentrations. This 
compartmentalisation of L-arginine has been proposed with compelling in vitro data 
demonstrating not only did regeneration of L-arginine from exogenous citrulline did not alter 
bulk intracellular L-arginine concentrations, but all the enzymes involved in the regeneration 
were directly associated with eNOS in the plasma membrane sub-compartment, the 
plasmalemmal caveolae,  in bovine aortic endothelial cells (Flam et al., 2001). The 
compartmentalisation of eNOS may allow cells to regulate the amount of active eNOS in 
contact with the CAT complex (Sbaa et al., 2005).  Intracellular L-arginine levels are also 
regulated by the enzyme, arginase, which converts L-arginine to L-ornithine and urea and an 
increase in their activity in certain conditions (including hypoxia) could deplete the intracellular 
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L-arginine pools away from eNOS. Thus the intracellular arginine concentrations would no 
longer be saturating the eNOS activity and would make the enzyme sensitive to extracellularly-
sourced substrate (Tousoulis et al., 2007).  
The second theory involves ADMA. As a potent inhibitor of eNOS, an increasing amount of 
ADMA (associated with many conditions, see section 1.9.12) would increase the ADMA/L-
arginine ratio, stopping the production of NO. L-arginine supplementation would therefore 
normalise the ratio by displacing ADMA from NOS, returning NO production to normal (Boger, 
2004). This process has been observed in patients suffering with hypercholesterolemia, 
hyperhomocysteinemia and hypertriglyceridemia, adding weight to the theory (Boger et al., 
1998, Lundman et al., 2001, Sydow et al., 2003). It is possible that due to the sensitivity of CAT-
1 to trans-stimulation, and the similarity of L-arginine and ADMA, that L-arginine uptake could 
be stimulated by an increasing presence of intracellular ADMA, and conversely an increasing 
extracellular concentration of L-arginine could stimulate the cellular exit of ADMA (Bode-Boger 
et al., 2007). However, there is currently no published experimental data demonstrating this. 
1.9.12. ADMA in health and disease 
If ADMA has a deliberate role in normal physiological processes is open to debate. Most 
believe it does not – that ADMA is merely a by-product of protein methylation – but it has 
been suggested that ADMA could be a mediator of vascular tone regulation through the 
inhibition of eNOS, resulting in vasoconstriction (Zoccali, 2006a). It was demonstrated in 
guinea pigs that a 10µM plasma concentration of ADMA is sufficient to increase blood pressure 
by 15% (Vallance et al., 1992a), although under normal healthy conditions ADMA plasma 
concentrations range from 0.5–1µM in humans (with similar concentrations in other 
mammals) (Lajer et al., 2008, Wang et al., 2008, Wang et al., 2009). Although, these healthy 
plasma concentrations are just sufficient to inhibit eNOS and nNOS, they are well below the Km 
and Vmax for both isoforms of DDAH (as mentioned in 1.9.11) and so unlikely to cause effects 
through the NOS pathway. Instead, it is the intracellular concentrations of ADMA which may 
play more of a role in physiological and pathophysiological processes. It has been 
demonstrated that the intracellular levels of ADMA from aortic endothelial cells were up to 10 
times more that those in plasma (Masuda et al., 1999). Similar intracellular concentrations 
were observed in freshly isolated rat brain slices (Cardounel and Zweier, 2002). These 
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concentrations would be more than sufficient to inhibit NO production, especially if DDAH 
activity was impaired.  
DDAHs are extremely sensitive to oxidative stress due to the presence of a sulfhydryl group 
on a cystine residue in their active sites (Knipp, 2006). The non-protein amino acid 
homocysteine has been demonstrated to oxidise this group, inhibiting DDAH-1 in vitro 
(Stuhlinger et al., 2001). Oxidative stress can result from many conditions with ADMA itself 
able to induce superoxide production. During conditions of BH4 depletion (critical cofactor in 
NO production, see figure 1.10), ADMA has been shown to uncouple eNOS, which causes NO 
production to be replaced by the production of superoxides, which inhibit DDAH and in-turn 
cause an increase in ADMA (Druhan et al., 2008). This cycle is therefore able to perpetuate 
production of oxidative stress in endothelial cells, leading to endothelial dysfunction, a feature 
associated with many diseases where ADMA is at  extracellular pathophysiological 
concentrations (Chen et al., 2008). These concentrations vary depending on the model and 
disease itself, but generally, a plasma concentration of around 2-5µM is reported in human 
pathologies (Boger, 2003, Boger and Ron, 2005, Bode-Boger et al., 2007, Teerlink et al., 2009). 
If these levels are high enough to induce or mediate pathophysiology in vivo remains 
uncertain, but they are unlikely to be high enough to cause any problems for DDAH 
metabolism, under normal healthy conditions. What may be more important regarding ADMAs 
role in disease are the intracellular levels (as mentioned previously), but these have not been 
thoroughly researched and remain an enticing line of investigation.  
It is also apparent that some conditions can upregulate the expression and activity of 
PRMTs in the production of ADMA. It was demonstrated 2000 that both native and oxidised 
low-density lipoprotein (LDL) cholesterol can upregulate activity of PRMTs in primary human 
endothelial cells, increasing production of ADMA (Boger et al., 2000), although the mechanism 
itself was not demonstrated. This finding could be very important, particularly in 
cardiovascular disorders where LDL cholesterols are well known mediators of disease.  
The metabolism of ADMA by the DDAHs may be an important regulator of endothelial 
permeability. It has been demonstrated that ADMA metabolism is able to determine 
pulmonary endothelial barrier function by modulation of small guanosine triphosphatases 
(GTPases), which are known regulators of cell adhesion through the organisation of junctional 
proteins and cell cytoskeleton proteins (Spindler et al., 2010). ADMA has been shown to 
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differentially regulate known actin dynamic regulators RhoA, Rac1 and Cdc42 in vitro (Wojciak-
Stothard et al., 2007). The authors of this work later described how ADMA down regulated Rho 
GTPase Rac1 activity in confluent monolayers of pulmonary endothelial cells and in vivo (both 
models deficient for DDAH-1) which resulted in an increase in paracellular permeability, 
through a protein kinase G (PKG) and NO pathway, involving vasodilator-stimulated 
phosphoprotein (VASP) and independent of ROS formation (Wojciak-Stothard et al., 2009). 
VASP link intercellular junction proteins and integrins with the actin cytoskeleton, under close 
association with Rac1, and changes in the phosphorylation of VASP by PKG have previously 
been shown to increase permeability (Benz et al., 2008). The authors stipulated that the 
increase in permeability induced by VASP could involve interactions with the TJ protein ZO-1, 
which was previously shown with protein kinase A (Comerford et al., 2002). 
Pathophysiological concentrations of ADMA appear sufficient enough to elicit human 
coronary and endothelial gene expression in vitro. ADMA was demonstrated to induce 
substantial changes in gene expression at doses as low as 2µM, some of which were 
independent of the NO pathway, even in the presence of >300µM L-arginine. One of the genes 
affected by ADMA encoded PRMT enzymes, demonstrating ADMA may be able to induce its 
own production, although no mechanism was demonstrated. In this revealing study, the 
authors argued that these NOS-independent changes in gene expression could explain why 
supplementation of L-arginine is sometimes unable to reverse the effects of increased ADMA 
levels, which has been noted in ADMA-associated kidney failure (Smith et al., 2005). 
As plasma ADMA levels are sourced from all over the body, they are good indicators of 
intracellular levels and therefore markers of dysfunction of the PRMT-ADMA-DDAH-NOS 
pathway. High levels of plasma ADMA have been the subject of intense study and are 
associated with a wide variety of diseases, in particular those affecting the cardiovascular, 
renal and hepatic systems and tissues with high NOS expression (Vallance et al., 1992a, Boger, 
2003, Siroen et al., 2006, Anderssohn et al., 2010, Mookerjee et al., 2007). Please see the 
references in this section for more detail on ADMA in these conditions. For the purposes of 
this thesis, I will focus on the role of ADMA in brain and cerebrovascular disease. 
1.9.13. ADMA and the brain 
Rather than a disease ‘cause or effect’ argument, it is perhaps more appropriate to debate 
ADMAs ‘marker or mediator’ role, particularly since several recent works describing increased 
 INTERACTIONS OF ENDOGENOUS AND EXOGENOUS MOLECULES WITH 




ADMA levels in disease and decreased L-arginine/ADMA ratios (see table 1.2) have advanced 
the latter notions in brain and cerebrovascular disease. 
Increased levels of ADMA have been noted in patients with AD. In perhaps the biggest 
study to date, (Arlt et al., 2008) demonstrated in 80 AD patients, an increase in plasma ADMA 
and a decrease in cerebrospinal fluid (CSF) levels compared to 80 control patients. These 
findings were similar in an earlier study using 25 AD patients and 25 controls (Selley, 2003). 
Both sets of authors argued that these finding could link ADMA to AD disease progression 
through an increase in NO production and oxidative stress in the cerebrovasculature and brain 
tissue. However, another study reported no such changes in ADMA concentrations in CSF or 
plasma (Mulder et al., 2002). These conflicting reports are likely due to the small cohorts used 
for the studies and as there are only a few groups looking into the associated of ADMA with 
AD, it requires further study to draw any accurate conclusions from these data. 
The majority of ADMA data from brain studies relates to its role in cerebrovascular disease 
and endothelial dysfunction through inhibition of NO production. A recent MRI study was 
performed on over 700 Japanese patients, 146 of which were identified as having 
microangiopathy-related cerebral damage (MARCD), and whom had their ADMA plasma 
concentrations determined using high performance liquid chromatography. The authors 
discovered a significant increase in levels of ADMA (0.6 µmol/l from 0.5µmol/l in controls) and 
decreases in the L-arginine/ADMA ratio, between MARCD patients and controls, all of whom 
were from a similar ethnic section of society (Notsu et al., 2009).  The authors pointed out that 
their findings supported earlier work showing how ADMA infusion induced a significant 
reduction in cerebral blood flow, without affecting overall blood-pressure in humans (Kielstein 
et al., 2006a), suggesting that both lines of evidence support a hypothesis that cerebral 
vasculature is either more sensitive to ADMA or has differing regulatory systems. This claim 
was supported by the authors of the original work, in a reviewer commentary titled ‘ADMA 
and the Brain: An unfolding Story’ (Kielstein and Kielstein, 2009). Notsu et al., continued that 
the fact that increases of plasma ADMA in most forms of vascular diseases (including 
cerebrovascular disease) are small in comparison to controls, suggests high sensitivity of the 
regulatory mechanisms involved, which in the brain is supported by the fact that nNOS is by far 
the most sensitive NOS to ADMA, a point demonstrated previously in vitro (Faraci et al., 1995). 
It has also been recently demonstrated that over expression of DDAH-1 in mice can reverse 
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neurovascular dysfunction induced by ADMA, emphasising the importance of functioning 
DDAH in the cerebrovasculature (Dayoub et al., 2008).  
Associations between ADMA and stroke have also been made in numerous studies. 
Elevated ADMA plasma levels have not only been indicated as an independent marker of acute 
stroke and transient ischemic attacks (Wanby et al., 2006), but they have also been shown to 
be directly associated with an increased risk of stroke in elderly patients (Yoo and Lee, 2001). 
Kielstein et al., argued that this could be down to ADMA-induced arterial stiffness, an 
independent predictor of stroke related to NO availability (Wilkinson et al., 2002), which they 
then demonstrated in healthy volunteers by non-invasive pulse wave analysis (Kielstein et al., 
2006a). In this way, ADMA was implicated as a mediator in the pathogenesis of 
cerebrovascular disease. Increased ADMA levels in CSF has also been associated with stroke 
severity (Brouns et al., 2009). 
If DDAH activity was decreased or inhibited during a cerebrovascular disease, it is possible 
that elevated levels of ADMA could induce an increase in BBB permeability through 
interactions with small GTPases and junctional proteins, as described in section 1.9.12. This is 
an interesting hypothesis considering the increase in plasma ADMA seen in AD, stroke and 
cerebrovascular disease, the conditions of which (such as hypoxia or ROS formation) would be 
able to inhibit DDAH activity at the BBB and cerebrovascular system. As the largest surface 
area for molecular exchange in the brain, it is somewhat surprising that the interaction of 
ADMA with the BBB has not been directly studied, and this is particularly relevant with regards 
to the association of ADMA with stroke and cerebrovascular disease. 
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1.9.14. Membrane transport of ADMA 
As an analogue of L-arginine, ADMA is also hydrophilic and therefore expected to poorly 
cross cell membranes by diffusion alone. L-arginine utilises CAA membrane transport systems 
for cellular movement as mentioned in section 1.9.5, and therefore it is believed ADMA uses 
similar mechanisms. The fact that concentrations of ADMA fluctuate in plasma demonstrates 
that the molecule must be a substrate for cellular exit transport systems, as well as influx 
systems (which can be both as with system y+), which allow the induction of the effects of 
administered and endogenously produced ADMA.  
System y+ is the only CAA transport system which is selective for CAAs and it helps to 
maintain a dynamic equilibrium between plasma and intracellular concentrations and so 
remains the most likely ADMA transport system. However, data elucidating ADMA transport is 
severely lacking, although there are several lines of indirect evidence using in vitro systems. 
Schmidt et al., demonstrated in a mouse glioblastoma cell line that related molecules L-NNA 
and the L-NMMA intermediate L-NMA could enter cells by system L and system y+  
transporters respectively (Schmidt et al., 1994) and  showed this in a mouse glioblastoma cell 
line (Schmidt et al., 1995). Around the same time, it was demonstrated that ADMA inhibits 
CAT-1 in human endothelial cells and mouse macrophages, competing with radiolabelled L-
NMMA (Bogle et al., 1995). Shortly afterwards, ADMA was shown to compete with L-arginine 
for entry to Xenopus laevis oocytes via human CAT-2B (Closs et al., 1997a), although the ADMA 
concentrations seen in physiological and pathophysiological conditions are unlikely 
outcompete physiological concentrations of L-arginine for transport. More recently, ATB0,+ was 
demonstrated to transport ADMA and other methylarginines in a Na+ dependent manner in 
vitro and when cloned and expressed in Xenopus laevis (Hatanaka et al., 2001).  
Data describing ADMA transport mechanisms are important with respect to disease 
research and therapeutic intervention. This is because the transporters involved are also 
regulating factors in the physiological and pathophysiological effects of ADMA, along with 
PRMT production and DDAH metabolism. As well as increases or decreases in expression and 
activity of the ADMA producing and metabolising enzymes, increase and decreases in 
expression and function of CAA transporters are also regulable through physiological and 
pathophysiological events. Oxidative stress, tissue damage, cell growth and repair are all 
factors that can regulate expression and function of CAA transporters, as well as DDAHs and 
PRMTs (Teerlink et al., 2009). If function of CAA transporters were inhibited, it is likely 
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intracellular concentrations of ADMA would increase, perpetuating the effects of ADMA on 
NOS dependent and NOS independent pathways. 
1.9.15. Endogenous molecule interactions at the BBB– a human in vitro BBB model 
The study of ADMA transport at the BBB is unprecedented. However, the transport of CAAs 
has been well described at the BBB in a variety of mammalian models including primary human 
BMECs (Oldendorf and Szabo, 1976, Stoll et al., 1993, Sanchez del Pino et al., 1995, Pardridge, 
1998, Omidi et al., 2003, Berezowski et al., 2004, Hawkins et al., 2006, O'Kane et al., 2006). 
Many investigations on the human BBB have used primary human BMECs as an in vitro model. 
However, primary BMECs are notoriously difficult to keep for more than a few passages before 
undergoing cellular senescence and are phenotypically unstable due to a failure to recreate 
the precise in vivo conditions they require to function and survive (Weksler et al., 2005). There 
are several immortalised human BMEC lines described in literature, but these have failed to 
gain widespread recognition as suitable immortalised human BBB cell lines due to their BBB 
phenotype specificity (Muruganandam et al., 1997, Gu et al., 2003, Kusch-Poddar et al., 2005, 
Ketabi-Kiyanvash et al., 2007). However, there is one well characterised immortalised human 
in vitro BMEC cell line – the human cerebromicrovascular endothelial cell line (hCMEC/D3) – 
that retains many BBB specific traits over a large amount of passages.   
The hCMEC/D3s were derived from brain tissue obtained following surgical excision of an 
area from the temporal lobe of an adult female with epilepsy carried out at King’s College 
Hospital, London, in accordance with the guidelines of the Local Ethics Committee and 
research governance guidelines.  It is now a commercially available cell line. The isolated cells 
were immortalised via lentiviral transduction of the catalytic subunit of human telomerase to 
prevent telomere shortening, and the oncogene SV40 large-T antigen, which transforms cell 
lines. The whole procedure is described in detail in the first paper describing the hCMEC/D3 
cell line (Weksler et al., 2005) with further characterisation in subsequent publications (Cucullo 
et al., 2008, Forster et al., 2008, Poller et al., 2008, Mkrtchyan et al., 2009, Tai et al., 2009c, 
Carl et al., 2010).  The hCMEC/D3 cell line is considered to be the most promising immortalized 
human BBB cell line available today, exhibiting many of the characteristics that are essential 
for a good predictive BBB in vitro model (Weksler et al., 2005, Poller et al., 2008).  These 
include expression of tight junction proteins and polarized expression of multiple ABC/SLC 
transporters (Dauchy et al., 2009, Tai et al., 2009c).  
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The hCMEC/D3 cells are the most suitable and user friendly human in vitro BBB model 
available to date and as such were chosen for the work in this thesis. 
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1.9.16. Endogenous molecule interactions at the BBB– aims: 
Plasma concentrations of ADMA are increased in several brain and cerebrovascular 
disorders indicating underlying roles for ADMA regulation in CNS disease pathogenesis. This is 
made even more interesting considering the high sensitivity of the cerebrovasculature and 
nNOS to ADMA concentrations combined with the fact that the brain is a major source of 
ADMA as well as site of DDAH-1 expression. It has also been demonstrated that in the 
peripheral endothelium, ADMA has been shown to induce endothelial dysfunction, altering 
endothelial permeability. These situations provide an exciting platform for the research 
detailed in this thesis, which have been investigated using the hCMEC/D3 human in vitro BBB 
model. 
The aims of this thesis are to:   
1) investigate the effects of ADMA on the integrity of the human BBB in vitro; 
2) elucidate the transport mechanisms utilised by ADMA at the human BBB and compare 
them to those used by L-arginine; 
3) investigate whether 
a. intracellular ADMA can trans-stimulate the transport of extracellular L-arginine 
into the hCMEC/D3s; 
b. extracellular L-arginine can trans-stimulate the transport of intracellular ADMA 
into the hCMEC/D3s; 
4) explain the role of ADMA in the L-arginine paradox. 
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1.10. Exogenous molecule interactions at the BBB – Drug transport 
As the largest continuous cell surface area in the brain, the BBB represents a gateway, not 
just for endogenous molecules and nutrients, but also for exogenous therapeutics. With an 
aging population, there comes an increase in neurological and neurodegenerative disease 
prevalence. This has resulted in an increased need to deliver therapeutic drugs to the brain 
and as such the BBB is likely to become an even more important area for future research in 
both academic institutions and the biopharmaceutical industry. When compared to 
cardiovascular and cancer acting drugs, CNS acting drugs have an extremely low clinical trial 
success rate, and this is mostly due to the presence of the BBB (Alavijeh et al., 2005) (figure 
1.13). 
 
Figure 1.13. Cumulative success rates of drugs through clinical trials to market by therapeutic 
area. Figure taken from (Alavijeh et al., 2005). 
 
 
It is estimated that up to 98% of all small molecule drug candidates fail to cross the BBB 
(Pardridge, 2002) and thus it remains a major challenge not only scientifically, but financially to 
design drugs for brain delivery. As a result of this low success rate, and despite its importance, 
it is apparent that <1% of biopharmaceutical companies have an active BBB drug targeting 
programme, with the number of academic research programmes studying the BBB also low 
(Pardridge, 2005). These figures are alarming when considering the amount of drugs currently 
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used to treat CNS conditions. It is therefore likely that a lack of understanding about how these 
drugs interact with the BBB is hindering their efficacy. This accentuates the need to 
understand and exploit the basic BBB properties for efficacy to be improved. A current 
example of this situation can be found in sub-Saharan Africa. 
1.10.1. Human African Trypanosomiasis 
Human African trypanosomiasis (HAT) is a neglected, zoonotic parasitic disease that affects 
the rural populations in 36 countries, of sub-Saharan Africa (see (Brun et al., 2010) for details 
of epidemiology). There are currently about 10,000 reported cases of HAT per annum (WHO, 
2010) and that 48,000 people died from the disease in 2008 (WHO, 2009). It is caused by 
Trypanosoma brucei gambiense (T. b. gambiense) and Trypanosoma brucei rhodesiense (T. b. 
rhodesiense), two species of parasitic flagellate protozoans belonging to the genus 
Trypanosoma that occupy distinct geographical regions (Burri and Brun, 2003) and cause 
different symptoms (Kuepfer et al., 2011).  
The parasites partially develop in and are transmitted by blood-feeding tsetse flies of the 
genus Glossina which feed on a variety of mammals (which themselves act as reservoirs for the 
parasites), thereby acting as both an intermediate host and a vector for the disease. The life 
cycle of the parasite is summarised in figure 1.14 below.  
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Figure 1.14. The life cycle of African trypanosomes. In man, the bloodstream forms of 
trypanosomes show a polymorphism with (A) dividing (black arrows) ‘slender’ forms, (B) 
‘intermediate’ forms, and (C) ‘stumpy’ forms. In the tsetse fly vector/intermediate host, 
bloodstream forms of trypanosomes transform to (D) dividing midgut forms, then (E) the 
migrating epimastigote forms, which develop in the salivary glands to (F) the infective 
metacyclic forms, which are injected into the blood of the mammalian host during fly feeding. 
Taken from (Brun et al., 2010). 
 
The clinical features of HAT arise from the two distinct stages of infection and disease 
progression. The first stage (S1) of HAT is known as the haemolymphatic stage and 
characterised by the presence of trypanosomes in the blood and lymphatic systems of patients 
(Priotto et al., 2007). Initially, S1 is asymptomatic, but once the parasite numbers increase 
patients can suffer from chronic and intermittent fever, pruritus and lymphadenopathy (Brun 
et al., 2010). To avoid detection and eradication by the host immune system, trypanosomes 
are able to continuously change their variant glycoprotein coats, allowing them to persist in 
the blood and lymphatic systems (see (Donelson et al., 1998) for a in depth review of this 
process).  
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Depending on the parasite involved, progression to the second stage (S2) of HAT, also 
known as the meningoencephalitic stage, can occur months (T. b. rhodesiense) or years (T. b. 
gambiense) after the initial infection (Odiit et al., 1997, Checchi et al., 2008). S2 of HAT is 
characterised by trypanosome invasion of the CNS as the parasites cross from the blood to the 
brain by traversing the BBB and leakier BCSFB. How the parasites do this is an ongoing area of 
research with some groups reporting trypanosomes are able to cross the BBB by transcytosis 
without affecting TJ proteins (Mulenga et al., 2001) or by an unidentified mechanism involving 
the pro-inflammatory cytokine interferon gamma (IFN-γ) (Masocha et al., 2007). Other groups 
have shown during S2 infections with T. b. brucei (the infectious bovine form) in rodents that 
the BBB is damaged (Philip et al., 1994) and it has been shown that transient increases in BBB 
permeability allow movement of T. b. rhodesiense across the human BBB in vitro (Grab and 
Kennedy, 2008). 
The trypanosome invasion of the CNS in S2 gives rise to a variety of debilitating CNS 
disorders. The hallmark of S2 is insomnia and changes in sleeping cycle which give the disease 
its nickname ‘sleeping sickness’. Other neurological symptoms include tremor, limb paralysis, 
motor weakness and Parkinson-like movements due to muscular hypertension (see 
(Kristensson et al., 2010) for a detailed review on CNS conditions arising from HAT). These 
conditions are not seen in S1 and increase in severity with the duration and progression of S2, 
until the patient falls into a coma with death following shortly afterwards. The progression of 
S2 HAT varies depending on the parasite involved. Typically, T. b. rhodesiense-induced disease 
progresses more rapidly (Balasegaram et al., 2009). 
For diagnosis of HAT, the card agglutination test for trypanosomiasis (CATT) is typically 
used, particularly for T. b. gambiense infections which tend to be asymptomatic at S1 
(Chappuis et al., 2002). CATT is a fast and practical serological diagnostic test that allows many 
individuals to be rapidly screened with a good percentage of accuracy and sensitivity (Checchi 
et al., 2008). Enzyme-linked immunosorbent assays are also used along with microscopic 
examination of lymph node aspirate and/or blood for more accurate confirmation of parasites 
(Brun et al., 2010). For S2 HAT, a lumbar puncture is required for CSF inspection. According to 
recommendations by the World Health Organisation (WHO), the presence of trypanosomes or 
more than 5 white blood cells per µl or CSF, or increased protein content (>370µg/µl) defines 
S2 (Brun et al., 2010). 
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HAT is 100% fatal if left untreated, which is of particular significance when considering not 
only the resource-poor setting of sub-Saharan Africa, but the initial asymptomatic disease 
manifestation meaning people do not seek medical intervention until the disease proper has 
manifested. It is lapses in disease surveillance that appear to be the main reasoning behind re-
emergence of HAT as it believed to be an eradicable disease by the WHO. This relationship is 
displayed in figure 1.15 below. 
 
Figure 1.15. Comparison between new cases of T. b. gambiense infection and populations 
placed under surveillance.  The number of reported cases (green bars) and populations 
screened (blue circles) in Africa between 1939 and 2004. Figure taken from (Brun et al., 2010). 
 
1.10.2. Treatment of HAT 
A small number of drugs are available for the treatment HAT, depending on the stage of 
disease. Pentamidine and suramin are used for S1, and melarsoprol, eflornithine and 
nifurtimox for S2 (see figure 1.16 for their respective chemical structures). All of these drugs 
are donated to the WHO by the manufacturers (Brun et al., 2010). Information on S1 and S2 
acting drugs against T. b. rhodesiense or T. b. gambiense and summarised in table 1.3. 
Following the drug descriptions below, information on their transport at the BBB is discussed 
in section 1.10.9. 
1.10.3. Pentamidine  
Pentamidine (C19H24N4O2 MW = 240.42 g/mol) is an aromatic diamine [1,5-bis (4-amidi-
phenoxypentane]) and the current drug of choice for S1 HAT caused by T. b. gambiense. It was 
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developed after a related compound, known as synthalin, was shown to have anti-
trypanosomal activity (Sands et al., 1985). Injected intramuscularly, pentamidine is water 
soluble and exhibits a slow anti-trypanosomal action against T. b. gambiense (Docampo and 
Moreno, 2003). By reaching high concentrations in the parasite it is believed that pentamidine 
inhibits multiple cellular targets in the parasites such as selectively inhibiting the plasma 
membrane transporter Ca2+-ATPase (Benaim et al., 1993), although the precise mechanisms of 
the anti-trypanosomal action has yet to be fully elucidated. Pentamidine accumulation within 
the parasite involves multiple transporters such as the P2 adenosine transporter which 
demonstrates affinity for adenosine and polyamines. Therefore it is believed that transporters 
are likely crucial to its mode of action of the drug as well as in its delivery (discussed further in 
section 1.10.9) (Basselin et al., 1997, Sanderson et al., 2009). Although generally well tolerated 
by patients, pentamidine can induce adverse reactions including diarrhoea, injection site pain 
and nausea. Drug resistance against pentamidine has also been identified with the loss of P2 
function also involved here (please see (Gehrig and Efferth, 2008) for a recent review of drug 
resistance amongst trypanosomes). 
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Suramin (C51H40N6O23S6 MW = 1297.29 g/mol) is a symmetrical polysulfonated 
naphthylamine polyanionic compound that is the current first choice S1 treatment drug used 
in infections by T. b. rhodesiense. It is a potent anti-trypanosomal drug which has been in use 
since 1922 (Docampo and Moreno, 2003). The potency of the drug gives patients severe 
adverse reactions (which include hypersensitivity reactions and peripheral neuropathy), and 
due to its extremely short half-life in air (must be solubilised in water) it must be intravenously 
injected rapidly after preparation over a lengthy treatment regime, which can last up to 30 
days (Brun et al., 2010). Suramin is believed to exhibit its anti-trypanosomal effects by binding 
to and inhibiting the parasite’s glycolytic enzymes (Wang, 1995). 
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Melarsoprol (C12H15AsN6OS2 MW = 398.341 g/mol), first used in 1949, is the most widely 
used drug is melarsoprol for S2 HAT induced by T. b. rhodesiense (Nok, 2003). The drug is 
poorly soluble in water, ether or alcohol and must be dissolved in propylene glycol before 
intravenous administration, with the solvent causing pain upon injection (Docampo and 
Moreno, 2003, Nok, 2003).  As an organoarsenic derivative, melarsoprol is highly toxic to 
patients and adverse reactions to its administration are common. In 5-10% of cases, 
melarsoprol induces severe encephalopathic syndrome which causes death in 50% of these 
patients (Kennedy, 2004). This encephalopathic syndrome itself requires careful management 
through labour intensive means and drug treatment.  
Melarsoprol is believed to work by inhibiting glycolytic enzymes as with suramin, but also 
by lysing the trypanosomes themselves, and it is believed this lysing action is a reason the drug 
is so toxic to patients (Balasegaram et al., 2005). It is also apparent that in some regions 
trypanosomes are developing resistance to melarsoprol, in which the trypanosome P2 
adenosine transporter is implicated (Barrett et al., 2007).  
Melarsoprol is also effective against T. b. gambiense but due to the toxicity of the drug in 
patients, eflornithine is the preferred alternative. 
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Eflornithine (DL-alpha-difluoremethylornithine or DFMO, C6H12F2N2O2 MW = 182.2 g/mol),  
has been nicknamed the ‘resurrection drug’ after its ability to revive comatose patients 
suffering from S2 HAT (Jennings et al., 1997). Initially synthesised as an anti-cancer drug, 
eflornithine has been used as a trypanocide since the 1980s as it inhibits the parasite’s 
ornithine decarboxylase, a key enzyme in the synthesis of polyamines needed for cell 
proliferation and reduced production of the trypanosome specific redox active metabolite 
trypanothione (Vincent et al., 2010). Due to the short half-life of the drug, treatment with 
eflornithine requires an extensive administration process – 4 infusions of 100mg/kg body 
weight daily for up to 2 weeks is not uncommon (Burri and Brun, 2003). Despite this intensive 
treatment regime and although several side effects are apparent, eflornithine is generally 
tolerated well by patients and so is now the recommended treatment choice for T. b. 
gambiense, being active against both S1 and S2 forms of the parasite. Unfortunately, it is 
ineffective against T. b. rhodesiense due to the parasites resilience to the drug through the 
parasites high ornithine decarboxylase turnover (Iten et al., 1997). The drug is also expensive, 
and this is again unrealistic in a resource-poor setting. There have also been instances of 
eflornithine therapeutic failure with relapse rates of 8.1% reported, meaning eflornithine, 
along with melarsoprol, remain far from an ideal treatments for S2 HAT (Balasegaram et al., 
2006). 
1.10.7. Nifurtimox 
Nifurtimox (C10H13N3O5S MW = 287.293 g/mol), currently licensed for treatment of the 
closely related American trypanosomiasis (Chagas disease) caused by Trypanosoma cruzi, was 
originally only used in HAT for compassionate melarsoprol refractory cases (Pepin et al., 1989) 
but due to the limitations of melarsoprol and eflornithine, the drug has recently come into the 
fray for fighting both S1 and S2 HAT. Nifurtimox is a trypanocidal nitrofuran and has several 
advantages compared to the intensive intravenous administration regimes of the current S2 
drugs, which are often accompanied by adverse reactions. These advantages include the facts 
that nifurtimox is orally active and considerably cheaper than current S2 drugs (Lutje et al., 
2010) and that it is also effective against T. b. gambiense and T. b. rhodesiense (albeit to a 
lesser extent) (Haberkorn, 1979, Bouteille et al., 2003, Lutje et al., 2010). Despite these 
advantages, treatment with nifurtimox can also have toxic side-effects which include 
neurological aggravations such as headaches, confusion and sleep dysfunction as well as 
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nausea/vomiting and dyspepsia (Priotto et al., 2007). However, nifurtimox is generally better-
tolerated than the other S2 HAT drugs, and many of the adverse condition associated are dose 
and duration dependent (Priotto et al., 2009).  
1.10.8. Parasite resistance 
Initiatives to counter the emergence of drug-resistant parasite populations, whilst 
improving efficacy and reducing the toxic side-effects of the anti-HAT drugs when used alone 
(monotherapy) have resulted in large-scale trials of combination therapy (CT).  CT of suramin 
with the three S2-acting drugs has shown improved cure rates compared to monotherapy in 
rodent models (Clarkson et al., 1984, Raseroka and Ormerod, 1986, Jennings, 1993). Other 
results from human trials combination therapy of melarsoprol with nifurtimox (NMCT) and 
eflornithine (MECT) have demonstrated improved efficacy compared to melarsoprol 
monotherapy, but toxicity was still a major issue (Mpia and Pepin, 2002, Bouteille et al., 2003, 
Priotto et al., 2006). One large-scale trail started in 2003 and finishing in 2008 tested 
nifurtimox and eflornithine combination therapy (NECT) and concluded NECT had an improved 
toxicity profile and shortened treatment regime compared to eflornithine monotherapy 
(Priotto et al., 2009). The authors argued that despite a more complicated logistic 
implementation, NECT represented the best form of treatment for S2 HAT (Priotto et al., 
2009). As a result, NECT is now the treatment of choice for S2 HAT caused by T. b. gambiense 
and implemented by the WHO (Simarro et al., 2011). 
1.10.9. BBB transport of anti-HAT drugs 
Besides slowing trypanosome drug resistance, the precise reasoning why CT improves drug 
efficacy against S2 HAT is not yet completely understood and led to the hypothesis that 
perhaps CT improves drug delivery to the brain (Enanga et al., 1998). This is of particular 
significance for S2 as the parasites are in the host CNS and for the drugs to be effective they 
must be able to cross the BBB. Despite this significance, interactions between S2 HAT-acting 
drugs and the BBB has been under-researched until fairly recently. This is even more alarming 
considering the fact that S2 HAT acting drugs are actively being used in the field. 
Much of what was known about the ability of the trypanocidal drugs to cross biological 
membrane has been deduced from their chemical structures and lipophilicity. Pentamidine for 
instance, is hydrophilic and poor at crossing biological membranes, yet has been shown to 
accumulate in trypanosomes at concentrations in excess of 1mM, which suggests there is 
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facilitated diffusion for the drug (Damper and Patton, 1976a, Damper and Patton, 1976b). It 
has since been demonstrated that pentamidine requires the action of several polyamine and 
adenosine transporters in the outer membranes of parasites to enter and exhibit trypanocidal 
action including the adenosine insensitive high-affinity and low-affinity pentamidine 
transporters and the adenosine P2 transporter already mentioned (see (de Koning, 2001) for 
more detail). 
As with pentamidine, suramin is poor at crossing intact biological membranes and it is 
believed the ability of trypanosome transporters to take up the drug from plasma owes to its 
success as a potent anti-trypanosomal agent. Because of its charged nature, suramin is able to 
bind to many serum proteins and it was suggested that perhaps it was transported into 
trypanosomes by binding to LDL and proceeding through RMT system and this was 
demonstrated in trypanosomes (Pal et al., 2002).  
Due to their poor lipophilic properties, pentamidine and suramin are believed not to cross 
the BBB and as such are used in S1 treatment only, although this was not looked at directly 
until work by our group using in situ brain perfusion mouse models of trypanosomiasis. For 
suramin, our group investigated the ability of the drug to cross the mouse BBB and the effects 
of CT on its brain distribution. It was discovered that suramin poorly crossed the BBB and was 
not affected by the presence of other trypanocidal drugs or by P-gp knockout animals, 
confirming the suspicion that it is a not a suitable S2-acting drug (Sanderson et al., 2007).  
Conversely in similar experiments, it was discovered that pentamidine was able to cross the 
BBB, but a large proportion was retained in the mouse BMECs, meaning the concentration that 
reached the brain would be insufficient for effective parasite removal (Sanderson et al., 2009). 
It was also shown that pentamidine was a substrate for MRPs and P-gp as demonstrated using 
FVB-Mdr1a/1b (+/+) and FVB-Mdr1a/1b (-/-) mice and that CT with nifurtimox, suramin and 
melarsoprol caused changes in brain distribution of pentamidine (increase, decrease and 
decrease respectively). These data demonstrated unequivocally that pentamidine (and 
possibly melarsoprol and nifurtimox) interacted with transport systems at the BBB and CVOs, 
particularly efflux systems. It is interesting to point out that several ABC transporter genes 
have been discovered in trypanosomes (Maser and Kaminsky, 1998), although it has not been 
demonstrated if trypanosomes are able to efflux drugs through these mechanisms. The results 
regarding suramin are more equivocal however, as trail data has shown improved rodent cure 
rates with CT involving suramin (see 1.10.8). It is unlikely that suramin interferes with 
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transport mechanisms at the BBB to improve delivery and so perhaps drug-drug interactions 
(DDI) reduced the toxicity of the S2-acting drugs which saw cure rate increases. 
Studies on melarsoprol distribution have revealed that the presence of its arsenoxide group 
confers lipid solubility, enabling BBB traversal (Pepin and Milord, 1994, Pepin et al., 1994). 
Melarsoprol is also transported into trypanosomes by the P2 adenosine transporter as with 
pentamidine and it is believed mutations in the transporter confer drug resistance to 
trypanosomes, but the utilisation of BBB transport mechanisms has not been demonstrated 
(de Koning, 2001). It therefore remains likely that it is the high lipophilicity of the drug allows it 
to cross the BBB to kill trypanosomes within the brain. 
As a S2-acting drug, eflornithine was assumed to cross the BBB and has been shown to 
accumulate intracellularly to millimolar ranges in bloodstream forms of trypanosomes (Iten et 
al., 1997). The study by Iten and colleagues showed similar intracellular concentrations were 
reached at 4°C and 26°C, indicating that passive diffusion was the method as opposed to 
facilitated diffusion. However, the study only looked at 60 minute time points and not early 
stage time points, which give better indications of facilitated diffusion via transporters. 
Intracellular levels of a charged molecule such as eflornithine are unlikely to reach such levels 
by passive diffusion alone. On the contrary, in an earlier study, it was shown that eflornithine 
uptake in trypanosomes was indeed temperature dependent, reminiscent of transport activity 
(Bellofatto et al., 1987). Work by our group showed that eflornithine poorly traversed the 
murine BBB and perhaps this was an explanation as to why such an intensive treatment regime 
using this is necessary – to get sufficient quantities of eflornithine into the brain to exhibit 
trypanocidal effects (Sanderson et al., 2008). The data here also showed no interaction 
between P-gp and eflornithine, but that CT with suramin improved distribution of eflornithine 
into the brain, the mechanism of which is unknown, but may be evidence of RMT of LDL-
suramin-eflornithine DDI complexes. CT with excess eflornithine, pentamidine, melarsoprol 
and nifurtimox caused no significant changes in brain distribution of eflornithine, suggesting a 
passive diffusion method of brain entry. However, perhaps a species difference in transporters 
could explain why eflornithine delivery to the brain is efficacious in humans but not mice, or 
that other transport systems are involved in eflornithine BBB transport that were not 
investigated.  
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As the name suggests, eflornithine is an analogue of the CAA ornithine and so this proposes 
that CAA transport systems could be involved in eflornithine transport at the BBB and in 
trypanosomes. Evidence for involvement of eflornithine in a CAA system was shown when 
ablation of the amino acid transporting gene TbAAT6 in T. brucei brucei conferred them both 
viable and resistant to the action of eflornithine (Vincent et al., 2010). More recent evidence 
from genome-wide RNAi screens revealed a loss-of-amino acid transporter 6 (AAT6) function, 
representing not only a method of eflornithine entry into parasites, but another method of 
drug resistance (Baker et al., 2011).  
With NECT becoming the treatment of choice for S2 HAT, our group also recently 
investigated the BBB-crossing abilities of nifurtimox, alone or in CT with other trypanocidal 
drugs. We showed that nifurtimox was highly lipophilic and able to cross the murine BBB, but 
was expelled by an unidentified efflux transport process not involving P-gp (Jeganathan et al., 
2011). The research demonstrated that CT of nifurtimox with pentamidine increased the brain 
distribution of nifurtimox, which is interesting because not only was pentamidine previously 
demonstrated to be a P-gp substrate, but P-gp deficient mice caused no changes in the brain 
distribution of nifurtimox in the in situ brain perfusion model. That nifurtimox caused an 
increase in pentamidine brain distribution suggests a different transport system is at work as 
well as P-gp and provides an opportunity for novel investigation.  
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1.10.10. Exogenous molecule interactions – AIMS: 
The fact remains that the difficulty of developing new drugs which are able to cross the BBB 
means it is unlikely that new S2 anti-HAT drugs will be developed in the near future. It is 
therefore crucial to understand the interactions of the HAT drugs with the BBB to improve 
their efficacy and harness all the potential CT has to offer.  
By studying L-arginine and ADMA transport at the human BBB in vitro by using the 
hCMEC/D3 cell line, this project also aims to: 
1) combine our lab expertise in anti-HAT drug delivery with the knowledge gained from 
CAA transport to research the possibility the eflornithine is a substrate for CAA 
systems;  
2) follow on from our previous in situ research to investigate if CT alters delivery of both 
eflornithine and nifurtimox to the brain;  
3) elucidate the efflux mechanisms utilised by the human BBB to expel nifurtimox 
compare with mouse data already published by our group. 
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2.1. The hCMEC/D3 cell line 
2.1.1. Source 
The hCMEC/D3 cells used in this thesis were provided by Professor Pierre O. Couraud 
(Institut Cochin, Université Paris Descartes, CNRS, Paris, France), Dr Ignacio Romero (The Open 
University, Department of Life Sciences, Walton Hall, Milton Keynes, UK), and Professor 
Babette Weksler (Weill Medical College of Cornell University, New York, New York, USA) under 
an academic material transfer agreement.  
The production of the hCMEC/D3 cells is described in section 1.9.15 and also in the original 
publication (Weksler et al., 2005). 
2.1.2. General culture conditions 
The cells were cultured in 25cm2 (T-25) or 75cm2 (T-75) flasks (Thermo Scientific Nunc™, 
Thermo Scientific Nunclon™, Loughborough, UK), pre-coated for 2 hours at 37ºC with 
0.1mg/ml of rat tail collagen type-I (Gibco, Invitrogen,) made in Hank’s balanced salt solution 
(HBSS, Sigma Aldrich Company Ltd, Poole, UK) before being washed twice with Dulbecco’s 
Phosphate-Buffered Saline with calcium, magnesium, but without phenol red (referred to as 
DPBS+) to remove suspended collagen.  
During the seeding procedure, viable cell numbers were calculated using a 
haemocytometer with 0.4 % Trypan Blue solution (Sigma Aldrich Company Ltd, Poole, UK) and 
seeded at a density of 2.5 x 104 cells/cm2, following media aspiration, washing with Dulbecco’s 
Phosphate-Buffered Saline without calcium, magnesium and phenol red (referred to as DPBS-) 
and trypsinisation with 0.25% Trypsin-EDTA solution (both from Gibco, Invitrogen,). All 
hCMEC/D3s used in this thesis were between the passages of 25 to 35.  
For routine culturing, hCMEC/D3 cells were grown using the Clonetics® EGM®-2MV 
BulletKit® (Lonza, Wokingham, UK).  The kit contains endothelial basal medium (EBM-2 ) which 
was supplemented with the enclosed SingleQuots™ of insulin-like growth factor-1, vascular 
endothelial growth factor, epidermal growth factor, hydrocortisone and basic fibroblast 
growth factor (bFGF) according to the manufacturer’s instructions and as previously described 
(Poller et al., 2008).  Lonza has optimised the composition of this medium and so declined to 
disclose the concentrations of the supplements.  Next, sterile filtered foetal bovine serum 
(FBS), also contained within the BulletKit®, was added to the media (becoming 2.5% of total 
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volume), along with penicillin-streptomycin (Gibco, Invitrogen, Paisley, UK) (also at 2.5%) and 
HEPES (Sigma Aldrich Company Ltd, Poole, UK) to 10mM. The final volume of the complete 
media was 500mls. Cells were grown in an incubator with a saturated humidity at 37°C in 5% 
CO2 and 95% fresh air and grown to 80-90% confluency before seeding (after 3-4 days) with 
media changed every 2-3 days.  
For storing, cells were frozen in 1ml aliquots in 95% FBS ‘gold’ (PAA the Cell Culture 
Company, Yeovil, Somerset, UK) with 5% dimethyl sulfoxide (DMSO, Sigma Aldrich Company 
Ltd, UK) for 24 hours at -80˚C, before being placed in liquid nitrogen.  When growing stocks of 
cells (frozen cells stored in liquid nitrogen), the vials were thawed quickly in a 37°C water bath 
and the contents added with warm media to a collagen pre-coated flask and media was 
renewed after 24 hours, allowing time for cells to attach and debris and DMSO to be removed. 
2.1.3. Culturing in 96-well plates 
For experiments examining the accumulation and toxicity of molecules in the hCMEC/D3 
cells, 96-well plates (Thermo Scientific Nunc™, UK) were pre-coated with 0.1mg/ml rat tail 
collagen type-I, and cells seeded and cultured as in section 2.1.2, except when 96 well plates 
were used for MTT assays assessing toxicity in permeability medium (see sections 3.2.2 for 
permeability medium description and section 2.5 for the MTT assay). They were then grown to 
100% confluency (reached at 4-5 days) and left for a further 3 days before experimentation 
(therefore 7-8 days after initial seeding to allow contact inhibition of cells to initiate 
differentiation into BBB phenotype) with media changed every 2-3 days. 
2.2. Accumulation assay 
Drug accumulation experiments were performed on confluent monolayers of hCMEC/D3s, 
grown in the centre 60 wells of sterile 96 well plates (see figure below). The accumulation 
assays used in this thesis are a modified version of a previous assay developed by our group 
(Chishty et al., 2004).  Medium was removed from wells and replaced with a 37˚C pre-heated 
200µl aliquot of accumulation buffer consisting of sterile distilled water (dH2O), 135mM NaCl, 
10mM HEPES, 5.4mM KCL, 1.5mM CaCl2, 1.2mM MgCl2, 1.1mM glucose, all sterile filtered with 
a 0.2µm filter and purchased from Sigma Aldrich Company Ltd, Poole, UK and adjusted to pH 
7.4 with 1M HCL.  The stock solutions of these accumulation buffer components are described 
in appendix section 1.1. The radiolabelled test molecule (labelled with tritium, [3H]), and 
carbon-14 labelled sucrose ([14C]sucrose, which is a marker of non-specific binding and 
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extracellular space because it has no transporter at the BBB and crosses only in negligible 
amounts (Ennis and Betz, 1986), with or without unlabelled transporter inhibitor/substrate 
(see Table 2.1 below) were then added to the accumulation buffer.  
Columns of wells (6 wells per column, 10 columns per plate) were exposed to the 
accumulation buffer for 1, 2.5, 5, 20 or 30 minutes. This allowed accumulation of the 
radiolabelled test molecules into the cells to be assessed. The accumulation assays were 
performed on a temperature-controlled shaker (THERMOstar, BMG Labtech, Offenburg, 
Germany) at 37˚C and 120 rpm. Once each column of cells had been exposed for the correct 
length of time to the radiolabelled test molecule containing buffer, the buffer was aspirated 
and wells were washed 3 times with ice-cold phosphate-buffered saline (PBS) 1x in dH2O 
(diluted from a 10x stock solution, pH 7.4, purchased from Gibco, Invitrogen, Paisley, UK) to 
stop any membrane transport processes and remove radiolabelled study molecules and buffer 
that had not accumulated in the cells.  The cells were then lysed by adding 200µl of 1% Triton 
x-100 in dH2O (Gibco, Invitrogen, Paisley, UK) per well for 1 hour at 37°C to liberate any 
accumulated radiolabelled test molecules and solubilise the cell proteins. 100µl of fluid from 
each well was then added to a scintillation vial along with 4 ml scintillation fluid (Optiphase 
Hisafe 2, PerkinElmer, UK) and counted using a Packard Tri-Carb 2900TR liquid scintillation 
counter to determine the radioactivity of each sample in disintegrations per minute (dpm). The 
remaining 100µl in each well were used to perform a BCA protein assay, using the wells around 
the central 60 as standards (see section 2.3). The procedure is outlined in figure 2.1. 
(Karunakaran et al., 2008, Zuzack et al., 1985, Yamauchi et al., 2009, Nadziejko and 
Reichberg, 1984, Mason et al., 2008, Matsson et al., 2009, O'Kane et al., 2006, Kakoki et al., 
2004, Weiss et al., 2007, Rosenbaum et al., 2005, Gibbs and Thomas, 2002, Sauer et al., 2010, 
Potschka et al., 2004) 
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Figure 2.1. Schematic diagram illustrating the standard accumulation assay. Cells 
(hCMEC/D3s) were grown in the centre 60 wells of 96-well plates for 7-8 days before 
experimentation. The media was removed and replaced with accumulation buffer containing 
the [3H]-labelled molecule of interest, [14C]sucrose as a marker of non-specific binding and 
extracellular space, with or without a transporter inhibitor/substrate (unlabelled drug on 
diagram). The cells were incubated in this buffer for a varying time up to 30 minutes 
depending on the type experiment (‘x’ minutes) before being lysed with 200µl 1% Triton X-100 
and taken for the BCA protein assay and liquid scintillation counting. 
 
2.3. BCA protein assay 
The Pierce® BCA protein assay (purchased from Thermo Scientific, Loughborough, UK) is a 
detergent-compatible kit using bicinchoninic acid (BCA) to colourimetrically quantify total 
protein from a sample. It is based on the reduction of Cu2+ to Cu1+ which in an alkaline 
environment reacts with BCA to produce a purple complex, whose absorbance can be read at 
562nm in a spectrophotometer. The kit reagents, ‘A’ and ‘B’ (mixed at a 50:1 ratio) were added 
to 100µl bovine serum albumin standards (BSA in dH2O) in empty wells on a 96-well plate, 
along with wells containing 100µl samples. The plates were then left at 37°C for 30 minutes 
and then read on a Labsystems Multiscan reader attached to a computer with Ascent 
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software. The protocol is outlined in detail in the manufacturer’s 2011 instruction manual 
(http://genome.med.yale.edu/images/a/aa/BCA.pdf). 
2.4. Expression of results 
Total accumulation of the radiolabelled study molecule was calculated as the sum of 
accumulation and efflux and termed the volume of distribution (Vd).  Vd is derived from the 
ratio of dpm/mg protein to dpm/µl buffer.  The Vd values for 
3H molecules were always 
corrected with the Vd values for background radiation (accumulation buffer alone without 
radioactive drugs in scintillation fluid) and [14C]sucrose, which was used as a marker of non-
specific binding, barrier integrity and extracellular space. 
2.5. (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) cytotoxicity assay 
The cytotoxic effects of the molecules used in this study were assessed using an (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole (MTT) assay, a 
colorimetric assay where MTT  is reduced to form a purple formazan in living cells, which can 
then be dissolved and measured spectrophotometrically (Denizot and Lang, 1986). The assay 
was performed on confluent monolayers of cells in 96-well plates grown in the medium type 
used for the particular study under investigation (normal or permeability media).   
Cells underwent incubations by the addition of a 200μl aliquot of accumulation buffer 
containing the radiolabelled and unlabelled test molecules into each well (see section 2.2). At 
the appropriate time, the buffer was aspirated and replaced with a 100μl aliquot of 1mg/ml 
MTT (Sigma Aldrich Company Ltd, UK) in Dulbecco’s modified Eagle’s medium (DMEM) without 
phenol red (Gibco, Invitrogen, UK). The cells were then placed for 4 hours at 37°C in an 
incubator, the solution was then removed and replaced with 100μl propan-2-ol (Sigma Aldrich 
Company Ltd, UK) per well, and the absorbance was measured at a wavelength of 560nm in 
the Multiscan reader with Ascent software as mentioned in section 2.3.  Absorbance values 
were corrected by protein content (determined using the BCA assay described in section 2.3 
on adjacent wells containing cells that were seeded at the same density) and expressed as 
percentage viability compared to control untreated cells. 
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2.6. Data analysis 
Comparisons were made between control plates of cells and differences at p < 0.05 
considered significant. Multiple-time accumulation, data were analysed by Two Way Repeated 
Measures ANOVA tests and Holm-Sidak posthoc tests, MTT assay and permeability assay data 
were compared against controls using One Way ANOVA and Bonferonni post-hoc tests using 
Sigma Plot version 11.0 software (SPSS Science Software UK Ltd, Birmingham UK). All data are 
expressed as mean ± SEM, except MTT data which are expressed as percentage viability. 
2.7. SDS-PAGE and Western blotting 
The expression of specific cell proteins under investigation were determined using the well 
known protein analytical techniques of sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and western blotting (WB). These procedures allow cell proteins to 
be denatured and separated by their molecular weight, transferred to a membrane and 
detected with specific antibody probing (Towbin et al., 1979). The procedure is outlined in 
brief in figure 2.2 below. The whole protocol was developed with personal communication 
from Dr. Rachel Brown’s WB protocol with permission and optimisation.   
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Figure 2.2. A schematic outlining the procedures of the protein analytical techniques of SDS-
PAGE and western blotting, based on personal communication with Dr Rachel Brown. 
2.7.1. Sample preparation 
To validate protein expression during experimental conditions, cells were grown in 6-well 
plates (Thermo Scientific Nunc™, Thermo Scientific Nunclon™, Loughborough, UK) for the 
same time period and in the same media used in experiments (see results chapters), before 
being turned into lysates for SDS-PAGE and WB. Once this stage was reached plates were 
placed on ice, media was aspirated from cells, and they were washed twice (wash, aspirate) 
with ice-cold PBS. 200µl of ice-cold TGN lysis buffer consisting of 50mM Tris, 150mM NaCl, 
10% glycerol, 50mM glycerophosphate B, 1% Tween-20 and 0.2% NP-40 (all purchased from 
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Sigma Aldrich Company Ltd, Poole, UK, see Appendix  1.2 for stock solution details) was then 
added to each well. The wells were then scraped repeatedly with a cold plastic cell scraper 
(Greiner Bio-One Ltd, Gloucestershire, UK) for several minutes and the cell suspension was 
transferred to a pre-cooled 1.5 ml tube along with a 1:100 aliquot of Proteoblock™ protease 
inhibitor cocktail (Fermentas Life Sciences, North Yorkshire, UK) and left on ice for 30 minutes, 
occasionally vortexed to maintain agitation and allow solubilisation of the proteins. The tubes 
were then centrifuged at 12,000 rpm for 20 minutes at 4°C using a Thermo Electron 
Corporation Heraeus Fresco17 bench-top micro-centrifuge. Following centrifugation, the 
supernatants were then aspirated into fresh pre-cooled 1.5 ml tubes on ice and the pellets 
discarded. The protein content of the supernatants was quantified using a BCA protein assay 
(section 2.3) and then stored at -20°C until use. Before SDS-PAGE, cell lysates were thawed at 
RT and had loading buffer added, before being boiled at 95°C for 5 minutes. The loading buffer 
was purchased from Fermentas (Fermentas Life Sciences, North Yorkshire, UK) in a 5x 
concentration and consisted of 0.313 M Tris-HCl (pH 6.8 at 25°C), 10% SDS, 0.05% 
bromophenol blue and 50% glycerol. 100µl of β-mercaptoethanol (Sigma Aldrich Company Ltd, 
Poole, UK) was added per 1 ml of the 5x loading buffer to act as a protein disulphide bridge 
reducing agent.  This mix was added with a sample of the thawed cell lysate to become 1x. The 
buffer not only allows the lysates to be viewed easily for loading into and running through the 
gel, but denatures the proteins along with the boiling step, allowing smooth migration of the 
proteins down the gel, with their migration patterns dependant on molecular weight (MW).  
2.7.2. SDS-PAGE 
Prior to one-dimensional electrophoresis, 1mm polyacrylamide gels were prepared.  
Polyacrylamide gels form from the polymerisation of acrylamide with the cross-linking agent N, 
N-methlenebisacrylamide (Bis).  The polymerisation is initiated with the addition of ammonium 
persulfate (APS) and N,N,N’,N’-tetramethylenediamine (TEMED). Gels differ by the relative size 
of their pores which is determined by the total amount of acrylamide and cross-linker present. 
These differences are denoted as percentages. The lower the percentage, the larger the pores 
and so the easier it is for larger proteins to move through the gel during electrophoresis. 
Polyacrylamide gels consist of stacking gels where protein is loaded and separating gels where 
the proteins are separated by their MW. The % of separating gels varied depending on the 
protein under investigation. For most WBs a 10% gel was used (see appendix 1.3 for the 
recipe). But in some circumstances a precast 4-20% gel was used (Biorad Europe, Hemel 
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Hempstead, UK). The stacking gels used in all SDS-PAGE in this thesis were 4% (please see 
appendix 1.3 for the recipe). Separating gels were constructed in Biorad Mini-Protean 3 tanks 
and left to set for about 1 hour before stacking gels were set on top for a further hour, 
complete with plastic combs that formed the protein loading wells when removed. The gels 
were then placed in Biorad mini gel apparatus which was filled with running buffer (see 
appendix 1.3). Prepared samples (see previous section, 2.7.1) were then loaded into the wells 
along with Page Ruler™ Prestained 10-170 kDa Protein Ladder (Fermentas Life Sciences, North 
Yorkshire, UK) and electrophoresis took place once the power was switched on to 125V until 
the blue dye ran to the bottom (anode) of the gel. The gel was then removed, resized and 
prepared for the transfer stage. 
2.7.3. Western blot 
Once the gel was removed, it was soaked in transfer buffer (see appendix 1.3) for 20 
minutes prior to the semi-dry transfer, using an Invitrogen Novex® Semi-dry blotter. While the 
gel was equilibrating, other components used to make the transfer sandwich (see figure 2.4), 
were prepared. Invitrogen filter paper was also pre-soaked in transfer buffer along with 
methanol-activated 0.45µm Immobilon-P polyvinylidene fluoride (PVDF) membrane (Millipore 
UK Ltd, Watford, UK). This membrane has a high affinity for amino acids and during the 
transfer, immobilises proteins to its surface which can then be probed with specific antibodies. 
Once all components were soaked, the sandwich was prepared carefully with a roller to 
remove any bubbles and the semi-dry blotter lid (cathode) was placed on top.  Transfer 
commenced for 30-50 minutes at constant 25V.   
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Figure 2.3.  The transfer sandwich. A schematic of the semi-dry transfer sandwich set-up used 
to transfer proteins from polyacrylamide gels used in western blotting. 
Following transfer, the PVDF membrane was removed and immediately incubated for 2 
hours under constant agitation at RT in blocking buffer consisting of PBS-Tween (PBS-T, see 
appendix 1.3) with 5% milk powder, (Tesco, UK) to stop non-specific binding of the antibodies 
to the membrane. After blocking, membranes were washed twice with PBS-T and incubated 
with the necessary protein specific primary antibody (see Table 2.2) in PBS-T with 0.5% BSA 
overnight at 4°C under constant agitation. Following the overnight primary incubation, 
membranes were washed three times (20 minutes each time) in PBS-T, before being incubated 
with the appropriate horseradish peroxidise (HRP) conjugated secondary antibody (see table 
2.2 below) for 1 hour at RT. HRP produces a detectable signal during enhanced 
chemiluminescence (ECL) which is visualised during the development phase.  
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Table 2.2. Details of antibodies used for protein expression studies. 









Ltd, Buckingham, UK). 
WB dilution - 1:1000 
in PBS-T with 0.5% 
BSA. IF dilution – 
1:500 in PBS. 
Goat anti-Rabbit HRP 
conjugated polyclonal 
(Abcam, Cambridge, 
UK). Dilution – 1:5000 
in PBS-T with 0.5% 
BSA. 
Goat anti-rabbit 
Alexa Fluor 488 
conjugated 
(Invitrogen, Paisley, 







UK). WB dilution - 
1:1000 in PBS-T with 





Dilution – 1:2000 in 






Cambridge, UK). WB 
dilution - 1:250 in 
PBS-T with 0.5% BSA. 
IF dilution – 1:100 in 
PBS. 
Goat anti-Rabbit HRP 
conjugated polyclonal 
(Abcam, Cambridge, 
UK). Dilution – 1:5000 
in PBS-T with 0.5% 
BSA. 
Goat anti-rabbit 
Alexa Fluor 488 
conjugated 
(Invitrogen, Paisley, 






UK). WB dilution – 
0.2µg/ml PBS-T with 
0.5% BSA. 




Dilution – 1:2500 in 








WB dilution – 1:2000 
in PBS-T with 0.5% 
BSA. 
Goat anti-Rabbit HRP 
conjugated polyclonal 
(Abcam, Cambridge, 
UK). Dilution – 1:5000 
in PBS-T with 0.5% 
BSA. 
__ 
 INTERACTIONS OF ENDOGENOUS AND EXOGENOUS MOLECULES WITH 








Manchester, UK). WB 
dilution – 1:2000 in 





Dilution – 1:2000 in 






UK). WB dilution – 






Dilution – 1:2000 in 





(Millipore UK Ltd, 
Watford, UK). IF 
dilution – 0.5µg/ml 
PBS. 
__ 
Goat anti-mouse 546 
conjugated polyclonal 
(Abcam, Cambridge, 





Stockport, UK). IF 




Alexa Fluor 488 
conjugated 
(Invitrogen, Paisley, 





UK). IF dilution – 
1µg/ml in PBS. 
__ 
Goat anti-rabbit 546 
conjugated polyclonal 
(Abcam, Cambridge, 
UK). Dilution – 1:1000 
in PBS. 
ATB0,+ – amino acid transporter B0,+, BCRP – breast cancer resistance protein, CAT-1 – cationic 
amino acid transporter 1, DDAH-1 – dimethylarginine dimethylaminohydrolase 1, eNOS – 
endothelial nitric oxide synthase, GAPDH - glyceraldehyde 3-phosphate dehydrogenase, IF – 
immunofluorescence, PBS – phosphate buffered saline, P-gp – P-glycoprotein, VCAM-1 – 
vascular cell adhesion molecule 1, vWF – von Willebrand factor, WB – western blot, ZO-1 – 
zonula occludens 1.  
 
After the secondary incubation, the membrane was washed three times (20 minutes each) 
in PBS-T before being taken to the dark room where 1:1 Pierce ECL Detection Reagent 1 and 2 
were added (Thermo Scientific, Loughborough, UK) and incubated with the membrane for 5 
minutes at RT. Membranes were then wrapped in cling film and exposed to Kodak(R) BioMax™ 
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XAR film (Sigma Aldrich Company Ltd, Poole, UK) which in turn was processed in an automatic 
Fuji table top X-ray developer machine. 
2.8. Immunofluorescence (IF) 
For protein visualisation studies, IF studies were performed. The protocols used were based 
on an adapted version of a published immunofluorescence procedure (Miecz et al., 2008) and 
advice from Mr. Enrico Cristante of Imperial College London (for filter staining).  
The hCMEC/D3 cells, grown on sterile rat-tail collagen type 1 coated glass coverslips or 12-
well transwell filters, had their medium removed and were washed twice rapidly with HBSS at 
RT, before being fixed with 4% formaldehyde (Sigma Aldrich Company Ltd) in PBS for 10 
minutes at 4°C. The coverslips and filters were then washed three times with PBS and 
permeablised for 5 minutes with 0.1% Triton X-100 in PBS at room temperature (RT). Next, 
coverslips and filters were washed three times in PBS and then non-specific binding was 
blocked by incubating the coverslips in PBS containing 10% goat serum (Sigma Aldrich 
Company Ltd) and 0.1% Triton X-100 for 30 minutes at RT. Following this, the coverslips and 
filters were incubated overnight at 4°C with primary antibody under constant agitation (please 
see table 2.2 above for list of antibodies). Following overnight incubation, coverslips were 
washed three times with PBS and the fluorescent secondary antibodies were added for 1 hour 
at RT under constant agitation. The coverslips were then washed in PBS twice, and incubated 
in PBS containing 0.1μg/ml 4',6-diamidino-2-phenylindole (DAPI) blue nucleus stain (New 
England Biolabs, Bristol, UK) for 30 minutes under agitation at RT. Coverslips and filters were 
subsequently washed a final time in PBS, dipped in dH2O and mounted onto slides with PVA-
DABCO® mounting medium (Invitrogen, Paisley, UK). Filters were mounted onto coverslips 
before being mounted onto slides. The slides were then left to dry at 4°C overnight before 
microscopy.  
2.9. Octanol saline partition coefficient (OSPC) 
A partition coefficient is a measure of differential solubility of a compound between two 
immiscible solvents which are at equilibrium (Leo et al., 1971). As such, it allows a prediction of 
a molecules distribution in the body. 1µCi/0.037 MBq of the radiolabelled test molecule was 
added to 3ml of 1 x PBS (pH 7.4, Gibco, Invitrogen, Paisley, UK) at room temperature (RT) and 
vortexed thoroughly. Then, equal volumes (0.75 ml) of the radioactive PBS and octanol (1-
octanol, purchased from Sigma Aldrich Company Ltd, Poole, UK) were added together in a 1.5 
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ml tube and shaken vigorously before being centrifuged at 4000 rpm for 5 minutes in a Thermo 
Electron Corporation Heraeus Fresco17 bench-top micro-centrifuge. The upper phase (octanol) 
and lower saline phase (aqueous) were then separated carefully and 3 times 100µl samples 
from each phase per tube were added to scintillation vials containing 3.5 ml scintillation fluid 
and the radioactivity was determined using the Packard Tri-Carb 2900TR liquid scintillation 
counter as described in section 2.2. The partition coefficient was calculated as the ratio of 
labelled substance in the octanol phase to concentration in the PBS/aqueous phase (Williams 
et al., 1996). All OSPC measurements were performed in triplicate. 
2.10. Software used for thesis 
The thesis was written using Microsoft Word 2007 edition from Microsoft Office, with 
diagrams made in Microsoft PowerPoint. Referencing was done using EndNote X3 software 
under licence from King’s College London. For confocal imaging, Zen 2009 software was used 
before photos were annotated in PowerPoint. Western blots were scanned and also annotated 
in PowerPoint. Data were collected and processed in Microsoft Excel and annotated in 
GraphPad Prism 5 before display here. 
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Chapter 3. Endogenous molecule 
interactions – Part I – Effects of ADMA on 
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3.1. Chapter 3 – Introduction and aims 
Associations between ADMA and endothelial dysfunction have been made in a variety of 
pathological conditions including chronic heart failure, renal failure, and a variety of diabetic 
complications such as renin-angiotensin system (RAS)-mediated diabetic retinopathy (Boger et 
al., 1998, Leiper et al., 2007, Chen et al., 2009, Chen et al., 2011). ADMA and DDAH have also 
recently been implicated as regulators of pulmonary endothelial barrier function through the 
modulation of small GTPases. This has been demonstrated in both in vitro and in vivo with 
mouse models (Wojciak-Stothard et al., 2007, Wojciak-Stothard et al., 2009). 
One of the hallmarks of endothelial dysfunction is an increase in leakiness via the 
paracellular route. Whereas the abovementioned studies investigated the effects of ADMA on 
endothelium away from the cerebral vasculature, no group has yet studied ADMA and the 
BBB. This is of particular importance because not only is BBB integrity paramount for 
maintaining homeostasis within the cerebral microenvironment, but concentrations of ADMA 
are increased in brain and cerebrovascular disorders such as ischemic stroke – where ADMA 
has also been implicated in endothelial dysfunction (Scherbakov et al., 2012).  
Therefore, with the association between ADMA and brain pathologies growing, we decided 
to investigate the effects of ADMA on the integrity of the human BBB in vitro using the 
hCMEC/D3 cell line in a paracellular permeability model. Other in vitro studies have only 
investigated ADMA in on-cerebral endothelial dysfunction at high concentrations (100µM), so 
we decided to look at a range covering the physiological and pathophysiological 
concentrations of ADMA. We hypothesised that ADMA would lead to increased BBB 
permeability, especially at higher concentrations in line with previous non-BBB studies, but 
didn’t rule out the possibility that lower concentrations may also induce permeability changes. 
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A major issue with BBB research (as with most other fields) is that the wide variety of 
models in use can make it difficult to relate and compare data, particularly between species. 
For example, much of the CAA transport work has utilised single cloned transporters expressed 
in Xenopus laevis oocytes and this is unlikely to give an accurate indication of the situation in 
mammalian systems where multiple transporters are present. To shed light on the situation at 
the human BBB and to keep our findings consistent throughout this thesis, we used the 
commercially available hCMEC/D3 immortalised in vitro BBB model in all of our investigations.  
3.2.1. Cell culture 
Please see chapter 2, sections 2.1.1 and 2.1.2 for details of hCMEC/D3 source and culture 
conditions.  
3.2.2. Culturing on Transwell filter inserts 
For experiments examining the transendothelial permeability of molecules across the 
hCMEC/D3 cell line, cells were seeded onto Transwell filter inserts (filters) on 12-well plates 
(Corning® Transwell® polyester membrane inserts, pore size 0.4μm, membrane diameter 1.12 
cm2, Sigma Aldrich Company Ltd, Poole, UK) at a density of 120,000 cells per filter (determined 
using a haemocytometer as described in section 2.1.2). Filters were pre-coated for 2 hours 
with 0.15mg/ml rat tail collagen type-I in HBSS, before being washed once with DPBS+ at 37˚C 
and then incubated in permeability media before seeding (0.5 ml in donor well/filter insert and 
1.5 ml in receiver wells, see figure 3.1 below).   
The permeability media is a reduced growth factor media which has been optimised by 
Professor Pierre O. Couraud’s group (Institut Cochin, Université Paris Descartes, CNRS, Paris, 
France) and follows an established protocol allowing the cells to differentiate and form 
restrictive tight junctions, restricting paracellular permeability (Poller et al., 2008, Zougbede et 
al., 2011). Permeability media consisted of EBM-2 endothelial basal medium from the 
Clonetics® EGM®-2MV BulletKit® with 5% FBS ‘gold’ (PAA the Cell Culture Company, UK), 1% 
penicillin-streptomycin (Gibco, Invitrogen, UK), 1.4µM hydrocortisone, 5µg/ml ascorbic acid, 
10mM HEPES and 1ng/ml bFGF, all purchased from Sigma Aldrich Company Ltd, UK. The cells 
were also grown in an incubator with a saturated humidity at 37°C in 5% CO2 and 95% fresh 
air. Media was changed every 2-3 days and cells used for experiments were between 8-10 days 
post-seeding. 
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Figure 3.1. The donor and receiver well arrangement on 12-well plates, used for permeability 
studies. Inserts contained 0.5ml media and donor wells contained 1.5ml media. 
3.2.3. Transendothelial electrical resistance (TEER) 
When studying transendothelial permeability of molecules across a BBB cell monolayer, it is 
important to check the paracellular tightness of any in vitro model. This is to ensure the effects 
you are seeing are down to transendothelial membrane permeation, rather than leakiness 
through the paracellular (TJ) pathway. TEER gives such a measurement of BBB integrity, 
functional tight junctions and overall cell monolayer paracellular restrictiveness by measuring 
ionic permeability. The method gives a real time reading in a discreet fashion, monitoring BBB 
‘physical barrier’ development in a model intended for the measurement of molecule 
permeability (such as drugs). Electrical resistance is derived from Ohm’s law where V=IR (V for 
voltage, I for current, R for resistance).  As current pulses are passed across the cell monolayer, 
the presence of effective tight junctions will impede the paracellular permeation of ion which 
carry the current, and therefore reduce the resulting voltage drop, registering as recording of 
resistance.   
TEER was measured with an STX-100C chopstick electrode pair connected to an EVOM 
meter (World Precision Instruments, WPI, Inc., Sarasota, FL, USA). Before measurement, the 
STX-100C chopstick electrode was first immersed in ethanol (70% v/v) for 20 minutes to 
sterilise it in a sterile hood. The electrode pair was then immersed in the same medium the 
cells were growing in (D5546) for 5 minutes to wash off the ethanol and equilibrate to the 
same conditions as the cells.  The 12-well plate cover was removed and replaced with a 
custom-made (Mr. B. Taylor, King’s College London) 12-well plate jig (first sterilised with 70% 
ethanol before use) for holding the electrode in place over the filters. The jig kept constant the 
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depth of the electrode pair in the inserts and the wells and produced a stable and reliable 
reading on the EVOM meter with minimal handling.   
To obtain the TEER of a cell monolayer, the resistance (Ω) of a collagen-coated blank filter 
insert (without cells but kept in the same media conditions and time-frame as cells) was 
subtracted from the resistance measured across the insert with cell monolayer. The resulting 
value was multiplied by the surface area of the filter insert (1.12 cm2) to express results as 
Ωcm2.  
This protocol and equipment were developed by Dr. Siti Yusof and Professor Joan Abbott 
and used with permission for the work described in this thesis. 
3.2.4. Expression of endothelial markers vWF, VCAM-1 and ZO-1 
As the hCMEC/D3 model was new to our group, it was necessary to inaugurate the cell line 
by looking for endothelial markers before moving on to investigations. The vascular 
endothelial markers vWF (Hirano et al., 2000) and inducible VCAM-1 (Li et al., 1993, Schram et 
al., 2003, Weksler et al., 2005) and the TJ protein ZO-1 (Wolburg and Lippoldt, 2002), were 
therefore visualised to confirm an endothelial phenotype and establish the hCMEC/D3 cell line 
in our group. The protocol is detailed in chapter 2, section 2.8. 
Briefly, following preparation and fixing, cells grown on rat tail collagen type-1 coated 
sterile glass the coverslips were incubated overnight at 4°C with primary antibody (either anti-
vWF at 1:200 in PBS, or anti-VCAM-1 at 0.5µg/ml PBS) and for cells grown on 12-well transwell 
filters incubated with anti-ZO-1 at 1µg/ml in PBS under constant agitation (please see table 2.2 
in chapter 2 for sources of antibodies). Following overnight incubation, coverslips and filters 
were washed with PBS three times and incubated with the fluorescent secondary antibodies. 
For vWF, goat anti-rabbit Alexa Fluor 488 conjugated secondary antibody was diluted at 1:200 
in PBS. For VCAM-1, goat anti-mouse 546 conjugated polyclonal was diluted at 1:1000 in PBS, 
and for ZO-1, goat anti-rabbit 546 conjugated polyclonal was diluted at 1:1000 in PBS (see 
table 2.2 for source details of secondary antibodies).  
Following mounting and drying, the slides were then left to dry at 4°C overnight before 
being viewed at 63x with oil emersion using a Zeiss LSM710 confocal microscope and image 
analysis software Zen 2009 (Zeiss, Germany).  
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As VCAM-1 expression is inducible by pro-inflammatory cytokines, it was required that cells 
were stimulated overnight with 5ng/ml human recombinant human tumour necrosis factor 
alpha (TNF-α, Gibco, Invitrogen, UK) before fixing and staining. Staining without TNF-α 
stimulation was also performed to investigate baseline expression. 
3.2.5. Permeability assay 
To investigate the effect of ADMA on the integrity of the hCMEC/D3s, the paracellular 
permeability was investigated using permeability assays on confluent monolayers of 
hCMEC/D3s grown on 12-well plate transwell filter inserts, as described in section 3.2.2. The 
assay was kindly demonstrated to me by Mr. Miguel Alejandro Lopez-Ramirez of the Open 
University, UK.  
At 8-10 days post seeding, the TEER of the monolayers on the filters was measured as 
described in section 3.2.3, at least 4 hours before the assay. Filters with TEERs less than the 
standard hCMEC/D3 TEER value of 30 ohm.cm2 were not used for the permeability assays. For 
the permeability assays, permeability media was replaced 24 hours before the assay in both 
the insert (0.5ml) and donor wells (1.5ml) with fresh media containing one of the following 
concentrations: 0.5µM ADMA, 3µM ADMA, 10µM ADMA, 100µM ADMA or 500µM ADMA. In a 
separate series of experiments, media was added to the cells for 24 hours containing either L-
NIO (a non-selective inhibitor of NOS isoforms, manufactured by Cayman Chemicals and 
purchased from Cambridge Bioscience Ltd, Cambridge, UK) at a concentration of 5µM (which is 
within the 3.9µM Ki range of eNOS (Rees et al., 1990), or 5ng/ml recombinant human TNF- α 
with 5ng/ml recombinant human IFN-γ (Gibco, Invitrogen, UK).  
On the day of the experiment, this media was removed from the transwell filter insert and 
the donor well, and 1.5ml pre-warmed (to 37°C) DMEM (without phenol red) + 2% FBS Gold 
was added to the wells of fresh 12-well plates.  40kDa fluorescein isothiocyanate labelled 
dextran (FITC-Dex) was diluted to 2mg/ml in a separate vial of DMEM + 2% FBS assay media 
and used as a BBB paracellular marker for the assay (Hoffmann et al., 2011) by adding 0.5ml of 
it to the transwell filter insert only (see figure 3.2).  
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Figure 3.2. Schematic of transwell permeability assay using FITC labelled dextran (40 kDa). 
hCMEC/D3 cells, seeded onto transwell filter inserts on 12-well plates were grown for 8-10 
days, before the permeability media in both the insert and donor wells was replaced with fresh 
permeability media containing either 0.5µM ADMA, 3µM ADMA, 10µM ADMA, 100µM ADMA 
or 500µM ADMA. 5µM L-NIO or 5ng/ml TNF-α & 5ng/ml IFN-γ were used also added to the 
media and incubated for 24 hours in a separate series of experiments. 24 hours later, the 
media was removed from the insert and donor well and DMEM + 2% FBS was added to well in 
a fresh 12-well plate. The inserts were then added to the DMEM + 2% FBS wells and DMEM + 
2% FBS with 2mg/ml 40kDa FITC-Dex was added to the insert only. The inserts were then 
moved to a fresh well every 10 minutes for 60 minutes, before the fluorescence of the wells 
were measured with a fluorescent plate reader. See text for further description. 
 
The filter was then moved into a new donor well on flat bottom 12-well plates (containing 
DMEM + 2% FBS) at 10-minute intervals for 60 minutes. The assay was performed in a sterile 
flow-cabinet and incubated in a cell culture incubator between filter insert moves. The 
fluorescence in each well of 12-well plate was then measured in a FlexStation® 3 Bench top 
Multi-Mode Microplate fluorescent plate reader at an excitation wavelength of 485nm and 
emission wavelength of 530nm, using SoftMax® Pro Microplate Data Acquisition & Analysis 
software.  
As a precautionary measure, the impact of media change on the TEER of the monolayers 
was also measured in a separate series of experiments. Cells on filters had their TEER 
measured before media change (at resting after 8 days post-seeding) and 1 hour after media 
change with either normal permeability media (as described in 3.2.4) or permeability assay 
media (DMEM + 2% FBS). 
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Permeability of FITC-Dex over the treatments is given as permeability coefficients which 
take into account the relation between the permeability of the monolayer and the 
permeability of empty filter pre-coated with rat-tail collagen type-1 (without cells). These 
calculations are based on work by (Dehouck et al., 1992) and (Cecchelli et al., 1999), and have 
been used in subsequent hCMEC/D3 publications (Weksler et al., 2005, Poller et al., 2008, Tai 
et al., 2009c). The clearance of each filter relates to clearance of empty filter wells. The 
equations are expressed below (equation 3.1 and equation 3.2). 
The cleared volume (in µl/ml) represents the volume of FITC-Dex solution passing through 
the cell monolayer at a particular time. It was calculated as: 




where AUa is the total fluorescence (arbitrary units) in the donor compartment, AUb is the 
background fluorescence, and Fi is the fluorescence of the initial solution (Au/ml). The volume 
cleared was plotted against time, and the slope curves were used to calculate permeability 





    
 
 
   




where PSef is the gradient of the curve for cells grown on filters, and PSf is the gradient of the 
curve for filter alone (both ml/min). PS is the permeability surface area of the cell monolayer 
(ml/min) and S is the surface area of the filter. The higher the Pe value, the more permeable a 
monolayer is to FITC-Dex (Tai et al., 2009c). 
3.2.6. Cytotoxicity assay 
The potential of the treatments used in this accumulation study to cause cytotoxicity to the 
hCMEC/D3 cells was assessed using an MTT assay, the protocol of which is described in section 
2.5. The effect of these compounds was compared to untreated control hCMEC/D3 cells.  
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3.2.7. eNOS and DDAH-1 expression  
To investigate the expression of eNOS and DDAH-1 in the hCMEC/D3s, SDS-PAGE and WBs 
were performed (as described in methods section 2.7) on whole cell lysates, prepared in TGN 
lysis buffer as described in 2.7.1. Lysates were prepared from cells grown for 8 days in 
permeability medium. 30µg of each lysate was loaded per well. For eNOS and DDAH-1 
expression, human umbilical vein endothelial cell (HUVEC) whole cell lysate in RIPA buffer 
(purchased from Santa Cruz Biotechnology, Inc, California, US) was used as positive controls 
(Murakami et al., 2006, Zhang et al., 2011).  
Goat anti-human DDAH-1 primary antibody was used at a dilution of 0.2µg/ml PBS-T with 
0.5% BSA as described in table 2.2. Rabbit anti-human NOSIII/eNOS primary antibody was used 
at a dilution of 1:2000 in PBS-T and 0.5% BSA also as described in table 2.2. Rabbit anti-goat 
HRP conjugated secondary antibody was used at a dilution of 1:2500 in PBS-T with 0.5% BSA 
for chemiluminescence detection for DDAH-1 and goat anti-rabbit HRP conjugated secondary 
antibody was used at a dilution of 1:5000 in PBS-T with 0.5% BSA for chemiluminescence 
detection for eNOS. GAPDH was probed as a loading control using mouse anti-human primary 
antibody at 1:2000 in PBS-T with 0.5% BSA, and rabbit anti-mouse HRP conjugated secondary 
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3.3.1. Expression of endothelial phenotype 
The hCMEC/D3 cell line (displaying an endothelial phenotype in figure 3.3) was examined 
for evidence of vascular endothelial cell markers vWF (figure 3.4 a), inducible VCAM-1 before 
(figure 3.4 b) and after (figure 3.4 c) TNF-α stimulation, and the TJ protein ZO-1 (figure 3.5). 
Phase contrast microscopy of the hCMEC/D3 cells showed a typical ‘cobble-stone to spindle-
shaped morphology’ (Malek and Izumo, 1996). The IF results indicate normal expression of the 
markers comparable to other publications (see (Norgall et al., 2007) for example of vWF 
expression,(Thompson and Debinski, 1999) for example of human endothelial VCAM-1 
expression and (Weksler et al., 2005) for hCMEC/D3 ZO-1 expression. 
 
 
Figure 3.3. Phase contrast microscopy of hCMEC/D3 cells approaching confluency. Cells in 
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Figure 3.4. Immunofluorescence and confocal microscopy of vascular endothelial markers in 
hCMEC/D3 cells. a| hCMEC/D3 cells were grown on rat tail collagen type-1-coated coverslips 
fixed with 4% formaldehyde and stained for vWF with primary and secondary antibody as 
described in section 3.2.4. Cell nuclei were counterstained with 1µg/ml DAPI. For negative 
staining, cells were stained with secondary antibody only along with DAPI (inserts). b| 
hCMEC/D3 cells were grown on rat tail collagen type-1-coated coverslips, fixed, and stained for 
VCAM-1 without TNF-α stimulus with primary and secondary antibody as described in section 
3.2.4. Data illustrate negligible expression. Cell nuclei were counterstained with 1µg/ml DAPI. 
For negative staining, cells were stained with secondary antibody only along with DAPI 
(inserts). c| hCMEC/D3 cells were stained for VCAM-1 following overnight incubation with 
5ng/ml TNF-α stimulation (as above and in section 3.2.4), demonstrating increased expression. 
Cell nuclei were counterstained with 1µg/ml DAPI. For negative staining, cells were stained 
with secondary antibody only along with DAPI (inserts). Cells viewed at 63x with oil emersion 
using a Zeiss LSM710 confocal microscope. IF was carried out 3 times in duplicate (n=3). 
Results displayed are representative of the 6 coverslips used per stain. 
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Figure 3.5. Immunofluorescence and confocal microscopy of integral TJ protein, ZO-1 in 
hCMEC/D3 cells grown on transwell filters. hCMEC/D3 cells were grown on rat tail collagen 
type-1-coated transwell filters for 7 days, fixed with 4% formaldehyde and stained for ZO-1 
with primary and secondary antibody as described in section 3.2.4. Cell nuclei were 
counterstained with 1µg/ml DAPI. For negative staining, cells were stained with secondary 
antibody only along with DAPI (inserts). Cells viewed at 63x with oil emersion using a Zeiss 
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3.3.2. Treatment effects on TEER of hCMEC/D3 monolayers 
Before performing the permeability assay, the effects of the permeability assay media 
(DMEM + 2% FBS) on the TEER of the cell monolayers in comparison to normal permeability 
media (EGM2-MV) was investigated over 1 hour incubations following media change. There 
were no statistically significant differences in TEER values between any of the treatments as 
measured using a One-way ANOVA with Bonferroni’s Multiple Comparison post hoc test. Data 
are displayed in figure 3.6.   
 
Figure 3.6. Effects of permeability assay media on TEER of hCMEC/D3 monolayers grown on 
transwell filters. As a precautionary measure, the impact of the media change on the TEER of 
the hCMEC/D3 cells was investigated and compared to cells grown for 8 days in normal 
permeability media (before media change). TEER values following replenishment with normal 
permeability media and assay media following 1 hour incubations were investigated and 
compared. Each whiskers plot represents 6 filters. Data were analysed with One-way ANOVA 
and Bonferroni’s post hoc test. 
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3.3.3. Effects of ADMA on hCMEC/D3 permeability 
To investigate the impact of ADMA on the integrity of the hCMEC/D3s, cells grown on 
transwell filters for 8-10 days were incubated with a range of ADMA concentrations for 24 
hours before permeability assays with FITC-Dex. The concentrations of ADMA used reflected 
the physiological (0.5µM), pathophysiological (3µM) human plasma ranges, as well as 10µM 
and 100µM (values used in previous in vitro studies). 500µM was used as an extreme reference 
point. The data are displayed in figure 3.7 below.  
There were no significant differences between the 0.5µM, 3µM and 10µM ADMA 
treatments between each other or control cells (untreated) on the permeability of the 
hCMEC/D3 cells to FITC-Dex. However, the incubation of the cells with 100µM ADMA saw a 
significant increase in the permeability to FITC-Dex when compared to controls (52% increase, 
p<0.05) and 10µM ADMA (53% increase, p<0.05).  
The incubation of 500µM ADMA caused a significant increase in permeability when 
compared to all other ADMA treatments and controls (p<0.01 in all instances); 84% increase 
vs. controls; 67% increase vs. 0.5µM ADMA; 73% increase when compared to 3µM; and an 
85% increase compared to 10µM ADMA. There were no significant differences in permeability 
coefficients between 100µM and 500µM ADMA treatments. 
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Figure 3.7. Impact of ADMA on hCMEC/D3 permeability to 40kDa FITC-Dex. Confluent 
monolayers of hCMEC/D3 cells, grown on rat tail collagen type-1 coated transwell filter inserts 
for 8-10 days, were incubated for 24 hours with a range of ADMA concentrations and then 
their permeability to  40kDa FITC-Dex investigated from insert-to-donor well direction, and 
compared to control (untreated) cells. Data represent means ± SEM from 12-15 transwell filter 
inserts per treatment. Data analysed with One-way ANOVA and Bonferroni’s post hoc test. 
ADMA – asymmetric dimethylarginine. 
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3.3.4. Effects of L-NIO, TNF-α and IFN-γ on hCMEC/D3 permeability 
The potent eNOS inhibitor L-NIO and the pro-inflammatory cytokines TNF-α and IFN-γ were 
incubated with the hCMEC/D3s grown on transwell filter inserts, to investigate their effects on 
permeability to 40kDa FITC-Dex. The data are displayed below in figure 3.8. 
When compared to controls, 5µM L-NIO caused no significant changes in permeability. 
When incubated with 5ng/ml TNF-α and 5ng/ml IFN-γ, hCMEC/D3 cells had significantly 
increased permeability to FITC-Dex when compared to controls (p<0.001) and L-NIO (p<0.001). 
The percentage increases were 200% compared control and 204% compared to L-NIO.  
 
Figure 3.8. Impact of L-NIO, TNF-α and IFN-γ on hCMEC/D3 permeability to FITC-Dex. 
Confluent monolayers of hCMEC/D3 cells, grown on rat tail collagen type-1 coated transwell 
filter inserts for 8-10 days, were incubated for 24 hours with either 5µM L-NIO or 5ng/ml TNF-
α & 5ng/ml IFN-γ and then their permeability to 40kDa FITC-Dex investigated from insert-to-
donor well direction, and compared to control (untreated) cells. Data represent means ± SEM 
from 12 transwell filter inserts per treatment. Data analysed with One-way ANOVA and 
Bonferroni’s post hoc test. IFN-γ – interferon gamma, L-NIO – N-iminoethyl-L-ornithine, TNF-α 
– tumour necrosis factor alpha. 
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3.3.5. Cytotoxicity of treatments on hCMEC/D3 cells 
The cytotoxic potential of all compounds used in this study over the 24 hour time-frame 
was assessed in the hCMEC/D3 cells using an MTT assay, comparing treated cells to untreated 
control cells.  
There were significant decreases in cell viability between 100µM ADMA (p<0.05), 500µM 
(p<0.01), 5ng/ml TNF-α and 5ng/ml IFN-γ (p<0.01) when compared to control untreated cells 
(figure 3.9 below). 
 
Figure 3.9. Cytotoxicity of permeability treatments on hCMEC/D3s. The treatments used in 
this chapter were assessed for any cytotoxic potential using an MTT assay with confluent 
monolayers of hCMEC/D3 cells in 96 well plates, grown in permeability medium as described in 
section 2.5. The results are expressed as percentage viability ± S.E.M and compared to control 
untreated cells, which were incubated in permeability medium alone. TNF-α and IFN-γ were 
used together at 5ng/ml each. n=3 (plates), 6 replicates per n (6 wells). ADMA – asymmetric 
dimethylarginine, IFN-γ – interferon gamma, L-NIO – N-iminoethyl-L-ornithine, TNF-α – tumour 
necrosis factor alpha. 
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3.3.6. hCMEC/D3 expression of eNOS and DDAH-1 
To look for expression of the ADMA interacting enzymes eNOS and DDAH-1, SDS-PAGE and 
WBs were performed on hCMEC/D3 whole cell lysate, with HUVEC whole cell lysate used as 
positive controls. GAPDH was used as a loading control.  
Blots at the expected sizes (140kDa for eNOS and 37kDa for DDAH-1) were visible in both 
the hCMEC/D3s and HUVEC positive controls. The blots are displayed below in figure 3.10.  
 
 
Figure 3.10. The expression of eNOS and DDAH-1 in hCMEC/D3 cells. hCMEC/D3 cells were 
grown for 8 days in permeability media before being turned to lysate with TGN lysis buffer as 
described in section 3.2.7 and probed for eNOS and DDAH-1 expression, as well as GAPDH as a 
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The idea that ADMA plays roles in endothelial dysfunction and disease pathogenesis is 
gaining momentum due the accumulating in vitro and in vivo data from a variety of studies on 
different body regions. In the context of the brain and cerebrovasculature, ADMA has been 
implicated as not only a marker, but also a mediator of cerebral perfusion and cognitive 
impairment in microangiopathy-related cerebral damage (Kielstein and Kielstein, 2009, Notsu 
et al., 2009). In acute stroke, increased levels of ADMA have been observed in transient 
ischemic attacks and cardioembolic infarctions (Wanby et al., 2006, Scherbakov et al., 2012) 
and ADMA levels in CSF are believed to be correlated with stroke severity in humans (Brouns 
et al., 2009). ADMA has also been implicated in humans as a mediator of cerebral vascular 
tone, by increasing arterial stiffness and decreasing cerebral blood flow independent of blood-
pressure (Kielstein et al., 2006a). In relation to the BBB however, the action of ADMA on 
vascular tone occurs upstream of brain capillaries which are devoid of smooth muscle cells 
(Pardridge, 1999). Despite this, pericytes of the NVU act as contractile cells and it has been 
recently shown that ischemia induces sustained contraction of pericytes in microvessels of the 
mouse brain, impeding capillary microcirculation (Yemisci et al., 2009). Nitric oxide has also 
been shown to relax cultured bovine retinal pericytes (Haefliger et al., 1994).  If ADMA has any 
direct or indirect effects on pericytes and the BBB has not been studied and is likely to have 
wider implications on the cerebrovasculature and indeed peripheral vasculature, particularly at 
the level of the endothelium. We therefore decided to investigate its effects on the human 
BBB by using the hCMEC/D3 in vitro BBB model. 
Before we started these studies, we sought to establish the hCMEC/D3 in our group with 
expression studies of vascular endothelial markers, demonstrating the presence of vWF, 
inducible VCAM-1 and the TJ protein, ZO-1. The expression of inducible VCAM-1 and ZO-1 
matches the findings described using fluorescence-activated cell sorting and IF studies in the 
original hCMEC/D3 paper (Weksler et al., 2005). vWF expression has also been previously 
confirmed in the hCMEC/D3s (Fasler-Kan et al., 2010). These data, combined with the fact that 
the cells were grown under well-established conditions and sourced from the creators, 
satisfied us that the model was a suitable for our investigations. 
To investigate the effects of ADMA on the BBB, we used a permeability assay where the 
hCMEC/D3 cells were grown to confluence on filters in permeability medium and were 
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incubated for 24 hours with a range of ADMA concentrations. The Pe values obtained in this 
study are similar to those previously published with 40-70kDa FITC-Dextrans for the 
hCMEC/D3s, although in the lower range (Weksler et al., 2005, Forster et al., 2008). At the 
concentrations of 100µM and 500µM we observed significant increases in permeability to 
40KDa FITC-Dex when compared to untreated controls.  The permeability increase seen with 
500µM ADMA was also significantly higher than all other treatments, bar the 100µM ADMA 
treatment. These data are consistent with previous in vitro studies investigating ADMA and 
endothelial dysfunction. In one such study, Chen et al., used bovine retinal capillary 
endothelial cells in a permeability model with transwell filters, and similarly incubated the cells 
with 100µM ADMA for 24 hours. They illustrated a similar result to the one obtained here that 
ADMA significantly increased permeability to their paracellular marker (horseradish peroxidise 
which is 44kDa) (Chen et al., 2011). They also demonstrated that ADMA downregulated the 
expression of the TJ protein occludin in their cells, following 24 hour incubation with 100µM 
ADMA. In another study by Wojciak-Stothard et al., porcine pulmonary artery endothelial cells 
were used in a transwell permeability model and also incubated with 100µM ADMA for 24 
hours. The authors noted a significant increase in permeability compared to control cells 
(Wojciak-Stothard et al., 2009). In a more recent study, these findings were echoed when 
ADMA was shown to increase the permeability of HUVECs on transwell filter inserts to 40kDa 
FITC-Dex and FITC-apelin-13 (MW 2053) in a dose-dependent (25-200µM ADMA) and time-
dependent (4, 8, 16 and 24 hour) manner (Wang et al., 2011a).  
Chen et al., showed cell proliferation was markedly decreased by ADMA in a dose-
dependent manner, but did not link these effects as a possible explanation behind their 
increase in permeability. In our study, 24 hour incubations with 100µM and 500µM decreased 
cell viability, which are likely to explain the permeability increases. The mechanism of toxicity 
in our model however, was not investigated here and varies between studies. Interestingly, 
Chen et al., authors used antioxidants to reverse the ADMA-induced permeability affects, 
suggesting that it was the formation of ROS induced by ADMA that caused the permeability 
increase by inducing endothelial dysfunction (Chen et al., 2011). Wang et al., also attributed 
ADMA-induced ROS formation to increases in endothelial permeability by inhibiting the 
NADPH oxidase pathway – the major source of ROS in endothelium (Wang et al., 2011a). 
Wojciak-Stothard et al., conversely, did not find any evidence of ADMA-induced cytotoxicity 
(to 100µM ADMA) or that ROS formation had changed in their porcine pulmonary artery 
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endothelial cells, following ADMA incubation, but instead showed ADMA-induced cytoskeletal 
and adherens junction remodelling via modulation of the small GTPase Rac1 (Wojciak-Stothard 
et al., 2009). Small GTPases are widely implicated in the control of microvascular permeability; 
with Rac1 a major GTPase required for barrier stabilisation and maintenance (Spindler et al., 
2010). These conflicting observations could suggest that the impact of ADMA on ROS 
formation could be cell/tissue specific and dependent on sensitivity to oxidative stress. The 
brain and the cerebrovasculature for example are extremely sensitive to oxidative stress, due 
in part to the increased expression of NADPH-oxidase in BECs compared to peripheral 
endothelial cells (Uttara et al., 2009, Tripathy et al., 2010). One way in which ADMA is believed 
to induce ROS formation is by eNOS uncoupling. In an uncoupled state, electron flow from the 
reductase domain to the oxygenase domain of the enzyme are diverted to molecular oxygen 
rather than to L-arginine, resulting in the production of superoxides instead of NO (Sydow and 
Munzel, 2003). With this in mind, we looked for and confirmed the expression of eNOS in our 
cells. The addition of the eNOS inhibitor L-NIO in our permeability experiments however, did 
not induce any significant differences in permeability, although the action of the inhibitor has 
not been demonstrated to induce ROS formation. Therefore, it remains possible that in our 
model ADMA could induce ROS formation via eNOS uncoupling – in a dose-dependent fashion 
– resulting in decreases in cell viability. Yemisci et al., showed microvessels are major site of 
superoxide and peroxynitrite production following ischemia (Yemisci et al., 2009).  
Another possibility is that under such conditions of oxidative stress, DDAH activity could be 
inhibited as a growing body of data suggest that DDAH enzymes are highly susceptible to 
oxidative and nitrosative stress, which decreases their ADMA-metabolising abilities (Sydow 
and Munzel, 2003, Sydow et al., 2003, Palm et al., 2007). For example, in one study, both 
human dermal microvascular endothelial cells and rat vascular smooth muscle cells incubated 
in high glucose (25.5mmol/L) showed significantly decreased DDAH activity compared to 
controls, due to the increased oxidative stress induced by the hyperglyemia (Lin et al., 2002). 
These effects were reversed by co-incubation with antioxidants. In another study using rat 
kidney homogenates, it was demonstrated that the superoxide donor 2,3-dimethoxy-1,4-
naphthoquinone was able to significantly reduce the activity of DDAH in a dose-dependent 
manner (Tain and Baylis, 2007). In conditions such as hypoxia and stoke, oxidative stress is 
increased in the cerebrovasculature, promoting conditions associated with diminished DDAH 
function (see (Sandoval and Witt, 2008) and (Chrissobolis et al., 2011) for extensive reviews). 
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We looked for the presence of DDAH-1 in our model, confirming its expression. The ADMA 
concentrations that impacted here and in previous studies are usually in the 100µM range – 
well above the clinically relevant plasma concentrations of ~3µM, although the intracellular 
concentrations of ADMA, especially in different disease states, have not been fully 
characterised and are likely to be relevant in future studies. Intriguingly, smaller 
concentrations of extracellular ADMA (1-10µM) have been shown to induce increases in ROS 
formation in mouse 3T3-L1 adipocytes (Yang et al., 2009) and cause vasoconstriction of 
cerebral vessels in rabbits (Faraci et al., 1995). If DDAH-1 were knocked-down or inhibited, 
then the action of ADMA on the BBB may be more pronounced and this would be a very 
interesting direction of study that could further implicate more relevant ADMA concentrations 
in a variety of cerebrovascular and brain pathologies where oxidative stress is an issue. Loss of 
DDAH-1 function in mice has been demonstrated to result in increased ADMA levels and 
endothelial dysfunction (Leiper et al., 2007). In relation to this, it has been demonstrated in 
vivo and in vitro with mice aorta and cerebral arterioles over-expressing DDAH-1 are protected 
against ADMA-induced endothelial dysfunction using 100µM ADMA (Dayoub et al., 2008).  
ADMA may also contribute to endothelial dysfunction via a mechanism independent of 
eNOS competitive inhibition. In a recent paper investigating the role of ADMA in chronic 
kidney disease, Kajimoto et al., demonstrated that ADMA concentrations representative of 
plasma levels in mice chronic kidney disease models (3-4µM) were able to reduce eNOS 
phosphorylation in HUVECs (Kajimoto et al., 2012). This feature was also suggested when 
Smith et al., argued that their data demonstrating that 2µM ADMA was shown to induce 
significant changes in expression of a variety of genes using gene chips in human coronary 
artery endothelial cells when incubated for 24 hours in the presence of >300µM L-arginine was 
also independent of eNOS competitive inhibition (Smith et al., 2005). The finding of Smith et 
al., is also extremely interesting because it demonstrates that ADMA is able to exert effects 
even in the presence of saturating L-arginine concentrations, and that extracellular 
concentrations of ADMA are able to modulate aspects of endothelial function. This is of 
particular interest because one of the major issues with our assay (indeed any assay involving 
ADMA and L-arginine) was the large amounts of CAAs present in the commercially purchased 
media. These high concentrations are likely to have effects on NOS activity and the metabolism 
of ADMA because not only would CAA transport systems would be saturated, but NOS would 
also be saturated, working at maximal rates even in the presence of ADMA that may normally 
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be inhibitory (Teerlink et al., 2009). It has also been demonstrated that in ranges of 50-400µM, 
L-arginine can dose dependently inhibit the degradation of ADMA by inhibiting the action of 
DDAH (Wang et al., 2006).  
By carefully controlling the cell media components to represent those of physiological 
significance, one may further reduce the restrictiveness of the already leaky hCMEC/D3 
barrier, highlighting a major issue with the hCMEC/D3 BBB model. Efforts have been made to 
reduce the paracellular permeability in this model, but thus far all methods have fallen short of 
achieving a model representative of the in vivo situation.  
TNF-α and IFN-γ have been show to increase BMEC permeability through disruption of cell-
cell junctional complexes (Minagar and Alexander, 2003) via activation of the transcription 
factor NFκB (Sandoval and Witt, 2008) and tyrosine-phosphorylation of adherens junction 
proteins via GTPases (Dejana et al., 2008). Their effect on hCMEC/D3 permeability has also 
been recently demonstrated (Fletcher et al., 2011) with a similar increase in permeability to 
FITC-Dex noted (albeit using 70kDa FITC-Dex). Combination of TNF-α and IFN-γ can also lead to 
cytotoxicity in endothelial cells, as demonstrated with murine vascular endothelial cells 
(Yamaoka et al., 2002). It appears likely that in our permeability model a combination of these 
effects was apparent in that the hCMEC/D3 junctional complexes were altered and that 
apoptosis of the cells also increased the permeability affect.  
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The data here show that ADMA is able to increase paracellular permeability in human BBB 
cells. Our BBB model has its limitations regarding leakiness, but it does express eNOS and 
DDAH-1, which make it a good human in vitro BBB model to use to study the effects of ADMA 
and NO inhibition. Although it was high ADMA concentrations that induced these permeability 
increases, that does not rule out the role of more clinically relevant concentrations, especially 
considering the sensitivity DDAH enzymes to oxidative stress which can be induced from 
several sources during various disease states. In the cerebrovasculature, BMECs are extremely 
sensitive to oxidative stress due in part to their high expression of NADPH-oxidase, and this 
makes them vulnerable to increased concentrations of ROS from other sources. ADMA has 
been demonstrated to induce ROS formation by uncoupling NOS so that it no longer produces 
NO, resulting in endothelial dysfunction. This could have serious implications in brain and 
cerebrovasculature pathologies, as well as on the integrity of the BBB itself, and this remains 
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4.1. Chapter 4 – Introduction and aims 
As closely related molecules, L-arginine and ADMA are believed to share similar CAA SLC 
transport mechanisms and limited data indirectly show this (see section 1.9.15). However, it is 
important to note that although data directly looking at ADMA membrane transport is lacking. 
Furthermore, at the site of the BBB, the transport of ADMA has yet to be investigated either 
directly or indirectly despite the emerging role of the molecule in brain and cerebrovascular 
pathologies. Contrary to this, the transport mechanisms for L-arginine at the bovine BBB have 
been described and it is well established that the principle L-arginine BBB transporters are 
CAT-1, CAT-2B and CAT-3, which are all members of system y+ (O'Kane et al., 2006). 
Interestingly, other data have embroiled the system y+L transporters y+LAT1 and y+LAT2 (Carl 
et al., 2010) in human in vitro models and the system B0,+ transporter ATB0,+ (Berezowski et al., 
2004, Czeredys et al., 2008) in bovine in vitro models, in CAA transport at the BBB (see section 
1.5.1).  
Thus we hypothesised that ADMA would have a similar transport profile to L-arginine in 
human brain endothelial cells and so compared the transport of the two molecules in a drug 
accumulation model using the established hCMEC/D3 BBB model.  
Furthermore, their transport and subsequent accumulation was investigated with well-
described CAA transporter inhibitors and substrates over short time-frames to record 
instances of cellular influx and longer time-frames to elucidate cellular efflux events. We 
hypothesised that the main transporter involved would be members of system y+, especially 
CAT-1 which is ubiquitously expressed throughout the body – heavily so at the rodent BBB 
(Stoll et al., 1993), but didn’t rule out the potential influence of other transporters, particularly 
ATB0,+ and y+LAT1 and y+LAT2. As a result of the functional studies we also investigated the 
presence of CAT-1 and ATB0,+ in the hCMEC/D3s, as the expression of CAT-1 has yet to be 
demonstrated in the cell line.  
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A description of the generation of the hCMEC/D3 cells can be found in the general methods 
chapter section 1.9.15. 
4.2.1. Cell culture 
Please see section 2.1.2 in chapter 2 for details of hCMEC/D3 culture conditions. 
4.2.2. Radioactivity studies – Materials 
Tritium labelled L-arginine was purchased from American Radiolabelled Chemicals, Inc., 
MO, US and had a specific activity of 43 Ci/mmol. [14C]sucrose was purchased from Moravek 
Biochemicals and had a specific activity of 4980 mCi/mmol. [3H]ADMA was custom 
radiolabelled by GE Healthcare, Amersham, UK and had a specific activity of 8 Ci/mmol. 
Unlabelled ADMA was purchased from Sigma Aldrich Company Ltd.  
4.2.3. L-arginine and ADMA Octanol-saline partition coefficient 
To gain an indication of the lipophilicity of the study molecules [14C]sucrose, [3H]ADMA and 
[3H]L-arginine, an OSPC was performed using 0.037 MBq (1 µCi) of each molecules in 1 ml of 
saline as described in the detailed protocol in section 2.9. These analyses were performed with 
fellow laboratory members Mr. Murat Dogruel and Mr. Mehmet Fidanboylu.  
4.2.4. L-arginine and ADMA accumulation 
To investigate the accumulation of [3H]L-arginine and [3H]ADMA (using [14C]sucrose as a 
correction value for non-specific binding and extracellular space) in the hCMEC/D3 cells, the 
protocol described in section 2.2 was used.  
4.2.5. Arginine 
[3H]L-arginine (0.0111 MBq or 300 nCi, 7nM) and [14C]sucrose (0.0148 MBq or 400 nCi, 
972nM) was added to every 1ml of accumulation buffer. The concentrations used were the 
lowest possible that still allowed accurate detection and discrimination of [3H] and [14C] 
radioactivity. Studies were performed in the absence and presence of varying CAA transport 
substrates and inhibitors (see table 2.1 in chapter 2 for source information and references). 
For self-inhibition experiments which provides evidence of influx mechanisms, 100µM 
unlabelled L-arginine – a similar concentration to that present in human plasma – was added 
to the accumulation buffer along with the [3H]L-arginine and [14C]sucrose.  
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The system y+ competitive substrate L-homoarginine (20mM) and the broad scale system A, 
system L and system B0,+ inhibitor 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) 
(4mM) were also used in separate groups of experiments for evidence of functional 
transporter activity. Leucine (100µM) was used to investigate the role of BAT transporters (y+L, 
b0,+ and ATB0,+) on the transport of L-arginine, as unlike system y+ which has a poor affinity for 
leucine, BAT transporters readily transport leucine in the presence of Na+ ions.  
As well as these molecules, in a separate series of accumulation experiments, the effects of 
a range of ADMA concentrations on [3H]L-arginine accumulation were also assessed. Thus the 
normal plasma concentration of 0.5µM, the 3µM concentration associated with pathological 
conditions, and a supraphysiological concentration of 500µM (as an extreme reference point) 
were added separately to the accumulation buffer alongside [3H]L-arginine and [14C]sucrose.  
4.2.6. ADMA 
[3H]ADMA was used at a concentration of 38nM (0.0111 MBq or 300 nCi in 1ml 
accumulation buffer) [14C]sucrose (used at the same concentration as with [3H]L-arginine; 
972nM). This ensured that the radioactivity could be detected appropriately. Evidence for 
influx transport activity was assessed by self-inhibition studies using 0.5µM, 3µM and 500µM 
unlabelled ADMA alongside [3H]ADMA and [14C]sucrose in the accumulation buffer. The 
influence of 100µM unlabelled L-arginine, 100µM leucine, 20mM L-homoarginine and 4mM 
BCH were also separately investigated. The results guided us to further uncover the influence 
of ATB0,+ and so the specific inhibitor of this transporter (α-methlytryptophan at 500µM) was 
used at the published concentration (Karunakaran et al., 2008). We also performed a 
[3H]ADMA and [14C]sucrose accumulation study in buffer absent of Na+ and Cl- ions based on a 
published recipe by (Tamai et al., 1995) and detailed in appendix 4, to stop the action of the 
Na+ and Cl- dependent ATB0,+ to investigate the role of this transporter in [3H]ADMA 
accumulation. 
4.2.7. MTT cytotoxicity assay 
The potential of the all the compounds used in this accumulation study to cause 
cytotoxicity to the hCMEC/D3 cells was assessed using an MTT assay following the protocol 
described in section 2.5. The effect of these compounds on hCMEC/D3 viability was compared 
to untreated control hCMEC/D3 cells. Triton x-100 was used as a positive control.  
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4.2.8. Expression of CAT1 and ATB0,+ 
The expression of both CAT-1 and ATB0,+ in the hCMEC/D3 cells and MCF-7 cells (positive 
control) were ascertained by SDS-PAGE, WB, and IF with confocal microscopy.  
For SDS-PAGE and WB, the protocol in chapter 2, section 2.7 was used and hCMEC/D3 cell 
lysate was prepared in TGN lysis buffer as described in section 2.7.1. 30µg was loaded in each 
well. Rabbit anti-human CAT-1 primary antibody was used at a dilution of 1:250 in PBS-T and 
0.5% BSA as described in table 2.2. Rabbit anti-human ATB0,+  primary antibody was used at a 
dilution of 1:1000 in PBS-T and 0.5% BSA also as described in table 2.2. Goat anti-rabbit HRP 
conjugated secondary antibody was used at a dilution of 1:5000 for chemiluminescence 
detection for CAT-1 and ATB0,+ WB. Whole wild-type MCF7 cell lysate, prepared in TGN lysis 
buffer as described in 2.7.1 acted as positive controls for these transporters – see 
(Karunakaran et al., 2011) for ATB0,+ and (Abdelmagid et al., 2011) for CAT-1 – and was a kind 
gift from Mr. Evangelos Pazarentzos (Imperial College London).  
Obtaining a clear blot of ATB0,+ was initially difficult because it is heavily N-glycosylated in 
mammalian systems (Broer, 2008). To deglycosylate the cell lysate, N-linked-glycopeptide-(N-
acetyl-beta-D-glucosaminyl)-L-asparagine amidohydrolase (PNGase F, from New England 
Biolabs) was used according to the manufacturer’s protocol and described in appendix 5. The 
PNGase F kit was kindly lent to us by Mr. Evangelos Pazarentzos. 
IF with confocal microscopy was performed on hCMEC/D3s grown on rat tail collagen type 
1 coated sterile glass coverslips was performed as described in section 2.8 for CAT-1 and 
ATB0,+. Goat anti-rabbit Alexa Fluor 488 conjugated secondary diluted at 1:200 in PBS was used 
for both proteins. More details of these antibodies can be found in table 2.2 of chapter 2.  
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4.3.1. Octanol-saline partition coefficient of [3H]L-arginine and [3H]ADMA 
As outlined in section 2.9, an OSPC was performed on all radiolabelled compounds to assess 
their lipophilicity which would give an indication of their potential to cross cell membranes by 
passive diffusion and accumulate in the cells. The mean octanol-saline partition values for 
[3H]L-arginine (MW 174.2 g/mol-1) and [3H]ADMA (MW 202.25 g/mol-1) were 0.0015 ± 0.0002 
and 0.0023 ± 0.0001 respectively (n=3) which was statistically significant (p<0.01). Our group 
also performed OSPC analysis on [14C]sucrose (n=3) obtaining a mean value of 0.0004 ± 
0.00001, which was statistically significant when compared to  [3H]L-arginine and [3H]ADMA 
(both p<0.001). 
4.3.2. [3H]L-arginine and [3H]ADMA control accumulation comparison 
Before transport mechanisms were assessed, the control values of [14C]sucrose and protein 
corrected [3H]L-arginine and [3H]ADMA accumulation assays were compared directly. The 
accumulation of [3H]ADMA increased in a time-dependent manner from a Vd of 13.58 ± 0.66 at 
1 minute, to a Vd of 61.24 ± 2.92 at 30 minutes. In a similar manner, the accumulation of [
3H]L-
arginine increased in a time-dependent manner from a Vd of 33.75 ± 1.70 at 1 minute, to a Vd 
of 106.79 ± 1.73 at 30 minutes At all time points, [3H]L-arginine Vd values were significantly 
higher than those from [3H]ADMA (p<0.001 at all time points). See table 4.1 below. 
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4.3.3. [14C]sucrose comparison from [3H]L-arginine and [3H]ADMA control 
accumulation 
The control values of protein corrected [14C]sucrose from [3H]L-arginine and [3H]ADMA 
accumulation assays were also compared directly. There were no significant differences 
between the treatments. See table 4.2 below. 
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4.3.4. Accumulation of [3H]L-arginine and [14C]sucrose – Role of CAA transporters 
To assess the roles of CAA transporters on the transport and accumulation of [3H]L-arginine 
in the hCMEC/D3s, 100µM unlabelled L-arginine, 20mM L-homoarginine, 100µM leucine, and 
4mM BCH were added individually to the accumulation buffer alongside [3H]L-arginine and 
[14C]sucrose, and compared to appropriate controls. The data are displayed in figure 4.1.   
4.3.5. [14C]sucrose in [3H]L-arginine studies 
No significant differences between [14C]sucrose accumulation was observed with any of the 
treatments involving 100µM unlabelled L-arginine, 20mM L-homoarginine, 100µM leucine or 
4mM BCH when compared to the controls cells which received no CAA interacting drugs 
(displayed as insert in figure 4.1). There were also no significant differences in [14C]sucrose 
accumulation when unlabelled ADMA treatments were used in the cross-competition studies 
(displayed as the insert in figure 4.2). 
4.3.6. [3H]L-arginine accumulation 
The addition of 100µM unlabelled L-arginine caused a marked decrease in the accumulation 
of [3H]L-arginine (p<0.001), with an average percentage decrease between the time points of 
73% (figure 4.1). Accumulation almost completely inhibited (an approximate decrease of 98% 
was seen across all time points) with the addition of 20mM L-homoarginine (p<0.001). The 
 INTERACTIONS OF ENDOGENOUS AND EXOGENOUS MOLECULES WITH 




addition of 4mM BCH and 100µM leucine to the accumulation buffer caused no significant 
changes in [3H]L-arginine accumulation.  
 
Figure 4.1. The roles of CAA transporters on accumulation of [3H]L-arginine and [14C]sucrose 
in hCMEC/D3 cells. To understand the roles CAA transporters played in the transport and 
subsequent accumulation of [3H]L-arginine, self-inhibition and the addition of known CAA 
transporter interacting drugs was performed in an accumulation model using confluent 
hCMEC/D3s. [14C]sucrose was used as a marker of non-specific binding, barrier integrity and 
extracellular space for accumulation experiments (insert). ***p<0.001.  [3H]L-arginine data are 
corrected for [14C]sucrose and protein content (with [14C]sucrose corrected for protein only) 
and expressed as means ± S.E.M, n=6 (plates) with 6 replicates (wells) per n. BCH – 2 -
aminobicyclo-(2,2,1)-heptane-2-carboxylic acid. 
To investigate the possible competitive effect of ADMA on the influx and accumulation of 
[3H]L-arginine, 0.5µM, 3µM, and 500µM unlabelled ADMA were added individually to the 
accumulation buffer. When 0.5µM and 3µM ADMA was added, there were no significant 
differences in accumulation when compared to [3H]L-arginine controls. However, an average 
[14C] sucrose 
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decrease in [3H]L-arginine accumulation of 83% across the time points was revealed with the 
addition of 500µM ADMA (p<0.001) when compared to controls (figure 4.2).  
 
Figure 4.2. The competitive effects of unlabelled ADMA on accumulation of [3H]L-arginine 
and [14C]sucrose in hCMEC/D3 cells. 0.5µM, 3µM and 500µM ADMA were added individually 
to accumulation buffer to observe and competitive effects on [3H]L-arginine accumulation in 
confluent monolayers of hCMEC/D3 cells. ***p<0.001. The addition of 0.5µM, 3µM and 
500µM ADMA caused no significant changes in [14C]sucrose accumulation over the 30 minute 
time period in the cells (insert). All [3H]L-arginine data are corrected for [14C]sucrose and 
protein content (with [14C]sucrose corrected for protein only) and expressed as means ± S.E.M, 
n=5-6 (plates) with 6 replicates (wells) per n. ADMA – asymmetric dimethylarginine. 
 
4.3.7. Accumulation of [3H]ADMA and [14C]sucrose – Role of CAA transporters 
To elucidate the transport mechanisms utilised by ADMA in the hCMEC/D3s, a series of 
accumulation experiments similar to those used for [3H]L-arginine were designed to assess the 
[14C] sucrose 
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effects of self-inhibition, competitive inhibition and CAA transporters on the transport and 
resulting accumulation of [3H]ADMA and [14C]sucrose. 
4.3.8. [14C]sucrose in [3H]ADMA studies 
There were no significant changes in the accumulation of [14C]sucrose with the self-
inhibition studies involving ADMA concentrations of 0.5µM, 3µM or 500µM unlabelled ADMA, 
or 100µM L-arginine, in the presence of [3H]ADMA (figure 4.3 insert). No differences were 
observed in [14C]sucrose accumulation with the addition of AA transporter affecting drugs 
20mM L-homoarginine, 4mM BCH, 500µM α-methyltryptophan, 100µM leucine or when Na+ 
and Cl- free buffer was used, as demonstrated in the figure 4.4 insert. 
4.3.9. [3H]ADMA 
To investigate self- and cross-competition on [3H]ADMA transport interaction and 
accumulation, 0.5µM, 3µM and 500µM unlabelled ADMA as well as 100µM L-arginine were 
added individually to the accumulation buffer with [3H]ADMA and [14C]sucrose. 0.5µM ADMA 
caused no significant changes to accumulation, but 3µM caused significant decreases at 20 
minutes and 30 minutes (both p<0.05). A decrease in [3H]ADMA accumulation of 87% was 
observed across all time points on the addition of 500µM ADMA (p<0.001). 100µM L-arginine 
also caused a decrease (average decrease of 36% across time points), but statistical 
significance was only apparent after 5 minutes 20 minutes and 30 minutes (p<0.05) (figure 
4.3). 
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Figure 4.3. The effect of self and competitive inhibition on the transport and accumulation of 
[3H]ADMA and [14C]sucrose in hCMEC/D3 cells.  To investigate self and competitive inhibition 
on [3H]ADMA transport and accumulation, 0.5µM, 3µM and 500µM unlabelled ADMA and 
100µM L-arginine were added individually to the accumulation buffer. *p<0.05, ***p<0.001. 
The addition of 0.5µM, 3µM and 500µM unlabelled ADMA and 100µM L-arginine individually 
to the accumulation buffer caused no significant changes in the accumulation of [14C]sucrose 
(insert). All [3H]ADMA data are corrected for protein content and [14C]sucrose (with 
[14C]sucrose corrected for protein only) and expressed as means ± S.E.M, n=5 (plates) with 6 
replicates (wells) per n. ADMA – asymmetric dimethylarginine. 
  
[14C] sucrose 
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The influence of CAA transporters on [3H]ADMA and [14C]sucrose was initially deduced 
using 20mM L-homoarginine and 4mM BCH. The addition of 20mM L-homoarginine caused a 
large decrease in accumulation of [3H]ADMA at all time points, which gained higher 
significance as the incubation time increased – at 1 minute p<0.05, 2.5 minutes to 30 minutes 
p<0.01. The percentage decreases in Vd induced by L-homoarginine were 47% for 1 minute, 
64% for 2.5 minutes, 75% for 5 minutes, 8%1 for 20 minutes and 76% for 30 minutes. The data 
are displayed in figure 4.4. The addition of 100µM leucine saw significant decreases in  
[3H]ADMA accumulation from 5 minutes (21% decrease), to 20 minutes (40% decrease) and 30 
minutes (38% decrease) (all p<0.05). Conversely, 4mM BCH induced a significant, 32% increase 
in accumulation at 5 minutes (p<0.05), and at 20 (36%) and 30 minutes (78%), both p<0.01.  
The ATB0,+ inhibitor α-methyltryptophan was also added (500µM) to the normal 
accumulation buffer alongside [3H]ADMA and [14C]sucrose, and also resulted in significant 
increases in accumulation at all time points from 5 minutes; 39% increase at 5 minutes 
(p<0.05), 81% at 20 minutes (p<0.01), and 88% 30 minutes (p<0.01). To investigate this 
observation further, Na+ and Cl- free accumulation buffer was used with [3H]ADMA and 
[14C]sucrose and caused a significant increase in [3H]ADMA accumulation at all time points 
from 5 minutes, increasing in significance with incubation time (46% increase at 5 minutes 
p<0.05, 68% increase at 20 minutes p<0.01 and 160% increase at 30 minutes p<0.001). These 
data are also displayed in figure 4.4.  
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Figure 4.4. Roles of CAA transport systems on the accumulation of [3H]ADMA and 
[14C]sucrose in hCMEC/D3 cells. To understand the roles CAA transporters played in the 
transport and subsequent accumulation of [3H]ADMA, the addition of known CAA transporter 
interacting drugs was performed in an accumulation model using confluent hCMEC/D3s. 
*p<0.05, **p<0.01 and ***p<0.001. The addition of 20mM L-homoarginine, 4mM BCH, 100µM 
leucine and 500µM α-methyltryptophan, as well as removal of Na+ and Cl- from the 
accumulation buffer caused no significant changes in [14C]sucrose accumulation over the 30 
minute time period (insert). All [3H]ADMA data are corrected for [14C]sucrose and protein 
content (with [14C]sucrose corrected for protein only) and expressed as means ± S.E.M, n=4-6 
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4.3.10. Cytotoxicity of compounds used in accumulation study 
The cytotoxic potential of all compounds used in this study over the 30 minute time-frame 
was assessed in the hCMEC/D3 cells using an MTT assay, comparing treated cells to untreated 
control cells. There were no significant differences in cell viability between the treatments 
except when using the positive control 1% Triton x-100 (p<0.01, figure 4.5 below).  
 
 
Figure 4.5. The cytotoxic effects of study compounds on confluent monolayers of hCMEC/D3 
cells. The study compounds were assessed for any cytotoxic potential using an MTT assay 
during 30 minute incubation with confluent monolayers of hCMEC/D3 cells in 96 well plates, as 
described in section 2.5. The results are expressed as percentage viability ± S.E.M and 
compared to control untreated cells, which were incubated for 30 minutes in culture medium. 
n=4 (plates), 6 replicates per n (6 wells). AC = accumulation, ADMA – asymmetric 
dimethylarginine, BCH – 2 -aminobicyclo-(2,2,1)-heptane-2-carboxylic acid. 
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4.3.11. Expression of CAA transporter CAT-1 in hCMEC/D3 cells 
Rabbit anti-human CAT-1 primary antibody was used with goat anti-rabbit HRP conjugated 
secondary antibody for WB detection of CAT-1 in the TGN lysed hCMEC/D3s and wt MCF7 
whole cell lysates. The blot revealed a positive expression of CAT-1 of the expected size of 60-
70kDa according to the antibody manufacturer (figure 4.6 a).  
CAT-1 expression was also observed with IF and subsequent confocal microscopy in the 
hCMEC/D3s (figure 4.6 b) using rabbit anti-human CAT-1 primary antibody and goat anti-rabbit 
Alexa Fluor 488 conjugated secondary antibody by the protocol described in section 4.2.8. It 
showed typical membrane/cytoskeletal-like patterning (Closs et al., 2004). 
 
Figure 4.6. Expression of CAT-1 in hCMEC/D3s. a| SDS-PAGE and WB analysis revealed CAT-1 
expression in hCMEC/D3 (passage 28) and wt MCF7 whole cell lysate lysed in TGN lysis buffer, 
as described in section 2.7. b| CAT-1 expression was also demonstrated by IF performed with 
hCMEC/D3 cells (passage 28) grown on rat tail collagen type-1-coated coverslips, fixed with 4% 
formaldehyde and stained for with primary and secondary antibody as described in section 
4.2.8. Cell nuclei were counterstained with 1µg/ml DAPI. For negative staining, cells were 
stained with secondary antibody only along with DAPI (inserts). 
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4.3.12. Expression of CAA and NAA transporter ATB0,+ in hCMEC/D3 cells 
Rabbit anti-human ATB0,+ primary antibody was used with goat anti-rabbit HRP conjugated 
secondary antibody for WB detection of CAT-1 in the TGN lysed hCMEC/D3s and wt MCF7 
whole cell lysates, before and after deglycosylation. PNGase F was used to deglycosylate the 
lysates. Following deglycosylation, the blot at an expected size of 55-70kDa was visible, 
confirming expression of the protein (figure 4.7 a). During the time of writing this thesis, a 
publication has also since confirmed functional expression of this transport protein (Kooijmans 
et al., 2012). 
The expression and localisation of ATB0,+ was also visualised by using the rabbit anti-human 
ATB0,+ primary antibody and goat anti-rabbit Alexa Fluor 488 conjugated secondary antibody 
with confocal microscopy (figure 4.7 b). It showed both membrane and cytoskeletal 
patterning, which is typical for this transporter (Czeredys et al., 2008). 
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Figure 4.7. Expression of ATB0,+ in hCMEC/D3s. a| Following deglycosylation with PNGase F, 
SDS-PAGE and WB analysis revealed ATB0,+ expression in hCMEC/D3 (passage 30) and wt MCF7 
whole cell lysate lysed in TGN lysis buffer, as described in section 2.7. b| ATB0,+ expression was 
also demonstrated by IF performed with hCMEC/D3 cells (passage 30) grown on rat tail 
collagen type-1-coated coverslips, fixed with 4% formaldehyde and stained for with primary 
and secondary antibody as described in section 4.2.8. Cell nuclei were counterstained with 
1µg/ml DAPI. For negative staining, cells were stained with secondary antibody only along with 
DAPI (inserts). 
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4.4. Chapter 4 – Discussion 
Numerous studies have indicated the presence of an increased ADMA concentration in the 
plasma of patients with cerebrovascular disease and brain pathologies compared to normal 
plasma concentrations in healthy patients (see table 1.2 in the introduction chapter). These 
differences in concentrations, although small, could have large implications in the cause and 
progression of disease due to the large number of effects ADMA can have on endothelium and 
NO production. Therefore, we decided to investigate the transport mechanisms of ADMA at 
the BBB using a human BBB in vitro model, the immortalised hCMEC/D3s. 
L-arginine and ADMA are very similar in structure and composition and so we decided to 
base the ADMA investigation on the results of those generated from L-arginine studies, 
hypothesising that both molecules would have a very similar transport profile. Before looking 
at the transport and accumulation of both molecules, we aimed to deduce the OSPC values for 
the molecules under investigation, giving us an indication of their lipophilicity and membrane 
penetration without the influence of transporters.  The data indicated that both [3H]L-arginine 
and [3H]ADMA had high hydrophilicity and low lipophilicity, with [3H]L-arginine having 
statistically lower lipophilicity than [3H]ADMA.  Both molecules had higher lipophilicity than 
that of [14C]sucrose, which is a common paracellular permeability and non-specific binding 
marker in BBB studies. This means without the interaction of transporters, the accumulation of 
[3H]L-arginine and [3H]ADMA in the cells should be low, but in a range similar or higher than 
[14C]sucrose. Therefore, our findings that both [3H]L-arginine and [3H]ADMA readily 
accumulated in the cells at values much greater than [14C]sucrose provides compelling 
evidence for transporter interaction.  
When directly compared, we saw that both molecules accumulated in a time-dependent 
manner – which is typical of transport interaction – but that the control [3H]L-arginine 
accumulated at significantly higher amounts when compared to control [3H]ADMA. Differences 
between the [14C]sucrose values of both control treatments failed to obtain statistical 
significance when directly compared.  These initial findings suggested that perhaps the 
transport systems at work favoured L-arginine over ADMA. 
The accumulation of [3H]L-arginine was decreased significantly with the addition of the 
normal adult L-arginine plasma concentration of 100µM (Moller et al., 1979, Moller et al., 
1983) indicating transport competition for influx mechanisms.  Further experiments with 
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20mM L-homoarginine revealed that the influx mechanisms utilised was a member of system 
y+, with an almost complete halt of accumulation immediately (98% decrease) and for the rest 
of the 30 minute time period observed with the addition of 20mM L-homoarginine. It is well 
established that L-homoarginine competitively inhibits system y+ (White, 1985) and the 
concentration used here was based on that of a previous in vitro BBB study using bovine 
BMECs (O'Kane et al., 2006). The impact of L-homoarginine here also dismisses the L-arginine 
transport roles of other CAA influx mechanisms such as system y+L transporters and ATB0,+ at 
the human BBB (O'Kane et al., 2006). The addition of BCH, a broad acting inhibitor of NAA 
transporters including ATB0,+ (Van Winkle et al., 1985) and the NAA leucine also supported the 
finding that system y+ appears to be the primary transport system used by L-arginine in these 
cells.  
These data were not unexpected, as it has been well established that system y+ is the 
principle CAA transport system in mammals. Which CAT isoform is responsible remains at 
large, but as CAT-1 is well characterised at the BBB, it remains likely that this protein is 
involved. The expression of CAT-1 was confirmed in the hCMEC/D3s through WB and IF 
analysis showing typical cytoskeletal/caveoli localisation where it is believed CAT-1 activity is 
modulated (Closs et al., 2004) (as previously demonstrated in pulmonary artery endothelial 
cells (McDonald et al., 1997, Zharikov et al., 2001).  
Unlabelled ADMA appeared to reduce accumulation of [3H]L-arginine, but failed to attain 
significance with 0.5µM and 3µM additions, but a large and significant decrease was observed 
following the addition of 500µM ADMA. This provides useful information in two ways.  In one 
respect, this finding provides evidence that both molecules can interact with the same 
transport mechanisms for entry to the cells. The other respect regards transport competition 
and that although a marked decrease in accumulation was observed, the concentration of 
500µM ADMA is supraphysiological and never likely to be reached in the body. Due to the low 
concentration of [3H]L-arginine used (7nM) it is therefore unlikely that the relevant 
physiological and pathophysiological concentrations of 0.5µM and 3µM would compete in the 
body for cellular entry via system y+, especially considering the average plasma concentration 
of L-arginine is in the region of 100µM in normal healthy individuals. A similar observation has 
been previously published using human dermal microvascular endothelial cells where 2.5µM 
and 10µM ADMA did not significantly reduce L-arginine accumulation (Xiao et al., 2001).  
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When investigating the accumulation of [3H]ADMA, self-inhibition was not evident with the 
additions of 0.5µM and 3µM, until 20 minutes when 3µM significantly decreased 
accumulation. 500µM ADMA saw a significant decrease at all time points (an average of 87% 
across the times points). These self-inhibition data collectively suggest the evidence of influx 
mechanisms, along with the decreases noted when 100µM L-arginine was added at the 5, 20 
and 30 minute incubation time points. The fact that the 38nM [3H]ADMA used was more than 
10 times less than the lowest concentration of addition unlabelled ADMA and not greatly 
affected by the ADMA additions until later time points, suggests either that the transporter 
being used has affinity for ADMA and required a very high concentration to slow influx action.  
The results from the addition of 100µM L-arginine show a slight decrease in accumulation 
(at the three last time points) despite being at a concentration more than 2000 times greater 
than [3H]ADMA, which, along with the decrease caused by 20mM L-homoarginine – which was 
not as dramatic as that seen with [3H]L-arginine – suggest the idea that multiple influx 
transporters are at work is certainly plausible. Indeed, our data illustrated decreases in 
accumulation of [3H]ADMA were apparent with the addition of the NAA leucine to the 
accumulation buffer at the approximate human physiological plasma concentration 
(Psychogios et al., 2011). This finding demonstrates that influx transport systems separate 
from system y+ could also be transporting ADMA as system y+ is insensitive to leucine 
(Rotmann et al., 2007). The most likely candidates are y+L and b0,+ proteins, which have 
affinities for both CAA and NAAs in the presence of Na+ ions dependent manner (O'Kane et al., 
2006, Rotmann et al., 2007), although the proteins were not looked for here, both have been 
recently demonstrated at mRNA level in the hCMEC/D3s recently (Carl et al., 2010). 
 Carl et al., are the only group other than us to have data that suggests the existence of 
several AA transporters in the hCMEC/D3 cells (Carl et al., 2010) which could be candidates for 
ADMA influx transporters. Their report describes SLC7A5-A9 and A11 mRNA expression, with 
SLC7A5, A6 and A11 having the highest mRNA levels respectively. In their paper, the authors 
described these genes as coding for system y+ CAA transporters, although these descriptions 
appear to be incorrect. According to the NCBI Gene database, in humans SLC7A5 codes for a 
large NAA transporter, SLC7A6 and SLC7A7 code for system y+L transporters y+LAT1 and 
y+LAT2, SLC7A8 codes for a system L NAA transporter, SLC7A9 codes for the heavy chain of the 
system b0,+ transporter, and SLC7A11 codes for the cystine and glutamate anionic AA 
transporter xCT. Interestingly, the paper also describes a large mRNA expression of SLC3A2, 
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the gene that codes for the ubiquitous transmembrane protein 4F2hc, involved in the 
formation of heterodimeric structures which exhibit y+L and xCT activity (Broer, 2008). There is 
also expression of SLC3A1 which codes for the light chain of the system b0,+  transporter. These 
data combined with our findings suggest that both system y+L and b0,+ could have functional 
proteins in the hCMEC/D3s which may possibly be utilised by ADMA (and L-arginine to a lesser 
extent), but also highlight the confusing nomenclature used to name AA transporters. It is 
likely that some confusion resulted from the naming of SLC transporters between different 
species. In several instances, names of human genes are similar in mice, but code for totally 
different transporters. For example, SLC7A11 codes for an anionic AA transporter in humans, 
but according to the NCBI Gene database in mice Slc7a11 codes for a system y+ transporter. It 
is also possible that the array descriptions could be incorrect and that the authors had in fact 
gone with the manufacturer’s descriptions rather than their own. It is important to note, the 
PCR array used by Carl et al., (RT2 Pathway-Focused Profiler Array, PAHS-70A from SA 
Biosciences) did not include transcripts for CAT-1 (SLC7A1) or ATB0,+ (SLC6A14) (nor did they 
look for CAT-2A, CAT-2B – both coded for by SLC7A2 – CAT-3 (SLC7A3) or CAT-4 (SLC7A4), and 
so the mRNA for these proteins was not investigated. We are subsequently the first to report 
the expression of CAT-1 in the hCMEC/D3 cells, with a recent paper reporting the protein 
expression of ATB in the hCMEC/D3s (Kooijmans et al., 2012).  
Perhaps a more surprising result was the evidence for an ADMA cellular exit transport 
system. The addition of 4mM BCH saw significant increases in [3H]ADMA at all time from 5 
minutes.  BCH is a broad ranging inhibitor of NAA systems including system L, system A and 
system B0,+ (Mann et al., 1989, Yamauchi et al., 2009) and as only system B0,+ is able to 
transport CAA, we decided to investigate this observation further by removing Na+ and Cl- ions 
from the accumulation buffer. The B0,+ transporter, ATB0,+ unlike CATs, is a dependent on Na+ 
and Cl- ions to exhibit CAA transport and when removing these ions from the buffer we 
observed a larger increase in [3H]ADMA accumulation from 5 minutes, with comparable values 
to BCH. CATs on the other hand would not be affected by such a change and would continue to 
transport [3H]ADMA into the cell. We also obtained a specific inhibitor of ATB0,+, α-
methyltryptophan, using it at 500µM – twice the half maximal inhibitory concentration (IC50) 
(Karunakaran et al., 2008), which produced very similar effects to those demonstrated by BCH 
and Na+ and Cl- free accumulation buffer.  
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To our knowledge, we are the first group to show this protein act as an AA exiting system or 
antiport transporter. ATB0,+ is normally shown as an influx cotransporter (symporter) where it 
utilises the Na+ and Cl_ gradient to influx its substrates (Broer, 2008), which results in inwards 
currents that are measurable by voltage-clamp techniques (Hatanaka et al., 2004). In a recent 
study using the hCMEC/D3s, ATB0,+ was shown to be a saturable influx transporter for cationic 
anti-influenza compounds, rather than an efflux system (Kooijmans et al., 2012). CAA efflux 
from cells is normally carried out by bidirectional transporters such as CATs (Torrents et al., 
1998); exchangers such as rBAT/b0,+ (Broer, 2008); or transporters that are susceptible to 
trans-stimulation such as CAT-1 (Hatzoglou et al., 2004). However, unlike ATB0,+, none of these 
transporters are dependent on the Na+ and Cl- gradient for CAA transport.  
The data here could suggest that ATB0,+ was exchanging freshly added extracellular Na+ and 
Cl- ions in the accumulation buffer for intracellular ADMA, which could explain why there was 
no significant increase in accumulation (when the ATB inhibitors and Na+ and Cl-  free buffer 
was used) until 5 minutes when perhaps the intracellular ADMA concentration had exceeded 
that of the extracellular concentration. This would only be plausible if the protein was an 
antiporter, which to our knowledge has not been demonstrated. A study looking into 
expression of ATB0,+ in a polarised model of the bovine BBB noted that the transporter 
appeared to be expressed predominantly at the apical membrane, but also at  basolateral 
membranes (Czeredys et al., 2008). If ATB0,+ is involved in substrate transport across the BBB in 
a unidirectional manner and expressed at both membranes in the hCMEC/D3s, then blocking 
the action of the transporter would also likely see an increase. Although the IF and WB 
expression of ATB0,+ were investigated, the polarisation of the transporter was not. The IF 
expression appears to show even distribution of the protein throughout the cell, not just the 
plasma membrane, which was also demonstrated in a recent study investigating the 
transporter as a means of drug targeting to cancer cells (Karunakaran et al., 2011). 
Interestingly, it has also been demonstrated that ATB0,+ is able to transport ADMA as well as a 
variety of methylarginines and inhibitors of NOS at high affinity in a study using cloned mouse 
ATB0,+(Hatanaka et al., 2001). Although these ATB0,+ data are somewhat equivocal, it seems 
more likely that the transporter is a unidirectional symporter expressed on both membranes 
for transport across the BBB. Further work using voltage-clamp techniques to show current 
direction and transporter over-expression would be required to fully deduce the role of ATB0,+ 
in ADMA transport, as well as studying the situation in vivo. 
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The results of this study demonstrate that both L-arginine and ADMA predominantly 
appear to use system y+ influx mechanisms to enter the hCMEC/D3 BBB cells, as predicted due 
to their close similarity and chemical composition. This transporter could be CAT-1, and the 
expression of this transporter was confirmed in our human BBB model. Other influx systems 
such as systems y+L and b0,+ appear to have lesser roles for L-arginine transport, but may have 
more important roles for ADMA influx. Based on these data, we can assume that physiological 
and pathophysiological extracellular concentrations of ADMA would be unlikely to compete 
with L-arginine for entry to the BBB due to the high substrate affinity of the transporters and 
that ADMA may use transport mechanisms separate from those used by L-arginine. We also 
observed evidence that ADMA is a substrate of an AA exiting mechanism, most likely the B0,+ 
transporter, ATB0,+, which was also expressed in the model, although the precise activity and 
role of this transporter would require some further investigation before more accurate 













 INTERACTIONS OF ENDOGENOUS AND EXOGENOUS MOLECULES WITH 












Chapter 5. Endogenous molecule 
interactions – Part III – The trans-









 INTERACTIONS OF ENDOGENOUS AND EXOGENOUS MOLECULES WITH 




5.1. Chapter 5 – Introduction and aims 
Many studies have demonstrated that both acute and chronic administration of L-arginine 
can improve endothelial function in patients suffering from conditions associated with NO 
dysregulation, but the precise mechanisms behind this improvement remain undisclosed and 
somewhat puzzling (Bode-Boger et al., 2007). This is because intracellular levels of L-arginine 
are in the millimolar range and eNOS has a half saturation constant (Km) in the µM range. 
Therefore, even before L-arginine supplementation, the enzyme should be fully saturated. In 
attempts to explain this ‘L-arginine paradox’, the role of ADMA has been considered. 
It is apparent that in conditions involving impaired NO production where by L-arginine 
supplementation is beneficial, the concentration of extracellular ADMA is increased – thus the 
L-arginine/ADMA ratio is decreased (see table 1.2) – and it has been hypothesised that the 
extra L-arginine is able to restore this ratio allowing affected endothelium to produce 
physiological amounts of NO (Boger, 2004). This may be possible because the major L-arginine 
transporter CAT-1 is physically associated with eNOS, but would imply that eNOS activity is 
regulated by extracellular concentrations of L-arginine and ADMA. However, our lab (chapter 
4) and others (Xiao et al., 2001) have demonstrated that extracellular pathophysiological 
concentrations of ADMA are unlikely to outcompete the physiological concentrations of 
extracellular L-arginine for CAA transport. Another possibility, therefore, is the relationship 
between intracellular and extracellular concentrations of ADMA and L-arginine. However, it 
has been demonstrated on numerous occasions that when pathophysiological plasma 
concentrations of ADMA are detected, NO production is inhibited in a variety of conditions, 
particularly those with cardiovascular and renal failure (Daniewska-Michalska et al., 1993, 
Anderstam et al., 1997). These data could point to the high Km values of CAA transporters or 
the combined actions of different uptake transport systems, as well as intracellular levels of 
ADMA, which have been reported to be 8-fold above the 1µM Ki of eNOS and nNOS, and 10- to 
20- fold higher than plasma concentrations (Teerlink et al., 2009). This in turn may suggest that 
both intracellular and pathophysiological plasma concentrations of ADMA are sufficient 
enough to inhibit NOS in the presence of physiological concentrations of L-arginine, and that 
supplementation of L-arginine could undo NOS inhibition by ADMA by restoring the L-
arginine/ADMA ratio. This could explain the ‘L-arginine paradox’, but experimental data 
demonstrating this is somewhat lacking. 
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The mechanism of this ADMA displacement by L-arginine has been hypothesised to be a 
result of a process called trans-stimulation, where the activity of a transporter is stimulated by 
substrate on the opposite side of the membrane (Teerlink et al., 2009). Of all the CAA 
transport systems, system y+ is by far the most sensitive to trans-stimulation, particularly CAT-
1 (Hatzoglou et al., 2004), but system y+L (Mann et al., 2003) and system b0,+ (Nguyen et al., 
2007) also demonstrate a degree of sensitivity. There has been no evidence of ATB0,+ trans-
stimulation.  
The hypothesis behind ADMA displacement is that the increased plasma concentrations of 
L-arginine would cause the cellular export of ADMA in exchange for L-arginine transport into 
the cell and that as intracellular levels of ADMA increase, more L-arginine would be 
transported into the cells.  
With an opportunity to test this trans-stimulation theory, we decided to investigate the role 
of ADMA in the trans-stimulation of CAA transport, observing cellular exit of radiolabelled 
ADMA and cellular uptake of radiolabelled L-arginine in an adapted accumulation model using 
the hCMEC/D3 cells. 
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The reader is directed to the general methods chapter (chapter 2) for detailed descriptions 
of the generation of the hCMEC/D3 cells. 
5.2.1. Cell culture 
Please see section 2.1.2 in chapter 2 for details of cell culture reagents and conditions. 
5.2.2. Radioactivity studies – Materials 
The radiolabelled molecules [3H]ADMA, [3H]L-arginine and [14C]sucrose are described in 
section the previous chapter 4.2.2. 
5.2.3. Trans-stimulation assays 
To investigate trans-stimulation in the hCMEC/D3 cells using ADMA and L-arginine, a series 
of trans-stimulation assays were designed to investigate either the influence of supplemental 
extracellular amounts of L-arginine (200µM L-arginine) on the cellular exit of preloaded 
[3H]ADMA with or without unlabelled ADMA, or the effect of increasing concentrations of 
intracellular ADMA on the influx of extracellular [3H]L-arginine to the hCMEC/D3 cells.  
The concentrations of ADMA preloaded with or without [3H]ADMA and ([14C]sucrose) were 
the physiological plasma concentration of 0.5µM; the pathophysiological plasma concentration 
of 3µM; and the supraphysiological concentration of 500 µM. Only one radiolabelled test 
substrate was investigated at a time (i.e. cellular exit investigated for [3H]ADMA and cellular 
influx investigated for [3H]L-arginine), but [14C]sucrose was included with the radiolabelled 
molecules as a control as outlined in section 4.2 for the accumulation experiments.  
The amount of L-arginine used in supplementation is treatment specific, but a plasma 
concentration of 200µM is achieved during the treatment of some cardiovascular conditions 
and was used here (Clarkson et al., 1996, Adams et al., 1997).  
The experiments were performed in the centre 60 wells of 96 well plates and were based 
on the accumulation assays outlined in section 2.2 but included a 20 minute preloading step to 
preload the cells with 200µl 37°C accumulation buffer containing either: 
1) preloading buffer alone (controls) or;  
2) [3H]ADMA (40nM) (and [14C]sucrose) or; 
3) 0.5µM, 3µM or 500µM unlabelled ADMA with [3H]ADMA (38nM) (and [14C]sucrose) or; 
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4) 0.5µM, 3µM or 500µM unlabelled ADMA alone (for [3H]L-arginine and [14C]sucrose  
influx experiments) 
This preloading stage is referred to the ‘preload’ step throughout the thesis. 
Following this 20 minute preload step, the buffer was removed and an accumulation assay 
was performed under the same conditions as those outlined in chapter 2, sections 2.2 and 4.2. 
The concentrations of radiolabelled molecules used for the trans-stimulation assay in this 
chapter were the same as those used in the previous chapter for the accumulation assay: 
[3H]L-arginine (0.0111 MBq or 300 nCi, 7nM); [3H]ADMA 38nM (0.0111 MBq or 300 nCi); and 
[14C]sucrose (0.0148 MBq or 400 nCi, 972nM), all per 1ml accumulation buffer.  
The subsequent accumulation assay following the preload step had three treatments: 
1) 200µl of fresh 37°C accumulation buffer alone (controls); 
2)  200µl of buffer containing  200µM unlabelled L-arginine alone (for [3H]ADMA 
experiments); 
3)  or 200µl of buffer containing 200µM unlabelled L-arginine and [3H]L-arginine (7nM).  
This accumulation assay had the same time points (1, 2.5, 5, 20 and 30 minute incubations) 
used in chapter 3 and halted with ice cold PBS and the radioactivity subsequently measured as 
described in section 2.2.  
5.2.4. Cytotoxicity assay 
Any cytotoxic effects of the trans-stimulation assay treatments on the hCMEC/D3 cells were 
determined using an MTT assay as outlined in section 2.5, except cells underwent both the 20 
minute preload and 30 minute incubation times (50 minutes in total under the same 
treatments used in the trans-stimulation assay described above). 
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5.3.1. Influence of unlabelled extracellular L-arginine on the trans-stimulation of 
preloaded [3H]ADMA  
To understand the influence of extracellular L-arginine on the trans-stimulation of 
preloaded intracellular ADMA, confluent monolayers of hCMEC/D3s were preloaded with 
[3H]ADMA with or without 0.5 µM, 3µM or 500µM unlabelled ADMA (and [14C]sucrose) in 
accumulation buffer for 20 minutes before being replaced for 30 minutes with accumulation 
buffer containing an L-arginine supplementation concentration of 200µM. The results are 
displayed in figures 5.1 to 5.4 below.  
5.3.2. [14C]sucrose in preloaded [3H]ADMA trans-stimulation studies 
The differences in [14C]sucrose accumulation between all the[3H]ADMA preload treatments 
([3H]ADMA and [14C]sucrose preload with 0.5 µM, or 3µM, or 500µM unlabelled ADMA) failed 
to obtain statistical significance when compared to controls in these groups ([3H]ADMA and 
[14C]sucrose preload alone without excess unlabelled ADMA) (see insert graphs in figures 5.1-
5.4). 
5.3.3. [3H]ADMA trans-stimulation studies 
When the cells were preloaded with [3H]ADMA and [14C]sucrose alone, the addition of 
unlabelled L-arginine in the subsequent accumulation assay saw a significant decrease in the 
accumulation of [3H]ADMA at all times points when compared to the addition of accumulation 
buffer alone (figure 5.1). The percentage decrease in accumulation was 34% at 1 minute, 47% 
at 2.5 minutes, 47% at 5 minutes, 114% at 20 minutes and 136% at 30 minutes (p<0.01 at all 
time points).  
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Figure 5.1.  The trans-stimulation effect of extracellular L-arginine on preloaded [3H]ADMA 
and [14C]sucrose. To investigate if intracellular ADMA could be trans-stimulated by 
extracellular L-arginine, confluent monolayers of hCMEC/D3 cells were preloaded with 
[3H]ADMA and [14C]sucrose (as a marker of non-specific binding, barrier integrity and 
extracellular space, see insert) in accumulation buffer for 20 minutes, before the preload 
buffer was replaced with accumulation buffer alone or accumulation buffer containing 200µM 
unlabelled L-arginine for 30 minutes. **p<0.01. [3H]ADMA data are corrected for [14C]sucrose 
and protein content (with [14C]sucrose corrected for protein only) and expressed as means ± 
S.E.M, n=5 (plates) with 6 replicates (wells) per n. ADMA – asymmetric dimethylarginine.  
 
A similar effect was also noted with the addition of unlabelled L-arginine following the 
incubation of [3H]ADMA with the ADMA physiological concentration of  0.5µM unlabelled 
ADMA (figure 5.2). The difference at all time points obtained the same significance (p<0.01), 
except for 20 minutes (p<0.05) with the percentage decrease averaging at 53%.   
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Figure 5.2. The trans-stimulation effect of extracellular L-arginine on preloaded [3H]ADMA 
with 0.5µM ADMA and [14C]sucrose. hCMEC/D3 cells were preloaded with [3H]ADMA along 
with 0.5µM unlabelled ADMA and [14C]sucrose (as a marker of non-specific binding, barrier 
integrity and extracellular space, see insert) in preload buffer for 20 minutes, before the being 
replaced with accumulation buffer alone or accumulation buffer containing 200µM unlabelled 
L-arginine for 30 minutes. *p<0.05, **p<0.01. [3H]ADMA data are corrected for [14C]sucrose 
and protein content (with [14C]sucrose corrected for protein only) and expressed as means ± 
S.E.M, n=4 (plates) with 6 replicates (wells) per n. ADMA – asymmetric dimethylarginine. 
 
When cells were preloaded with [3H]ADMA and the pathophysiological plasma 
concentration of 3µM ADMA (figure 5.3), the addition of accumulation buffer with 200µM 
unlabelled L-arginine saw a large significant decrease in accumulation at all time points when 
compared to the control treatment of accumulation buffer alone (p<0.001). As with the 
previous experiments, the percentage change between the treatments decreased over time 
from 33% at 1 minute, to 150% at 30 minutes.  
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Figure 5.3.  The trans-stimulation effect of extracellular L-arginine on preloaded [3H]ADMA 
with 3µM ADMA and [14C]sucrose. To investigate the trans-stimulation of intracellular ADMA 
by extracellular L-arginine, confluent monolayers of hCMEC/D3 cells were preloaded with 
[3H]ADMA and 3µM ADMA along with [14C]sucrose (as a marker of non-specific binding, barrier 
integrity and extracellular space, see insert figure) in preloading buffer for 20 minutes, before 
being  replaced with accumulation buffer alone or accumulation buffer containing 200µM 
unlabelled L-arginine for 30 minutes. ***p<0.001. [3H]ADMA data are corrected for 
[14C]sucrose and protein content (with [14C]sucrose corrected for protein only) and expressed 
as means ± S.E.M, n=5 (plates) with 6 replicates (wells) per n. ADMA – asymmetric 
dimethylarginine.  
 
The preloading of hCMEC/D3 cells with [3H]ADMA and the supraphysiological concentration 
of 500µM ADMA also saw significant decreases in [3H]ADMA accumulation following addition 
of 200µM unlabelled L-arginine compared to accumulation buffer controls (figure 5.4). With 
the exception of 1 minute, all time points saw significant decreases (p<0.05). The percentage 
decreases were 130% for 2.5 minutes, 280% for 5 minutes, 100% for 20 minutes and 233% for 
30 minutes.  
 INTERACTIONS OF ENDOGENOUS AND EXOGENOUS MOLECULES WITH 





Figure 5.4. The trans-stimulation effect of extracellular L-arginine on preloaded [3H]ADMA 
with 500µM ADMA and [14C]sucrose. 200µM extracellular L-arginine was added with fresh 
accumulation buffer to assess the impact of L-arginine on the trans-stimulation of preloaded 
[3H]ADMA and 500µM ADMA along with [14C]sucrose (as a marker of non-specific binding, 
barrier integrity and extracellular space, see insert), compared to the addition of accumulation 
buffer alone. *p<0.05. [3H]ADMA data are corrected for [14C]sucrose and protein content (with 
[14C]sucrose corrected for protein only) and expressed as means ± S.E.M, n=5 (plates) with 6 
replicates (wells) per n. ADMA – asymmetric dimethylarginine.  
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5.3.4. Influence of pre-loaded unlabelled ADMA on the trans-stimulation of 
extracellular [3H]L-arginine  
To investigate if intracellular ADMA could trans-stimulate extracellular [3H]L-arginine with 
the 200µM supplementation concentration, confluent monolayers of hCMEC/D3 cells were 
preloaded with preload buffer alone or preload buffer containing 0.5µM, 3µM or 500µM 
unlabelled ADMA for 20 minutes, before the buffer was removed and replaced with 
accumulation buffer containing either [3H]L-arginine and [14C]sucrose alone or [3H]L-arginine 
and [14C]sucrose with 200µM unlabeled L-arginine. The data are exhibited in figure 5.5. 
5.3.5. [14C]sucrose in [3H]L-arginine trans-stimulation studies 
No significant differences in [14C]sucrose accumulation were detected between any of the 
ADMA preloads in the extracellular [3H]L-arginine experiments when compared to the control 
group (preload buffer alone) (see insert in figure 5.5). 
5.3.6. [3H]L-arginine trans-stimulation studies 
A preload of 0.5µM ADMA saw significant increases in [3H]L-arginine when compared to 
preloading with preload buffer alone at all time points except 30 minutes (all p<0.01 until 
p<0.05 at 20 minutes, figure 5.5). The percentage increases seen at each time point were 553% 
at 1 minute, 275% at 2.5 minutes, 175% at 5 minutes, and 54% at 20 minutes, which show 
there was a decrease in the percentage change as incubation time in the accumulation assay 
increased.  
In a similar fashion, the preloading of 3µM ADMA also induced significant increases in the 
subsequent [3H]L-arginine accumulation when compared to preloading with preload buffer 
alone at all time points except 30 minutes (all p<0.01 until p<0.05 at 20 minutes). The 
percentage increases seen at each time point were 655% at 1 minute, 312% at 2.5 minutes, 
233% at 5 minutes, and 41% at 20 minutes, which also demonstrate was a decrease in the 
percentage change as accumulation assay incubation time increased. When compared directly, 
there were no significant differences in the [3H]L-arginine accumulation between the 0.5µM 
and 3µM ADMA preloading treatments at any time point. 
Preloading with 500µM ADMA saw a large and significant increase in [3H]L-arginine 
accumulation compared to both preloading with preload buffer alone and the 5µM and 3µM 
ADMA preload treatments (p<0.001 in all cases). Large percentage increases in [3H]L-arginine 
accumulation were noted between 500µM ADMA and the control (preload buffer alone) 
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incubation; with a 1736% increase noted at 1 minute; a similar 1387% increase at 2.5 minutes, 
908% at 5 minutes, 595% at 20 minutes, and 564% at 30 minutes. 
  
Figure 5.5. The trans-stimulation effect of intracellular ADMA on extracellular [3H]L-arginine 
with 200µM unlabelled L-arginine and [14C]sucrose. hCMEC/D3 cells were preloaded with 
preload buffer containing 0.5µM, 3µM and 500µM unlabelled ADMA to assess the trans-
stimulation effect on extracellular [3H]L-arginine with 200µM unlabelled L-arginine and 
[14C]sucrose (a marker of non-specific binding, barrier integrity and extracellular space, see 
insert). Data were compared to cells preloaded with preload buffer only. *p<0.05, **p<0.01, 
***p<0.001 . [3H]L-arginine data are corrected for [14C]sucrose and protein content (with 
[14C]sucrose corrected for protein only) and expressed as means ± S.E.M, n=6 (plates) with 6 
replicates (wells) per n. ADMA – asymmetric dimethylarginine. 
 INTERACTIONS OF ENDOGENOUS AND EXOGENOUS MOLECULES WITH 




5.3.7. Cytotoxicity of trans-stimulation treatments 
The cytotoxic potential of all compounds used in this study over the complete 50 minute 
time-frame (20 minute preload and the subsequent 30 minute accumulation assay) was 
assessed in the hCMEC/D3 cells using an MTT assay, comparing treated cells to untreated 
control cells. There were no significant differences in cell viability between the treatments 
(figure 5.6 below).  
 
Figure 5.6. The cytotoxic effects of study treatments on confluent monolayers of hCMEC/D3 
cells. The study treatments were assessed for any cytotoxic potential using an MTT assay 
during initial 20 minute preloads followed by 30 minute incubations with confluent 
monolayers of hCMEC/D3 cells in 96 well plates, as described in section 2.5. Buffer alone refers 
to 20 minute preloading and 30 minute incubation with accumulation buffer alone. The 
remaining bar descriptions refer to a 20 minute preload with a varying unlabelled ADMA 
concentrations before 30 minute incubation with either buffer alone or 200µM unlabelled L-
arginine. The data were compared to untreated cells and the results are expressed as 
percentage viability ± S.E.M and compared to control untreated cells, which were incubated 
for 30min in culture medium. n=3 (plates), 6 replicates per n (6 wells). Buffer alone treatment 
= 20 minute preload in preload buffer alone + 30 minute incubation with accumulation buffer 
alone, ADMA – asymmetric dimethylarginine, BCH – 2 -aminobicyclo-(2,2,1)-heptane-2-
carboxylic acid. 
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5.4. Chapter 5 – Discussion 
As more conditions associated with increased ADMA plasma concentrations are recognised, 
the role of the L-arginine/ADMA ratio is likely to become more clinically relevant. This ratio is 
of particular importance considering the effects of L-arginine supplementation on attenuating 
endothelial dysfunction and NO impairment in the conditions where ADMA may be acting 
pathophysiologically – despite the fact that physiological plasma concentrations of L-arginine 
are well above the Km for all form of NOS (Tsikas et al., 2000). It has been hypothesised by 
numerous authors that ADMA can explain this ‘L-arginine paradox’, and that the mechanism 
could be uptake transport competition or the trans-stimulation of intracellular ADMA 
transport by extracellular L-arginine. However, this has not been directly investigated until this 
present study. Because we had demonstrated that physiological and pathophysiological 
extracellular ADMA did not induce significant decreases in L-arginine transport into the cell, we 
decided to investigate the latter of these hypotheses by using the hCMEC/D3 cells in an 
adapted model of accumulation where an ADMA preloading step was included. 
The findings of this study show that preloaded [3H]ADMA was readily exported from the 
cells once the preload buffer was replaced with accumulation buffer – without the presence of 
extracellular L-arginine – and this was likely to be due to the movement of the molecule along 
its concentration gradient from a high (intracellular) concentration to a low (extracellular) 
concentration. We also demonstrated that at almost all time points, and regardless of the 
preloaded unlabelled ADMA concentration, the addition of extracellular L-arginine in the 
subsequent accumulation assay induced a significant decrease in the [3H]ADMA accumulation 
values in the hCMEC/D3s compared to the controls. These decreases in accumulation indicate 
that the transport of preloaded intracellular [3H]ADMA was trans-stimulated to exit the cells by 
the addition of extracellular L-arginine.  
The transport of extracellular L-arginine was also investigated by using [3H]L-arginine, 
showing that the presence of preloaded unlabelled intracellular ADMA significantly increased 
the uptake of [3H]L-arginine in the following accumulation assay when compared to preload 
only controls, and also that increasing preload concentrations of intracellular ADMA from 3µM 
to 500µM proportionally increased [3H]L-arginine uptake. Collectively, these data provide 
evidence for trans-stimulation via the action of bidirectional CAA transport systems in the 
hCMEC/D3 cells.  
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In the context of the ‘L-arginine paradox’, our data add weight to the theory that 
intracellular ADMA is exported via the trans-stimulation of CAA transport systems by 
extracellular L-arginine, but there are issues with the model and theory. It is all well to preload 
cells with ADMA in the absence of competitive CAAs, but when ADMA is in the presence of L-
arginine we have already shown in the previous chapter that ADMA outcompeting L-arginine 
for uptake is an unlikely event. As eNOS is complexed with CAT-1, that hCMEC/D3s express 
CAT-1, and as both L-arginine and ADMA appear to be predominately using system y+, it is 
likely that this transporter is the one implicated in our trans-stimulation data. Therefore, if L-
arginine is preferentially transported by CAT-1 compared to ADMA, it remains puzzling how in 
a more physiological setting, in vitro or in vivo, extracellular ADMA could accumulate in the 
endothelium and sufficiently inhibit eNOS. However, as CAT-1 has large affinities for its CAA 
substrates, it is possible that both L-arginine and ADMA could both accumulate in the cell at 
concentrations sufficient for their action on eNOS. Indeed, a previous study by Cardounel et 
al., using bovine aortic endothelial cells, demonstrated that in the presence of 100µM 
extracellular L-arginine, 5µM extracellular ADMA was able to accumulate in the cells and exert 
a significant 12% inhibition of NO production (Cardounel et al., 2007). If the pathophysiological 
concentration of 3µM ADMA is sufficient enough to infer eNOS uncoupling inducing 
subsequent superoxide production has not been demonstrated. An extracellular ADMA 
concentration of 100µM however, is enough to elicit such an effect (Sud et al., 2008). 
Interestingly, Cardounel et al., also noted that 100µM L-arginine only reduced ADMA uptake 
by 65%, suggesting that either there were different transporters in use, or that the transport 
proteins involved favoured ADMA to L-arginine. The authors went on to demonstrated that in 
the absence of L-arginine, extracellular ADMA concentrations of 0.5µM and 10µM significantly 
increased intracellular ADMA to 4.4µM and 68.4µM respectively, and that with L-arginine 
present, an extracellular concentration of 10µM gave rise to intracellular concentrations of 
23.5µM (Cardounel et al., 2007). This suggests that it is extracellular concentrations of L-
arginine and ADMA that regulate NO production.  
Intriguingly, in a recent study, Shin et al., used L-arginine ethyl esters that are not 
transported by CAT-1, but readily accumulate in cells (by passive diffusion) to show that L-
arginine accumulation in human A549 endothelial cells via passive diffusion did not alter NO 
production, in contrast to L-arginine accumulation via CAT-1 (Shin et al., 2011). Their data also 
suggest that it is indeed extracellular concentrations and not intracellular concentrations of L-
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arginine entering the cells via CAT-1 that regulate NO production, and that intracellular pools 
of L-arginine were separate from the eNOS/CAT-1 complex. The data of Shin et al., suggests 
that some intracellular pools of L-arginine are not accessible to eNOS. This notion is also 
supported by the finding of two intracellular pools of L-arginine in human EA.hy926 
endothelial cells, one of which is accessible to eNOS, and one which is not (Closs et al., 2000). 
Another study by the same laboratory using human umbilical vein endothelial cells 
demonstrated two sub-compartments of the eNOS accessible pool; one that consisted of 
citrulline to L-arginine recycling that could be depleted by extracellular NAAs; and one that was 
nourished by protein breakdown that could not be depleted by extracellular CAAs or NAAs. 
The authors argued that this second sub-compartment represented an area in the cell where 
ADMA could accumulate and have direct function on eNOS under pathophysiological 
conditions (Simon et al., 2003). If compartmentalised intracellular ADMA produced by PRMTs 
has access to eNOS has yet to be demonstrated and little is generally known about intracellular 
ADMA levels in disease.  Intriguingly, Cardounel et al., elegantly demonstrated a 3.6-fold 
increase of intracellular ADMA in a rat carotid model of experimentally-induced balloon injury 
– 28 days post injury – which was able to significantly impair endothelium-dependent vascular 
relaxation and be alleviated by exogenous L-arginine supplementation. Their results 
demonstrated for the first time that intracellular ADMA is elevated under pathological 
conditions and could reach levels sufficient to inhibit NOS function (Cardounel et al., 2007). A 
more recent study also exhibited data to suggest that plasma ADMA poorly reflects 
intracellular concentrations of ADMA in rabbit models of critical illness (Davids et al., 2011).  
Work is required to look at the eNOS accessible intracellular pools for the presence of 
ADMA, especially during pathophysiological conditions where plasma ADMA is increased to 
see if there is also an increase intracellularly. It is also crucial to deduce if eNOS inhibition by 
ADMA is a result of extracellular concentrations, intracellular concentrations or a combination 
of the two. This is because we have demonstrated that extracellular ADMA can be 
accumulated and trans-stimulated from human BMECs, which could support the theory that 
pathophysiological concentrations of intracellular ADMA involved in pathogenesis could be 
removed by L-arginine supplementation, but if it turns out that it is the intracellular pools of 
ADMA which are not accessible to the extracellular fluid that are responsible for eNOS 
inhibition, then this would discount the role of trans-stimulation in the ‘L-arginine paradox’.  
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It is also debatable if the ‘L-arginine paradox’ is a paradox at all. Shin et al., also argued that 
their finding that the L-arginine Km of cellular (not purified) eNOS is 36.2 ± 9.8µM, would 
suggest that the ‘L-arginine paradox’ is not even a paradox because this Km is within the range 
of normal plasma concentrations of L-arginine, which when increased with supplementation to 
around 200µM would increase NO production (Shin et al., 2011). 
Modelling the ‘L-arginine paradox’ in vitro to investigate the roles of ADMA is difficult 
because it would require careful control of cellular access to amino acids as well as 
measurements of the different intracellular pools and extracellular concentrations of amino 
acids at all stage of the study. Regarding our experimental design, it may have been more 
beneficial physiologically to perform the accumulation of ADMA in the presence of 
physiological concentrations of extracellular L-arginine and other CAAs, before L-arginine 
supplementation to see if this would’ve induced trans-stimulation. Although these steps would 
be easier to perform in vitro than in vivo, there are still issues involving the saturation of cell 
culture media with AAs. DMEM for example contains 300-400µM L-arginine alone, but no L-
ornithine which has a physiological concentration around 55-65µM (Psychogios et al., 2011).  
Although our trans-stimulation and accumulation experiments were performed in buffer 
with a controlled composition (i.e. no CAAs), the culture media used to grow the hCMEC/D3s 
was likely to contain high concentrations of CAAs (the manufacturers declined to reveal the 
media composition).  We also did not measure intracellular and extracellular concentrations of 
ADMA and L-arginine throughout the culturing or experimental stages.   
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We have demonstrated that extracellular L-arginine can significantly induce the export of 
preloaded intracellular ADMA at a variety of concentrations via trans-stimulation of CAA 
transporters, most likely the system y+ protein CAT-1, and that preloaded intracellular ADMA 
can significantly increase the uptake of extracellular L-arginine in a concentration dependent 
manner. These data could provide evidence for the involvement of ADMA in the ‘L-arginine 
paradox’, that supplementation of L-arginine could trans-stimulate the efflux of intracellular 
ADMA during conditions of eNOS inhibition by the methylarginine, returning the L-arginine 
ratio and NO production to normal. However, this would imply extracellular concentrations of 
ADMA are responsible for inhibiting eNOS, yet the pathophysiological plasma concentrations 
are unlikely to compete with other CAAs for cellular transport. Even if these pathophysiological 
concentrations did enter the cells, it does not explain how ADMA would exhibit an inhibitory 
effect on eNOS in the presence of saturating L-arginine concentrations. It therefore seems 
more plausible that the higher intracellular concentrations of ADMA, which are likely to have 
access to eNOS could be exhibiting the effects, especially considering the evidence of an eNOS 
accessible intracellular sub-compartment that accumulates L-arginine and other 
methylarginines from protein breakdown events. During disease and pathophysiological 
conditions, it is possible that DDAH could become dysfunctional, accumulating more ADMA in 
this sub-compartment, which could be sufficient enough to inhibit or uncouple eNOS in the 
presence of physiological concentrations of L-arginine. Supplementation could then possibly 
revert this, explaining the ‘L-arginine paradox’. However, the roles of the L-arginine 
metabolising enzyme arginase and other eNOS inhibiting methylarginines such as L-NMMA 
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Chapter 6. Exogenous molecule 
interactions – Part I – Eflornithine 
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6.1. Chapter 6 – Introduction and aims 
The drug eflornithine is an analogue of the CAA ornithine and used in treatment of S2 HAT. 
In trypanosomes it targets the enzyme ornithine decarboxylase which causes severe 
impairment of polyamine synthesis and results in retarded cell growth (Vincent et al., 2010). 
The trypanosome species T. b. gambiense is highly sensitive to the action of eflornithine 
because of its slow replenishment of ornithine decarboxylase (Phillips et al., 1987), which gives 
eflornithine potent anti-trypanosomal action. T. b. rhodesiense however, have a much higher 
turnover of ornithine decarboxylase which makes them resistant to eflornithine (Iten et al., 
1997). As well as this failing, eflornithine is also relatively expensive in the resource-poor 
setting of sub-Saharan Africa, as well as requiring intensive administration, and instances of 
therapeutic short fallings have been reported (Lutje et al., 2010). 
In an attempt to increase the action of eflornithine as well as counter the emerging 
resistant populations of trypanosomes, CT of anti-HAT drugs has become a successful strategy, 
particularly with nifurtimox-eflornithine combination therapy (NECT). How CT improves the 
treatment of S2 HAT compared to monotherapy is not clear, but has been suggested to be a 
result of improved drug delivery to the brain. For drugs to enter the brain to target the 
trypanosomes that cause S2-HAT they must cross the BBB, and so work by our group has 
investigated this in murine models. The results from our in vivo investigations revealed that 
eflornithine poorly entered the mouse brain, possibly explaining why intensive treatment 
regimes are required to ensure efficacy (Sanderson et al., 2008). The work also illustrated that 
combination of eflornithine with suramin improved the delivery of eflornithine to the mouse 
brain, possibly by drug-drug interactions (DDIs) between suramin and [3H]eflornithine which 
induced eflornithine endocytosis via suramin endocytosis (Sanderson et al., 2007, Sanderson et 
al., 2008). 
As well as investigations into CT, the mechanism of eflornithine entry to trypanosomes has 
also produced interesting data supporting a hypothesis that eflornithine is able to utilise AA 
transport systems due to its similarity with ornithine. Studies have shown that eflornithine 
uptake is temperature dependent (Bellofatto et al., 1987) and saturable (Phillips et al., 1987) – 
hallmarks of transporter activity. It is also apparent that the zwitterionic, charged amino acid 
properties of eflornithine would also make the drug unfavourable for passive diffusion 
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(Vincent et al., 2010). Vincent et al., also been recently demonstrated that loss of a 
trypanosome AA transporter gene conferred eflornithine resistance to T. brucei brucei.  
These data combined with our knowledge of anti-HAT drugs and CAA transporters at the 
BBB make it pertinent to investigate eflornithine transport in the hCMEC/D3s. We therefore 
decided to investigate if eflornithine utilises CAA transport systems and if CT with other HAT 
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A description of the generation of the hCMEC/D3 cells can be found in the general methods 
chapter (chapter 2) section 2.1. 
6.2.1. Cell culture 
Please see section 2.1.1 in chapter 2 for details of hCMEC/D3 culture conditions. 
6.2.2. Radioactivity studies – Materials 
Tritium labelled eflornithine hydrochloride was custom radiolabelled (500 mCi/mmol, 
radiochemical purity 97.6%) by Moravek, CA, USA. It was used in the accumulation 
experiments alongside varying CAA transport substrates and inhibitors (see table 2.1 in 
chapter 2 for source information and references) and the anti-HAT drugs nifurtimox, 
melarsoprol  (both kind gifts from Professor Croft; London School of Hygiene and Tropical 
Medicine, London, UK), eflornithine, pentamidine and suramin (all from Sigma, UK).  
6.2.3. Eflornithine accumulation 
To investigate the accumulation of [3H] eflornithine (and [14C]sucrose as a correction value 
for non-specific binding and extracellular space) in the hCMEC/D3 cells, the protocol described 
in section 2.2 was used over a 30-minute time period.  
For self-inhibition experiments which provide evidence of influx mechanisms, 250µM 
unlabelled eflornithine, or 55µM ornithine was added to the accumulation buffer along with 
[3H]eflornithine (0.0111 MBq or 300 nCi, 720nM) and [14C]sucrose (0.0148 MBq, 400 nCi, 
972nM). For cross competition experiments, 100µM of L-lysine, 100µM L-arginine, 100µM 
ADMA or 100µM leucine were added. The y+ competitive substrate L-homoarginine (20mM) 
and the broad scale system A, system L and system B0,+ inhibitor 2-aminobicyclo-(2,2,1)-
heptane-2-carboxylic acid (BCH) (4mM) were also used separately for initial evidence of 
transporter activity. We also performed a [3H]eflornithine and [14C]sucrose accumulation study 
in the previously described buffer absent of Na+ and Cl- ions, to stop the action of the Na+ and 
Cl- dependent ATB0,+ and investigate the role of the transporter in [3H]eflornithine 
accumulation. Part of these CAA investigative experiments were performed by BSc project 
student Ms. Gayathri Sekhar, under supervision.  
As well as these molecules, in a separate series of accumulation experiments, the effects of 
anti-HAT CT on [3H]eflornithine accumulation were also assessed. The clinically relevant doses 
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from our previous studies (Sanderson et al., 2007, Sanderson et al., 2008, Sanderson et al., 
2009, Jeganathan et al., 2011) of 6µM nifurtimox, 10µM pentamidine, 150µM suramin or 
30µM melarsoprol were used in the accumulation buffer alongside [3H]eflornithine and 
[14C]sucrose. Apart from suramin which is water soluble, the remaining anti-HAT drugs were 
pre-dissolved in dimethyl sulfoxide (DMSO) and added to the accumulation buffer so that the 
final DMSO concentration was 0.05%. For the CT study involving DMSO, a DMSO 
[3H]eflornithine and [14C]sucrose control accumulation assay was performed. 
6.2.4. MTT cytotoxicity assay 
The potential of the compounds used in this accumulation study to cause cytotoxicity was 
assessed using an MTT assay, the protocol of which is described in section 2.5. The effect of 
these compounds was compared to untreated control hCMEC/D3 cells.  
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6.3.1. Influence of CAA transporters and substrates on the accumulation of 
[3H]eflornithine and [14C]sucrose 
The roles of self-inhibition, CAA substrates and inhibitors on the accumulation of 
[3H]eflornithine and [14C]sucrose was assessed in the hCMEC/D3s and displayed below in 
figures 6.1 to 6.3. 
6.3.2. [14C]sucrose in CAA studies 
The transport and subsequent accumulation of [14C]sucrose was used as an internal control 
for the accumulation experiments. There were no significant differences between any of the 
treatments investigated when compared to controls. Data are displayed as inserts in figures 
6.1 to 6.3. 
6.3.3. [3H]eflornithine in CAA studies – Self-inhibition 
To look for evidence of transporter interaction, self-inhibition experiments were initially 
performed with [3H]eflornithine by using 250µM unlabelled eflornithine and the closely related 
CAA ornithine at 55µM. Intriguingly, the addition of 250µM eflornithine caused no significant 
changes in the accumulation of [3H]eflornithine, but the addition of 500µM eflornithine 
induced significant decreases at all time points, with an average decrease of 38%  (p<0.01). 
55µM ornithine induced significant decreases of 36% and 37% at 20 and 30 minute time 
periods respectively when compared to controls (p<0.05 in both instances). The data are 
presented in figure 6.1 below. 
  
 INTERACTIONS OF ENDOGENOUS AND EXOGENOUS MOLECULES WITH 





Figure 6.1. The influence of unlabelled eflornithine and ornithine on the accumulation of 
[3H]eflornithine and [14C]sucrose in hCMEC/D3 cells. Confluent monolayers of hCMEC/D3 cells 
grown in 96-well plates were incubated in accumulation buffer containing [3H]eflornithine and 
[14C]sucrose either alone, with 55µM ornithine, 250µM or 500µM eflornithine. [14C]sucrose 
was used as a marker of non-specific binding, barrier integrity and extracellular space for 
accumulation experiments (displayed in the insert). *p<0.05, **p<0.01. All [3H]eflornithine 
data are corrected for [14C]sucrose and protein content (with [14C]sucrose corrected for protein 
only) and expressed as means ± S.E.M, n=3-5 (plates) with 6 replicates (wells) per n. 
 
6.3.4. [3H]eflornithine in CAA studies – Cross competition 
 To look for evidence of transporter interaction, cross-competition experiments were 
performed with [3H]eflornithine by using the CAAs 100µM L-lysine, 100µM L-arginine and 
100µM ADMA and the NAA 100µM leucine. At all time points, the addition of ADMA caused 
significant decreases in the accumulation of [3H]eflornithine, which increased in significance 
over time (p<0.05 from 1 minute to 5 minutes, and p<0.01 at 20 minutes and 30 minutes). In 
percentages these ADMA-induced decreases were 64% at 1 minute, 71% at 2.5 minutes, 69% 
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at 5 minutes, 78% at 20 minutes and 79% at 30 minutes. Similar significant decreases were 
noted with L-lysine from 5 minutes (35%, p<0.05) to 20 and 30 minutes (68% and 69%, p<0.01). 
It was not until 20 and 30 minutes when both L-arginine and leucine induced decreases in 
[3H]eflornithine accumulation (all p<0.05). Data are outlined in figure 6.2 below. 
 
Figure 6.2. The influence of cross-competition on the accumulation of [3H]eflornithine and 
[14C]sucrose in hCMEC/D3 cells. Confluent monolayers of hCMEC/D3 cells grown in 96-well 
plates were incubated in accumulation buffer containing [3H]eflornithine and [14C]sucrose 
either alone, with 100µM of each of the CAAs L-lysine, L-arginine and ADMA or 100µM of the 
NAA,  leucine. [14C]sucrose was used as a marker of non-specific binding, barrier integrity and 
extracellular space for accumulation experiments (displayed in the insert). *p<0.05, **p<0.01. 
[3H]eflornithine data are corrected for [14C]sucrose and protein content (with [14C]sucrose 
corrected for protein only) and expressed as means ± S.E.M, n=3-4 (plates) with 6 replicates 
(wells) per n. 
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6.3.5. [3H]eflornithine in CAA studies – transporter inhibition 
By adding the y+ interacting drug L-homoarginine (20mM), the broad scale system A, 
system L and system B0,+ inhibitor BCH (4mM) and removing Na+ and Cl- ions from the 
accumulation buffer, the role of AA transport systems in [3H]eflornithine uptake were 
investigated. At all time points, L-homoarginine caused a significant decrease (p<0.001) in the 
uptake and accumulation of [3H]eflornithine, which averaged at 80%. The data are illustrated 
in figure 6.3 below. 
 
Figure 6.3. The influences of AA transport inhibition on the accumulation of [3H]eflornithine 
and [14C]sucrose in hCMEC/D3 cells. Confluent monolayers of hCMEC/D3 cells grown in 96-
well plates were incubated in accumulation buffer containing [3H]eflornithine and [14C]sucrose 
either alone, with 20mM of the system y+ inhibitor L-homoarginine, 4mM of the system A, 
system L and system B0,+ inhibitor BCH or in Na+ and Cl- free accumulation buffer. [14C]sucrose 
was used as a marker of non-specific binding, barrier integrity and extracellular space for 
accumulation experiments (displayed in the insert). ***p<0.001. [3H]eflornithine data are 
corrected for [14C]sucrose and protein content (with [14C]sucrose corrected for protein only) 
and expressed as means ± S.E.M, n=3 (plates) with 6 replicates per n. 
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6.3.6. Influence of anti-HAT drugs on the accumulation of [3H]eflornithine and 
[14C]sucrose 
The roles of CT of anti-HAT drugs on the accumulation of [3H]eflornithine and [14C]sucrose 
was assessed in the hCMEC/D3s and displayed below in figures 6.4 and 6.5. 
6.3.7. [14C]sucrose in CT studies 
The transport and subsequent accumulation of [14C]sucrose was used as an internal control 
for the CT accumulation experiments. There were no significant differences between any of 
the treatments investigated compared to control studies. Data are displayed in the inserts of 
figures 6.4 and 6.5. 
6.3.8. Influence of CT on the accumulation of [3H]eflornithine 
By adding the clinically relevant doses of the anti-HAT drugs pentamidine (10µM), 
melarsoprol (30µM) and nifurtimox (6µM) in the presence of DMSO (final volume 0.05%), we 
were able to assess the influence of CT on the uptake and accumulation of [3H]eflornithine 
(figure 6.4). Out of all the treatments, only the addition of pentamidine caused significant 
changes in [3H]eflornithine accumulation. Apart from 1 minute where there was no change in 
accumulation when unlabelled pentamidine was present, a significant decrease was seen at all 
other time points (p<0.01) with an average decrease of 62.75%. 
. 
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Figure 6.4. The influence of anti-HAT drug CT on the uptake and accumulation of 
[3H]eflornithine and [14C]sucrose in hCMEC/D3 cells in the presence of DMSO. Confluent 
monolayers of hCMEC/D3 cells grown in 96-well plates were incubated in accumulation buffer 
containing [3H]eflornithine and [14C]sucrose either alone, with the anti-HAT drugs pentamidine 
(10µM), melarsoprol (30µM) and nifurtimox (6µM). [14C]sucrose was used as a marker of non-
specific binding, barrier integrity and extracellular space for accumulation experiments 
(displayed in the insert). **p<0.01. [3H]eflornithine data are corrected for [14C]sucrose and 
protein content (with [14C]sucrose corrected for protein only) and expressed as means ± S.E.M, 




Suramin (150µM) is water soluble and so was added to the accumulation buffer without 
DMSO and compared to control [3H]eflornithine, also without the presence of DMSO. There 
were no significant differences in [3H]eflornithine accumulation between the treatments 
(figure 6.5). There were also no significant [3H]eflornithine or [14C]sucrose control between 
experiments in the absence and presence of DMSO. 
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Figure 6.5. The influence of the anti-HAT drug suramin on the uptake and accumulation of 
[3H]eflornithine and [14C]sucrose in hCMEC/D3 cells in the absence of DMSO. Confluent 
monolayers of hCMEC/D3 cells grown in 96-well plates were incubated in accumulation buffer 
containing [3H]eflornithine and [14C]sucrose either alone, with the anti-HAT drug suramin 
(150µM). [14C]sucrose was used as a marker of non-specific binding, barrier integrity and 
extracellular space for accumulation experiments (displayed in the insert). [3H]eflornithine 
data are corrected for [14C]sucrose and protein content (with [14C]sucrose corrected for protein 
only) and expressed as means ± S.E.M, n=4 (plates) with 6 replicates per n. 
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6.3.9. Cytotoxicity assay 
The cytotoxic potential of compounds used in this study (not studied in previous chapters) 
over the 30 minute time-frame was assessed in the hCMEC/D3 cells using an MTT assay, 
comparing treated cells to untreated control cells. There were no significant differences in cell 
viability between the treatments (figure 6.6 below).  
 
Figure 6.6. The cytotoxic effects of study compounds on confluent monolayers of hCMEC/D3 
cells. The study compounds were assessed for any cytotoxic potential using an MTT assay 
during 30 minute incubation with confluent monolayers of hCMEC/D3 cells in 96 well plates, as 
described in section 2.5. The results are expressed as percentage viability ± S.E.M and 
compared to control untreated cells, which were incubated for 30 minutes in culture medium. 
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The prospect of survival for patients suffering HAT is poor if diagnosis is not made during S1 
of the disease. This is because during S2, the parasites enter the brain and are effectively 
protected from the action of trypanocidal drugs by the BBB. To kill the parasites in the brain, 
sufficient concentrations of the drugs must be able to cross to be efficacious. It therefore 
remains perplexing why little is known about the interactions between the S2 acting drugs and 
the BBB, and as such this area has been a major field of research by our group over the past 5-
7 years with in vivo models of HAT. In this study, we decided to investigate the interactions of 
one S2-acting drug – eflornithine – with the newly established hCMEC/D3 BBB in vitro model in 
terms of uncovering evidence of CAA transport interaction and CT impact on drug uptake. 
Eflornithine, as the name suggests, is a closely related molecule to the CAA ornithine (see 
figure 6.7 below) which is a product of L-arginine metabolism by arginase in the urea cycle 
(Kawano et al., 2006).  
 
Figure 6.7. Eflornithine (left) is a derivative of ornithine (right) and so proposed to be a CAA 
transport substrate. Figure taken from (Vincent et al., 2010). 
 
Because ornithine is transported by CAA transport systems such as CAT-1 (Kaneko et al., 
2007), it is somewhat logical to assume that eflornithine may also use CAA transport 
mechanisms. To investigate this in the hCMEC/D3s we used our drug accumulation assay with 
a variety of CAA and AA transport substrates and inhibitors to assess any impact on the uptake 
and subsequent accumulation of tritiated eflornithine. Our data show that eflornithine was 
able to readily accumulate in the hCMEC/D3 cells despite having low lipophilicity as 
demonstrated by its previously published OSPC value of 0.00487 ± 0.00010 (Sanderson et al., 
2008), possibly suggesting evidence of an influx transport system. Furthermore, we showed 
that co-incubation of [3H]eflornithine with unlabelled ornithine induced a significant decrease 
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in [3H]eflornithine accumulation at 20 and 30 minute time points which provide evidence of 
competitive transport interactions. These competitive findings were echoed with the addition 
of CAAs L-lysine, L-arginine, ADMA and the NAA leucine showing significant decreases in 
eflornithine accumulation. These data suggest that eflornithine may be using a variety of CAA 
transport systems, including those not specific for CAAs such as system y+L and b0,+ which are 
known to transport leucine as well as CAAs (Mann et al., 2003) and are expressed at mRNA 
level in the hCMEC/D3s (Carl et al., 2010) as discussed in chapter 4. The transporter ATB0,+ was 
not implicated here due to the lack of significant differences between control [3H]eflornithine 
accumulation and accumulations with either BCH or Na+ and Cl- free accumulation buffer.  We 
were also able to narrow the chief transport system to y+ when we used L-homoarginine 
showing a highly significant decrease in [3H]eflornithine accumulation during co-incubation.  
However, these data are in contrast to those previously demonstrated by our group using in 
situ brain perfusion models, where no evidence of influx transport system for [3H]eflornithine 
(radiolabelled alone and radiolabelled with 250µM unlabelled eflornithine) interaction was 
found. Despite this contradiction between studies, our finding that co-incubation of tritiated 
eflornithine with 250µM unlabelled eflornithine caused no change in accumulation was similar 
to that of our previous in vivo work (Sanderson et al., 2008). Interestingly, a significant 
decrease in accumulation was only noted when 500µM eflornithine was used – an experiment 
not previously performed in situ. This finding may be explained by a very high affinity of the 
CAA systems for eflornithine. Another possibility could also be supported by the results 
obtained from leucine and ADMA co-incubation that eflornithine may be using a variety of 
transport systems to gain entry to the cells. These are likely to include CAT transporters as well 
as system y+L and b0,+ transporters, but could include a different transporter all together. siRNA 
studies investigating eflornithine resistance in T. brucei brucei found that a specific amino acid 
transporter called TbAAT6 was responsible for transporting eflornithine into the trypanosome 
(Vincent et al., 2010). Although no physiological function has been attributed to the 
transporter, the authors point out that other AAT family members have had arginine transport 
and polyamine transport function attributed to them in other trypanosome species and 
Leishmania spp. parasites. This makes it possible that other AA transport systems at the 
human BBB could be implicated in eflornithine transport. Further studies inhibiting/down 
regulating the action of or over-expressing specific transport systems is likely to better 
organise the findings described in our study.  
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We also took the opportunity to investigate CT on eflornithine uptake and accumulation in 
the hCMEC/D3s. The only result to gain statistical significance was the addition of 10µM 
pentamidine (in the presence of DMSO) to the accumulation buffer, which induced a decrease 
in the accumulation of [3H]eflornithine at all time points from 2.5 minutes. This is of particular 
interest because not only is it in contrast to the in vivo data previously published by our group, 
but it could link in with the TbAAT6 finding published by Vincent et al, where polyamine 
transport may be implicated due to the polyamine transport functions of some AAT family 
members. It is well established that pentamidine is transported into parasites including 
Leishmania spp and trypanosomes by polyamine and nucleoside transporters such as the 
adenosine-sensitive pentamidine transporter P2, and so the decrease in accumulation of 
eflornithine could be attributed to influx competition for a pentamidine-sensitive transporter.  
This would support the idea that there may be influx systems for eflornithine separate from 
CAA transporters. As far as candidates go at the BBB, polyamine transport has not been 
extensively investigated, although data from the 1980s in rats suggests that polyamine 
transport at the BBB is highly limited, although not completely absent (Shin et al., 1985).  In 
vitro data from the human endothelial cell line HUVEC suggested presence of two polyamine 
carriers, but their expression at the BBB or in the hCMEC/D3s is not known.  
Pentamidine was previously directly studied by our group in the in situ brain perfusion 
mouse model and showing that it readily accumulates in the endothelial pellet but poorly 
enters the brain due to it being a substrate for the efflux transporter P-gp (Sanderson et al., 
2009). Although it was not directly investigated here, our finding that pentamidine decreases 
eflornithine accumulation suggests eflornithine is not a substrate for P-gp as this would have 
resulted in an increase following pentamidine co-incubation. This is in line with our previous in 
situ data (Sanderson et al., 2008).   
In contrast to our previous eflornithine data, suramin did not change the accumulation of 
[3H]eflornithine in the hCMEC/D3s. Although it is of course difficult to directly compare in situ 
brain distribution data with in vitro accumulation data – especially so between different 
species – it was previously demonstrated that suramin improved the delivery of eflornithine to 
all brain regions, especially to the mouse brain capillary endothelium (Sanderson et al., 2008). 
We speculated that due to our earlier finding that suramin directly interacted with plasma 
membranes of CVOs, that perhaps DDIs between eflornithine and suramin lead to increases in 
accumulation and brain uptake of eflornithine through endocytotic events (Sanderson et al., 
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2007, Sanderson et al., 2008). This finding was not evident in our hCMEC/D3 model of BBB 
drug accumulation. 
We also did not demonstrate any differences between control eflornithine accumulation 
and eflornithine accumulation following incubation with 250µM unlabelled eflornithine, 
melarsoprol or nifurtimox. These findings were previously demonstrated in our earlier anti-
HAT drug BBB interactions (Sanderson et al., 2008). This may have implications for the 
reasoning behind the increased efficacy of NECT compared to monotherapy strategies – that 
NECT does not improve drug uptake at the BBB, but counters eflornithine/nifurtimox 
resistance at the level of the parasite.  
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In summary, we have presented data that provides evidence for the first time in a BBB 
model that eflornithine is able to utilise AA transport systems to accumulate in the 
hCMEC/D3s, most likely to be CAA transporters such as system y+ proteins, but 
polyamine/nucleoside transporters could also be implicated due to our finding with 
pentamidine. In the field, the fact remains eflornithine requires intensive treatment regimes in 
humans to gain sufficient efficacy, which suggests the lack of a specific transport system for 
the drug at the BBB. The success of eflornithine combination therapy with nifurtimox is likely a 
riposte to eflornithine resistance at the level of the parasite rather than improvements in drug 
delivery to the brain, although as previous in vivo evidence illustrates interaction of anti-HAT 
drugs with multiple-transporters, improved drug delivery cannot be ruled out – especially 
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Chapter 7. Exogenous molecule 
interactions – Part II – Nifurtimox 
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7.1. Chapter 7 – Introduction and aims 
Our research group previously investigated the ability of pentamidine, suramin, eflornithine 
and nifurtimox to cross the murine BBB using an in situ brain/choroid plexus perfusion 
technique in anaesthetised mice (Sanderson et al., 2007, Sanderson et al., 2008, Sanderson et 
al., 2009, Jeganathan et al., 2011).  Our most recent in situ study focused on nifurtimox, an 
anti-parasitic nitrofuran that was originally used to treat Chagas disease; a closely related 
condition to HAT caused by the trypanosome Trypanosoma cruzi (Haberkorn and Gonnert, 
1972, Gonnert and Bock, 1972), but has since been used in compassionate treatment for HAT 
when other methods have failed (Moens et al., 1984, Van Nieuwenhove, 1992).  It is now used 
against S2 in combination with eflornithine (NECT) (Checchi et al., 2007).   
Nifurtimox, compared to eflornithine is cheap, orally active and effective against T. b. 
gambiense and, to a lesser extent, T. b. rhodesiense (Haberkorn, 1979, Bouteille et al., 2003, 
Lutje et al., 2010). Importantly, our group have previously demonstrated that nifurtimox is able 
to cross the murine BBB in situ, but undergoes a BBB efflux removal process from the brain via 
an unidentified process, in which P-gp is not involved (as demonstrated with P-gp knockout 
mice (Jeganathan et al., 2011). The identify of this efflux mechanism is of particular interest 
with the fact that NECT is now becoming the first course of treatment against HAT S2 (Yun et 
al., 2010), having been shown to both improve efficacy and reduce harmful side effects 
associated with the other anti-HAT drugs (Priotto et al., 2007, Priotto et al., 2009).  The precise 
mechanisms behind the success of NECT have yet to be fully elucidated; but it is possible CT 
could improve drug delivery to the brain.  We have recently shown that nifurtimox delivery to 
the mouse brain is improved with the addition of the S1 acting drug pentamidine (Jeganathan 
et al., 2011), which we previously identified as being a substrate for cellular transport 
mechanisms at the BBB, including P-gp (Sanderson et al., 2009). These findings highlight the 
need to both elucidate the transport mechanisms utilised by nifurtimox and the effect of CT on 
the delivery of other anti-HAT drugs at the BBB.  
In order to translate the research to the human situation from our earlier work which 
focused on in vivo murine models of the BBB, this present study uses the hCMEC/D3 cell line.  
The following study is the first to investigate nifurtimox transport interactions in a human 
model of the BBB, and has recently been published and inserted at the back of the thesis after 
the appendices (Watson et al., 2012). 
 INTERACTIONS OF ENDOGENOUS AND EXOGENOUS MOLECULES WITH 





A description of the generation of the hCMEC/D3 cells can be found in the general methods 
chapter (chapter 2) section 2.1. 
7.2.1. Cell culture 
Please see section 2.1.1 in chapter 2 for details of hCMEC/D3 culture conditions. 
7.2.2. Radioactivity studies - Materials 
Nifurtimox (MW 287.30) was custom labelled with tritium (3H 3,4 furam ring) specific 
activity: 2 Ci/mmol) by Moravek Biochemicals (California, USA). [14C]sucrose (4980 mCi/mmol) 
was purchased from Moravek Biochemicals.  Unlabelled suramin, eflornithine and pentamidine 
were purchased from Sigma, UK. Unlabelled nifurtimox and melarsoprol were a kind gift from 
Professor S. Croft (London School of Hygiene and Tropical Medicine, UK). Probenecid, 
indomethacin and dimethyl sulfoxide (DMSO) were purchased from Sigma, UK.   
Dexamethasone and Pheophorbide A (PhA) were purchased from Acros Organics, (Fisher 
Scientific, Loughborough, UK). Para-aminohippuric acid (PAH) and taurocholic acid (TCA) were 
purchased from MP Biochemicals, UK.  Ko143 and haloperidol were purchased from Tocris 
Bioscience (Bristol, UK) and Sigma, UK, respectively 
7.2.3. Drug accumulation assays: 
Drug accumulation experiments were performed on confluent monolayers of hCMEC/D3s, 
grown in the centre 60 wells of 96 well plates as described in methods section 2.2. Medium 
was removed from wells and replaced with a 200µl aliquot of [3H]nifurtimox (0.0111 MBq or 
300 nCi, 120nM per 1ml accumulation buffer) and [14C]sucrose (0.0148 MBq, 400 nCi, 972nM 
per 1ml accumulation buffer) in accumulation buffer. We first aimed to investigate the role of 
CT on [3H]nifurtimox accumulation, before deducing the efflux processes and any transporter 
interactions involved. 
7.2.4. Combination therapy 
In a series of experiments to assess the impact of CT on [3H]nifurtimox cellular 
accumulation, the clinically relevant concentrations of nifurtimox (6µM), pentamidine (10µM), 
melarsoprol (30µM), suramin (150µM) or eflornithine (250µM) were added to accumulation 
buffer.  Unlabelled suramin, eflornithine and pentamidine isethionate sodium salt were 
purchased from Sigma Chemical Company (Dorset, UK). DMSO was used to dissolve nifurtimox, 
pentamidine and melarsoprol to give a final concentration of 0.05% DMSO.  Control 
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experiments here also contained 0.05% DMSO. For unlabelled eflornithine and suramin and 
the appropriate controls, no DMSO was used as the molecules are water soluble. There were 
no significant differences between accumulation of [3H]nifurtimox with or without 0.05% 
DMSO at any time point (data comparison not shown).  
7.2.5. Self- inhibition assays: 
To study the transport mechanisms being utilised by nifurtimox, a range of unlabelled 
nifurtimox concentrations in the presence of 0.05% DMSO (6µM, 12µM, 60µM and 150µM) 
were also used alongside [3H]nifurtimox and [14C]sucrose in the accumulation buffer to assess 
the effect on [3H]nifurtimox efflux from the cells. 
7.2.6. Transporter inhibition assays  
To study the transport mechanisms being utilised by nifurtimox, a series of established 
transporter interacting (substrates and inhibitors) drugs were used alongside [3H]nifurtimox 
and [14C]sucrose in the accumulation buffer. The impact of these drugs on [3H]nifurtimox and 
[14C]sucrose accumulation in the cells was assessed at 1, 2.5, 5, 20 and 30 minutes. Haloperidol 
(40µM), ko143 (1µM), indomethacin (10µM) pheophorbide A (PhA) (1µM), taurocholic acid 
(TCA) (200µM), para-aminohippuric acid (PAH) (500µM), dexamethasone (200µM) or 
probenecid (350µM) were added to accumulation buffer in the presence of 0.05% dimethyl 
sulfoxide (DMSO) in individual experiments to inhibit different transport systems (see methods 
table 2.1).  
To further assess the impact of the ATP dependant ABC-transporters on the accumulation 
of [3H]nifurtimox, cells were depleted of ATP by incubating them for 1 hour in glucose-free 
DMEM containing 10mM 2-deoxy-D-glucose (2-DG, Sigma), and cellular ATP was determined 
using the Promega Enliten® ATP Assay System kit (Promega, Southampton, UK). Cells were 
grown in rat tail collagen type-1 coated 24 well plates (Thermo Scientific Nunclon™, 
Loughborough, UK) for 7 days before their medium was removed, washed twice with 1 ml of 
warm glucose free DMEM (Gibco, Invitrogen) and incubated for 1 hour in 1 ml glucose-free 
DMEM containing 10mM 2-DG which is a well documented inhibitor of glycolysis and results in 
a decrease in intracellular ATP in vitro (Wang et al., 2011b). After this incubation step, the 2-
DG solution was removed and cells were incubated in 100µl of 2% trichloroacetic acid (TCA, 
Sigma, UK) in glucose-free DMEM, also containing 0.002% xylenol blue dye (a pH colour 
indicator, Sigma, UK) at RT for 10 minutes following the manufacturer’s direction. TCA both 
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depletes cellular ATP and inhibits enzymes that degrade ATP (Whiteman et al., 2002). As TCA 
also inhibits the downstream assay, it was neutralised with Tris-acetate (pH 7.75) to bring the 
total TCA percentage to 0.1% following the manufacturer’s direction. Samples were then taken 
and added with the reconstituted luciferase/luciferin reagent mix from the kit in a sterile white 
96-well plate (Nunc) and the ATP luminescence determined in a Biotek Synergy HT 
luminometer using KC4 software and compared to control cells not treated with 2-DG. For 
accumulation, cells were treated with 10mM 2-DG before incubation with [3H]nifurtimox as 
described in the accumulation assay. We would like to thank Dr. Matthew Arno of the KCL 
Genomics centre for his help with this assay. 
7.2.7. Cytotoxicity assay 
The potential of the compounds used in this accumulation study (not investigated in 
previous chapters) to cause cytotoxicity to the hCMEC/D3 cells was assessed using an MTT 
assay following the protocol described in section 2.5. The effect of these compounds on 
hCMEC/D3 viability was compared to untreated control hCMEC/D3 cells.  
7.2.8. Expression of P-gp and BCRP 
For SDS-PAGE and WB, the protocol in chapter 2, section 2.7 was used and hCMEC/D3 cell 
lysate was prepared in TGN lysis buffer as described in section 2.7.1. The expression of P-gp 
and BCRP by the hCMEC/D3 and HepG2 cell lines were analysed using Abcam primary mouse 
anti-P-gp/MDR1 [C219] (ab3364) and mouse anti-BCRP/ABCG2 [BXP-21] (ab3380) monoclonal 
antibodies at 1:80 and 1:1000 dilutions in PBS-Tween (PBS-T, PBS with 0.05% Tween 20) with 
0.5% BSA, (Sigma) respectively. Mouse anti- GAPDH monoclonal antibody [6C5] (ab8245), was 
used as a loading control, 1:1000 in PBS-T with 0.5% BSA. Details of these antibodies can be 
found in table 2.2.  HepG2 cells were a kind gift from Mr. Enrico Cristante (Imperial College 
London, UK) and used as positive controls (Vander Borght et al., 2008, Wojtal et al., 2006). For 
P-gp, a precast 4-20% gradient gel was used (Bio-Rad Europe, 456-1093S). For BCRP, a 10% 
SDS-PAGE acrylamide/bisacrylamide gel was used with the recipe in appendix section 3.  
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7.3.1. Combination therapy and [3H]nifurtimox and [14C]sucrose accumulation 
With CTs becoming the treatments of choice for HAT, the effect of their addition to the 
accumulation buffer was observed on [3H]nifurtimox and [14C]sucrose accumulation.  
7.3.2. [14C]sucrose in CT studies 
 [14C]sucrose was used as an internal control for the accumulation experiments. There were 
no significant differences between any of the treatments investigated. Data are displayed as 
inserts in figures 7.1 to 7.2. 
7.3.3. Effects of combination therapy on [3H]nifurtimox accumulation 
The accumulation of [3H]nifurtimox in the hCMEC/D3s was not significantly affected by 
unlabelled melarsoprol (30µM), whereas unlabelled pentamidine (10µM) caused an increase 
at 2.5 minutes (p<0.01) and this was maintained onwards to 30 minutes (p<0.001), with an 
average increase of 111% over the time points in comparison to the appropriate [3H]nifurtimox 
controls (figure 7.1).   
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Figure 7.1. Combination of [3H]nifurtimox and [14C]sucrose with melarsoprol and 
pentamidine. The anti-HAT drugs melarsoprol (30µM) and pentamidine (10µM) were added 
with [3H]nifurtimox and [14C]sucrose in the accumulation buffer (in the presence of 0.05% 
DMSO) to assess their impact on accumulation. Unlabelled melarsoprol caused no significant 
change, but pentamidine induced a significant increase in accumulation of [3H]nifurtimox, from 
2.5 minutes onwards (**p<0.01, ***p<0.001). There were no significant treatment-induced 
differences in [14C]sucrose accumulation when compared to control values (insert). 
[3H]nifurtimox data are corrected for [14C]sucrose and protein content (with [14C]sucrose 
corrected for protein only). All data expressed as means ± S.E.M, n= 6 (plates) per graph, with 
6 replicates (wells) per plate. 
 
There was no effect of eflornithine (250µM) and suramin (150µM) on the accumulation of 
[3H]nifurtimox (all without the presence of DMSO as the molecules are water soluble, figure 
7.2).  
[14C]sucrose 
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Figure 7.2. Combination of [3H]nifurtimox and [14C]sucrose with suramin and eflornithine. 
The anti-HAT drugs suramin (30µM) and eflornithine (10µM) were added with [3H]nifurtimox 
and [14C]sucrose in the accumulation buffer (without DMSO) to assess their impact on 
accumulation. Both unlabelled melarsoprol and eflornithine caused no significant change in 
the accumulation of [3H]nifurtimox. There were no significant treatment-induced differences in 
[14C]sucrose accumulation when compared to control values (insert). [3H]nifurtimox data are 
corrected for [14C]sucrose and protein content (with [14C]sucrose corrected for protein only). 
All data expressed as means ± S.E.M, n= 6 (plates) per graph, with 6 replicates (wells) per plate. 
 
7.3.4. Influence of self-inhibition on [3H]nifurtimox accumulation 
As nifurtimox has been previously demonstrated to be a substrate of an efflux transport 
system in our mouse models and no influx system has been demonstrated, we incubated a 
range of concentrations of unlabelled nifurtimox in accumulation buffer alongside 
[3H]nifurtimox and [14C]sucrose to see if any efflux system could be detected in the 
hCMEC/D3s. Accumulation of [3H]nifurtimox  was not significantly affected by the addition of 
unlabelled nifurtimox at a clinically relevant dose of 6µM or an increased dose of 12µM (figure 
7.3). The addition of 60µM and 150µM unlabelled nifurtimox however, caused significant 
increases in [3H]nifurtimox accumulation at all time points (p<0.001 for both treatments at all 
time points) compared to DMSO [3H]nifurtimox controls. 60µM induced an average increase of 
310% across all time points, and 150µM induced a larger 400% increase across the time points.  
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Figure 7.3. Influence of self-inhibition on [3H]nifurtimox and [14C]sucrose accumulation. 
Unlabelled nifurtimox was added to accumulation buffer in the ranges of 6µM - 150µM in 
0.05% DMSO to view the impact of self-inhibition on the accumulation of [3H]nifurtimox in 
confluent monolayers of hCMEC/D3 cells. At concentrations of 6µM and 12µM, unlabelled 
nifurtimox caused no change in accumulation of [3H]nifurtimox, but at concentrations of 60µM 
and 150µM, a highly significant increase in [3H]nifurtimox accumulation compared to controls 
was observed at all time points (***p<0.001). [3H]nifurtimox data are corrected for 
[14C]sucrose and protein content (with [14C]sucrose corrected for protein only). All data 
expressed as mean ± S.E.M, n=4-6 (plates), with 6 replicates (wells) per plate. 
 
7.3.5. Roles of P-gp and BCRP in [3H]nifurtimox accumulation 
The influences of P-gp and BCRP in the transport of [3H]nifurtimox, were tested using four 
drugs that have previously been shown to decrease the functions of these transport proteins 
(table 2.1). There were no significant differences in [14C]sucrose accumulation between any 
treatments (see figure 7.4 and 7.5 inserts). For P-gp assessment we used haloperidol (40µM) 
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and dexamethasone (200µM) and for BCRP, ko143 (1µM) and pheophorbide A (PhA) (1µM).  
The results showed that the P-gp acting drugs, haloperidol and dexamethasone, had no affect 
on [3H]nifurtimox accumulation (figure 7.4), whereas significant increases in [3H]nifurtimox 
accumulation were observed with the addition of the BCRP acting drugs, ko143 and PhA (both 
p<0.001 against controls) (figure 7.5).  
To further assess roles played by ABC transporters in [3H]nifurtimox accumulation, cellular 
ATP was depleted using 10mM 2-deoxy-D-glucose (as described in the methods). This 
depletion step resulted in a 76% depletion of intracellular ATP compared to untreated controls 
(luminescence data not shown). ATP-depletion effectively increased the accumulation of 
[3H]nifurtimox in the cells compared to controls at all time points (p<0.01 at 1 minute and 
p<0.001 for the remaining time points). When comparing the effect of ATP depletion to that of 
inhibiting P-gp transport (figure 7.4), there was a significant difference with ATP depletion 
causing an increased [3H]nifurtimox accumulation when compared with P-gp inhibition by both 
drugs (p<0.01 at all time points for both P-gp treatments). In contrast, comparing the effect of 
ATP depletion to that of BCRP inhibition (figure 7.5) showed that these two treatments caused 
similar changes to [3H]nifurtimox accumulation after 1, 2.5, 5 and 20 minutes, although it was 
noted that after 30 minutes ATP depletion caused a significantly greater increase (by 17-20%) 
in [3H]nifurtimox accumulation (p<0.05). 
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Figure 7.4. The effects of P-gp on [3H]nifurtimox and [14C]sucrose accumulation.  To assess 
the roles played by the ABC transporter, P-gp, in the accumulation of [3H]nifurtimox and 
[14C]sucrose, the accumulation of [3H]nifurtimox in confluent monolayers of hCMEC/D3 cells in 
96 well plates was observed with or without the known P-gp interacting drugs dexamethasone 
and haloperidol in the presence of 0.05% DMSO.  The P-gp substrate and inhibitor 
(dexamethasone and haloperidol respectively) caused no significant alteration in the 
accumulation of [3H]nifurtimox. ATP depletion caused a significant increase at all time points 
compared to both control data and P-gp inhibition (**p<0.01 and ***p<0.001 vs. control, 
**p<0.01 vs. dexamethasone and haloperidol). [3H]nifurtimox data are corrected for 
[14C]sucrose and protein content (with [14C]sucrose corrected for protein only). All data 
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Figure 7.5. The effects of BCRP on [3H]nifurtimox and [14C]sucrose accumulation.  To assess 
the roles played by the ABC transporter, BCRP, in the accumulation of [3H]nifurtimox and 
[14C]sucrose, the accumulation of [3H]nifurtimox in confluent monolayers of hCMEC/D3 cells in 
96 well plates was observed with or without known BCRP interacting drugs PhA and ko143 in 
the presence of 0.05% DMSO.  The BCRP substrate and inhibitor (PhA and ko143 respectively) 
caused significant increase in the accumulation of [3H]nifurtimox at all time points when 
compared to controls. ATP depletion caused a significant increase at all time points compared 
to both control data and P-gp inhibition (**p<0.01 and ***p<0.001 vs. control, *p<0.05 vs. PhA 
and ko143). [3H]nifurtimox data are corrected for [14C]sucrose and protein content (with 
[14C]sucrose corrected for protein only). All data expressed as mean ± S.E.M, n=4-6 (plates), 
with 6 replicates (wells) per plate. PhA – pheophorbide A. 
 
7.3.6. Roles of MRP, OATPs and OATs in [3H]nifurtimox accumulation 
Probenecid (350µM) was used to assess contributions to [3H]nifurtimox and [14C]sucrose 
accumulation from proteins separate to P-gp and BCRP; namely multi-drug resistance 
associated proteins (MRP) 1 and 2, organic anion-transporting polypeptides (OATPs) and 
organic anion transporters (OATs). There were no changes in [14C]sucrose accumulation 
between the treatments (insert of figure 7.6) Figure 7.6 illustrates the significant time 
dependent effect of probenecid on [3H]nifurtimox accumulation from 2.5 minutes and 5 
[14C]sucrose 
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minutes (p<0.01) to 20 and 30 minutes (p<0.001) which induced an average increase in 
accumulation of 114% across all time points.  This effect was not matched by the presence of 
the MRP-1 inhibitor Indomethacin (10μM), where no significant change to [3H]nifurtimox was 
observed at any time point.  Taurocholic acid (TCA, 200µM) and para-aminohippuric acid (PAH, 
500µM) were then used to assess function of OATPs and OATs respectively.  The addition of 
TCA caused significant changes in [3H]nifurtimox accumulation from 2.5 minutes (p<0.01) and 
onwards when all three time-points showed significant increases (p<0.001 figure 7.6), albeit 
less than those observed with the BCRP inhibitors.  PAH caused no significant differences in 
accumulation of [3H]nifurtimox at any time point.  
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Figure 7.6. The effects of OATs, OATPs and MRPs on [3H]nifurtimox accumulation. To assess 
the roles played by members of the transport families OATs, OATPs and MRPs in the transport 
of nifurtimox, the accumulation of [3H]nifurtimox in confluent monolayers of hCMEC/D3 cells 
in 96 well plates was observed, with or without known transporter interacting drugs, in the 
presence of 0.05% DMSO. The OAT interacting drug, PAH and the MRP1 interacting drug, 
indomethacin, caused no significant changes in the accumulation of [3H]nifurtimox. From 2.5 
minutes onwards, both probenecid (OATs, OATPs and MRPs) and TCA (OATPs) caused 
significant increases in the accumulation (**p<0.01, ***p<0.001). [3H]nifurtimox data are 
corrected for [14C]sucrose and protein content (with [14C]sucrose corrected for protein only). 
All data expressed as means ± S.E.M, n= 4-6 (plates), with 6 replicates (wells) per plate. PAH - 
para-aminohippuric acid, TCA - taurocholic acid. 
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7.3.7. Cytotoxicity of compounds used 
The potential of the compounds used in this study to cause cytotoxicity was assessed using 
an MTT assay and the effect compared to untreated control hCMEC/D3 cells (figure 7.7). There 
were no significant differences on cell viability after 30 minutes exposure to the drugs. 
 
Figure 7.7. Cytotoxic effects of compounds used in the study. The test compounds were 
assessed for any cytotoxic effects using an MTT assay during 30 minute incubations with 
confluent monolayers of hCMEC/D3 cells in 96 well plates, as described in section 4.7 of 
experimental procedures. The results are expressed as percentage viability ± S.E.M and 
compared to control untreated cells, which were incubated for 30 minutes in normal medium. 
None of the compounds induced a significant change in cell viability.  All data means ± S.E.M, 
n= 4-6 with n=3 (plates), 4 replicates per n (4 wells). 
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7.3.8. BCRP and P-gp protein expression in hCMEC/D3s 
Mouse anti-human BCRP/ABCG2 and mouse anti-human P-gp/MDR1 monoclonal 
antibodies were used to detect protein expression of BCRP and P-gp in the hCMEC/D3s using 
SDS-PAGE and western blotting.  Bands detected at the expected molecular weights of 170kDa 
for P-gp and 70kDa for BCRP confirmed their expression using SDS-PAGE and Western blot 
analysis (figures 7.8 a and 7.8 b respectively). HepG2 cell lysates were used as positive controls 
(Wojtal et al., 2006, Vander Borght et al., 2008).  
 
Figure 7.8. Expression of P-gp and BCRP in the hCMEC/D3 cells. Confluent monolayers of 
hCMEC/D3s and flasks of HepG2 cells were lysed in TGN buffer and the expression of P-gp (a) 
and BCRP (b) were analysed using western blotting, as described in section 7.2.8 of the 
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Human African trypanosomiasis has a large impact, both socially and economically, on 
affected sub-Saharan communities. A combination of constant surveillance and careful 
implementation of preventative measures is required by the authorities if the disease is to be 
successfully combated.  Collapses of disease surveillance and changes in political agenda have 
allowed HAT’s prevalence to increase and this is one of the reasons the disease has not been 
eradicated despite drops in the numbers of reported cases.  Another reason is due to the 
unsatisfactory treatment of the disease which in turn is down to the facts that the anti-HAT 
drugs available are expensive, can be extremely difficult to successfully administer, have 
limited efficacy and can cause severe adverse reactions.  These features combined with a lack 
of understanding about anti-HAT drugs and their BBB interaction highlights the need for more 
research into the treatment of this disease. 
The aim of this study was to investigate whether BBB transport proteins were being utilised 
by the emerging drug of choice for treating HAT, nifurtimox, and also investigated the effects, 
if any, of anti-HAT CT on its delivery. Our group has previously shown that nifurtimox is a 
substrate for an efflux protein at the murine BBB, which is unlikely to be P-gp, as shown by the 
use of P-gp deficient animals (Jeganathan et al., 2011). P-gp is expressed at the luminal 
membrane of the human BBB and removes a wide variety of substrates from the endothelial 
cell cytoplasm (Abbott et al., 2006).  The lack of interaction between nifurtimox and P-gp was 
also evident in the hCMEC/D3s through the use of the P-gp substrate dexamethasone and the 
specific P-gp inhibitor (at 40μM) haloperidol, which did not cause any significant differences in 
[3H]nifurtimox accumulation over the 30 minute incubation period. However, a promising 
potential efflux transporter for nifurtimox was suggested in our earlier animal study 
(Jeganathan et al., 2011). Further investigation in the hCMEC/D3s revealed this efflux 
transporter to be BCRP through the use of the BCRP substrate PhA and the BCRP specific 
inhibitor (when used in the range of 0.1-1μM (Matsson et al., 2009) k0143 , identified through 
the large increases in accumulation which can be attributed to the efflux process being 
affected. BCRP, like P-gp, is expressed luminally at the BBB and both these proteins are 
members of the ABC transporter superfamily which play key physiological roles in protecting 
tissues from toxic xenobiotics and other potentially harmful endogenous metabolites.  ABC 
transporters require energy to function. This energy comes in the form of ATP and so we 
decided to manipulate this aspect by depleting cellular ATP by inhibiting glycolysis using the 
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established glycolysis inhibitor 2-DG (Whiteman et al., 2002, Wang et al., 2011b). This ATP-
depletion resulted in [3H]nifurtimox accumulation values comparable to those achieved using 
the BCRP interacting drugs, but not those generated from the P-gp investigations. At the 30 
minute stage, accumulation of [3H]nifurtimox was 83% of the accumulation seen following ATP 
depletion. These similar increases in accumulation by ATP-depletion further support the 
evidence that BCRP appears to play a crucial role, whereas P-gp plays little or no role in 
nifurtimox transport. The protein expression of these efflux transporters were confirmed in 
our model by Western blot, which is consistent with the findings of several other recently 
published studies using the hCMEC/D3s (Weksler et al., 2005, Poller et al., 2008, Tai et al., 
2009a).  These data suggest that not only is BCRP functional in the hCMEC/D3s but perhaps 
inhibiting BCRP could improve the delivery and efficacy of nifurtimox.  Indeed, that nifurtimox 
could be a substrate for BCRP has been previously suggested (Garcia-Bournissen et al., 2010, 
Jeganathan et al., 2011).  In a study investigating nifurtimox transfer in breast milk, Garcia-
Bournissen et al, suggested that as the antibiotic nitrofurantoin is structurally related to 
nifurtimox and is a substrate for BCRP (Merino et al., 2005), perhaps nifurtimox may also be a 
substrate (Garcia-Bournissen et al., 2010). The findings of our study provide direct evidence of 
this hypothesis for the first time in a human in vitro BBB model.  
To investigate the roles of other transport systems in nifurtimox transport, a variety of 
other drugs were used to affect transport activity of MRPs, OATs and/or OATPs. MRPs, other 
members of the ABC transporter superfamily that also mediate brain-to-blood efflux, play 
important roles in vivo to protect the brain from xenobiotics.  OATs and OATPs are membrane 
transport proteins that play large roles in the transport of endogenous molecules across cell 
membranes.  MRP1 expression has previously been shown in the hCMEC/D3s at mRNA (Carl et 
al., 2010) and protein levels (Weksler et al., 2005). The expression of MRPs 2,3,4 and 5, OATP1, 
OATPD and OATP2A1 have been shown at mRNA level only in the hCMEC/D3s (Poller et al., 
2008, Carl et al., 2010), and they are also expressed in the human brain (Gibbs and Thomas, 
2002).  However, neither protein nor mRNA expression has not been demonstrated for 
members of the OAT superfamily in the hCMEC/D3 cell line.  The data here comply with this 
knowledge somewhat, suggesting that nifurtimox appears to be a substrate of functional OATP 
and MRP systems from the increases in [3H]nifurtimox from 2.5 minutes onwards, but OAT 
appear not to be involved. This was demonstrated by use of the broad spectrum MRP, OAT 
and OATP inhibitor, probenecid; the MRP1 inhibitor, indomethacin; the OATP competitive 
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inhibitor, TCA and the OAT competitive inhibitor, PAH. OATPs have been suggested as being 
bidirectional drug transporters (Nozawa et al., 2005) and the increases in accumulation with 
the addition of TCA could provide some evidence for their role in nifurtimox transport.  
However, although indomethacin is commonly used as a MRP1 inhibitor, it has been shown to 
be a substrate of OATPs and OATs, albeit at different concentration ranges than used here 
(Parepally et al., 2006). The increases in [3H]nifurtimox accumulation were also lower than that 
seen with the BCRP specific drugs, suggesting lesser roles for OATPs and MRPs in comparison.  
It is also important to point out that some groups have found that probenecid is a BCRP 
substrate in vitro, and this is also a possible explanation for the increase in [3H]nifurtimox 
accumulation using this drug (Merino et al., 2006). However, other groups have found no such 
evidence of BCRP/probenecid interaction (Pan et al., 2007). It has also been reported that 
neither TCA (Suzuki et al., 2003) nor indomethacin (Elahian et al., 2010) interact with BCRP. 
The concentrations of drugs used in this study were carefully chosen to follow those used in 
previous in situ studies by our group, to be in line with the clinically relevant doses used in the 
field (with the anti-HAT drugs) and to be in line with those reported in publications such as 
Matsson et al (Matsson et al., 2009). These data and findings by other groups highlight that 
drugs affecting transport activity must be used at specific concentrations to affect specific 
transport proteins. The broadness of some transporter interacting drugs also illustrates the 
need for use of more specific inhibitors, at specific concentrations which will yield clearer 
results. 
With combination therapy now the most promising method of clinical S2 HAT treatment, 
we also investigated whether other unlabelled anti-HAT drugs could modulate the 
accumulation of [3H]nifurtimox in human brain endothelium.  In line with previous work by our 
group, an increase in [3H]nifurtimox accumulation was seen with the addition of 10µM 
pentamidine.  Pentamidine, a S1 HAT acting drug, has been previously shown by our group to 
be a substrate for P-gp and is also transported by other transport proteins including MRP. This 
present study with P-gp inhibitors suggests that perhaps this drug also interacts with other 
membrane transporters.  BCRP and members of the MRPs or OATPs could be candidates as 
indicated by their interactions with PhA, k0143, probenecid and PAH.  However, no other 
drugs from the CT experiments, including eflornithine, caused any significant changes in 
[3H]nifurtimox accumulation in the cells, which contradicts our previous findings that 
eflornithine, suramin and melarsoprol caused decreases in the brain distribution of 
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[3H]nifurtimox in situ (Jeganathan et al., 2011).  One must of course be careful when 
comparing in situ brain distribution and in vitro accumulation data.  When observing the in situ 
BBB endothelial cell pellet analysis for [3H]pentamidine previously published by our group, it 
was evident that the drug accumulated in the cells (Sanderson et al., 2009). [3H]nifurtimox 
accumulated to a lesser degree in situ, although the differences in accumulation with CT were 
similar to those reported here with an increase observed with the addition of unlabelled 
pentamidine and little or no difference with the other drugs (Jeganathan et al., 2011). The 
reasoning behind the improved cure rates of patients using NECT compared to eflornithine 
alone, based on our results, is unlikely to be due to the interactions of the drugs with 
membrane transporters.  It has been stipulated that the arrestment of parasite defences 
caused by eflornithine allows the efficacy of nifurtimox to be improved and perhaps this is the 
main reason behind NECT success (Priotto et al., 2009). 
The mechanism by which nifurtimox enters into the cells remains unknown. It is likely that 
the highly lipophilic properties of nifurtimox (with octanol-saline partition coefficient of 
5.46(Jeganathan et al., 2011) allows it to cross cell membranes by passive diffusion and 
previous work has shown that it not only appears to use a transcellular route of entry, but 
enters the mouse brain at sufficient amounts to be effective in killing trypanosomes 
(Jeganathan et al., 2011). However, the role played, if any, by blood-to-brain transporters 
remains elusive. Any effects the drugs had on the expression of transporters have also not 
been assessed here. It has been shown previously that some drugs can upregulate functional 
expression of drug transporters such as P-gp, and this is well documented with 
dexamethasone (Narang et al., 2008), but the 30 minute time frames of the experiments in this 
report were unlikely to be sufficient at inducing any significant increase in expression or 
activity. That some of the drugs used here, although carefully chosen to be within published 
concentration ranges, had over-lapping affinity for different transport systems only highlights 
in some cases the difficulty in drawing accurate conclusions to which of the transport systems 
were being utilised.  
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Studying nifurtimox interactions with the BBB is crucial to improving treatment of second 
stage HAT, especially now that NECT is fast becoming the treatment of choice. Considering the 
current usage of NECT, it is somewhat surprising that very little is known about the 
mechanisms being used by these drugs to gain entry to the brain. We report here that 
nifurtimox appears to be a substrate of BCRP and possibly members of the transport families 
OATP and MRP in an in vitro model of the BBB. We also demonstrate that, with regards to the 
combination therapy approach to treating HAT, the combination of eflornithine and nifurtimox 
does not appear to hamper or improve entry of nifurtimox into the BBB and the reasoning 
behind its success in the field is unlikely due to transporter interactions at the BBB. In addition, 
our data suggests that pentamidine could actually improve the delivery of nifurtimox, which is 
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8.1. Chapter 8 – General discussion 
The purpose of this thesis was to gain first insights into the interactions of clinically relevant 
endogenous and exogenous molecules with the human BBB using the well established 
immortalised hCMEC/D3 in vitro model of the human BBB. The investigations were designed 
according to prior knowledge in the subject areas – both our own and that of the scientific 
literature – and allowed us to explore highly novel areas with relation to the human BBB. The 
information gained from the endogenous studies on ADMA and L-arginine allowed us to design 
experiments for the exogenous molecule investigations with the anti-HAT drug and CAA 
analogue eflornithine. Nifurtimox was also investigated due to its link with eflornithine and 
because of the particular interest of our laboratory in trypanosomiasis chemotherapy.  
8.2. Endogenous molecules – L-arginine and ADMA 
ADMA is very much a ‘hot-topic’ of investigation in vascular biology research due to its 
potency as an inhibitor of NO production and implications in ROS production (Teerlink et al., 
2009). It is therefore of acute interest to researchers investigating highly specialised 
vasculature, the integrity of which is paramount to maintaining precise function. This is no 
more palpable than at the BBB, and because the role of ADMA in brain and cerebrovascular 
pathologies is becoming more and more questioned (Kielstein and Kielstein, 2009), we decided 
this was a perfect opportunity to gain a first insight into interactions between the human BBB 
and the molecule. 
8.2.1. Chapter 3 – ADMA on the paracellular integrity of the BBB 
Chapter 3 investigated the impact of ADMA on the permeability of the confluent hCMEC/D3 
monolayer grown on transwell filter inserts with the hypothesis in line with previous in vitro 
investigations using peripheral endothelium that supraphysiological concentrations of ADMA 
would induce permeability increases – although the affects of lower more clinically relevant 
concentrations on the barrier were not ruled out. Our findings confirmed our initial hypothesis 
in line with previous studies (Wojciak-Stothard et al., 2007, Wojciak-Stothard et al., 2009, Chen 
et al., 2011, Wang et al., 2011a), although we linked this increase in permeability to a loss in 
cell viability which could be induced by the production of ROS through the uncoupling of eNOS 
(Sydow et al., 2003) – the protein of which was expressed in the hCMEC/D3s alongside the 
ADMA metabolising enzyme DDAH-1. However, due to time constraints neither ROS 
production nor the role of small GTPases in cytoskeletal or junctional restructuring (that has 
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been linked to ADMA in previous studies (Wojciak-Stothard et al., 2009, Chen et al., 2011) 
were investigated.  
Thus, this first insight into ADMA and the human BBB demonstrated that the barrier is 
indeed sensitive to the molecule (albeit at high concentrations), but results in further 
questions requiring further investigation. Firstly, the study was designed to assess 24 hour 
exposure of ADMA. In the body it is possible that in certain conditions, chronic exposure of the 
vasculature to ADMA is likely to occur. Under such chronic conditions it is possible that 
smaller, more clinically relevant concentrations of ADMA would elicit effects on endothelium, 
and this may go some way to explaining the difference between intracellular and extracellular 
concentrations of ADMA. It would be interesting to investigate a variety of incubation times to 
assess this. This would be somewhat difficult to physiologically model however as not only 
would it require careful intracellular and extracellular measuring, it would also likely require 
constant replenishment of extracellular ADMA as the molecule has a short plasma half-life of 
23.5 ± 6.8 minutes in humans (although likely more in vitro due to the lack of a complete 
physiology system (Kielstein et al., 2004) and the activity of PRMTs and DDAH-1 would need to 
be assessed. This leads to the second point, that the expression and activity of DDAH-2 was not 
investigated. This is likely to have implications at the BBB because DDAH-2 is predominantly 
expressed in endothelial cells compared to DDAH-1 which is expressed more extensively 
throughout the body (Palm et al., 2007). eNOS expression was confirmed, but its functional 
activity was also not investigated. If functional, then this could add weight to the ADMA-
induced eNOS uncoupling theory, especially if the presence of ROS formation was 
demonstrated by incubation of the hCMEC/Ds with ADMA.  
Perhaps an interesting investigation to follow on from chapter 3 would be to look at the 
effects of ADMA on pericytes which are the contractile cells situated at the BBB that regulate 
local capillary blood flow (Yemisci et al., 2009). Data demonstrated with pericytes and BMECs 
is likely to have greater implications physiologically than just with a cell monolayer model and 
may implicate NO, to which mouse brain pericytes are sensitive in vitro (Kovac et al., 2011).  
8.2.2. Chapter 4 – Transport interactions of ADMA at the BBB  
Chapter 4 explored the transport processes utilised by ADMA in relation to those used by L-
arginine, due to the similarity of their chemical structures. This first look at interactions 
between ADMA and CAA transporters is novel with respect to the human BBB and has wider 
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implications due to the ubiquitous expression of CAA transporters throughout the body. Very 
little investigation has been performed on ADMA transport, especially in human endothelial 
cell systems due to the assumption that it uses system y+ transporters as with L-arginine 
(Teerlink et al., 2009). We demonstrated that [3H]ADMA uses a variety of CAA transport 
systems that included system y+ alongside L-arginine – with CAT-1 expression confirmed in the 
cell line – but also leucine sensitive systems which could be members of the BAT transport 
family such as system y+L transporters and system b0,+ transporters, which have been 
described at mRNA level in the hCMEC/D3s (Carl et al., 2010). It appeared that the transport 
systems present on the hCMEC/D3s favoured [3H]L-arginine over [3H]ADMA (based on Vd 
values alone) although, to get an accurate indication of this, kinetic studies determining Km and 
Vmax would need to be performed.  
One of the most intriguing findings of chapter 4 was the strong indication that [3H]ADMA 
was being effluxed from the cells by a Na+ and Cl--sensitive transport system, that appeared to 
be the system B0,+ transporter ATB0,+; the protein expression of which was confirmed. These 
data were extremely perplexing as ATB0,+ should co-transport ions and substrate in the same 
direction (symporter) (Sloan and Mager, 1999, Hatanaka et al., 2004), so when Na+ free buffer 
was used and [3H]ADMA accumulation increased this was suggestive of an antiport system. It 
would require electrophysiology techniques such as voltage-clamp to look at the direction of 
ion currents as well as polarisation studies to look for the location of the transporter – if 
located on both luminal and abluminal membranes as a system of movement from the blood-
to-brain direction only, these increases in accumulation when blocking the action of ATB0,+ may 
also be explainable as ADMA uses a variety of transporters for entry, but possibly only ATB0,+ 
for exit. Another possibility is that the ‘specific’ inhibitor for ATB0,+, α-methlytryptophan 
(Karunakaran et al., 2008), is not actually specific and could be affecting a variety of different 
cellular exit transport systems. 
It is also important to point out that we did not look at the mRNA levels of transport 
proteins in this thesis (as mentioned in chapter 7), so we cannot rule out the possibility of 
increased expression or increased membrane translocation of CAA transporters at the 
membrane upon changing media for accumulation buffer or with the introduction of 
transporter interacting drugs. Increased membrane translocation of GLUT4 from transporter 
stores in intracellular vesicles has been demonstrated in adipocytes following stimulation with 
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insulin (Karlsson et al., 2002) and a similar increase in endothelial membrane translocation has 
been demonstrated for CAT-1 following stimulation with high-density lipoprotein from healthy 
subjects in vitro (Besler et al., 2010). If this phenomenon was occurring in our model in 
response to an extracellular stimulus, this is interesting to investigate, but it seems unlikely 
given the short time frames of the accumulation assays. 
8.2.3. Chapter 5 – The trans-stimulation of ADMA and the ‘L-arginine paradox’ 
The premise behind chapter 5 was to assess if intracellular ADMA could be trans-stimulated 
by extracellular L-arginine and therefore help to explain the phenomenon known as the ‘L-
arginine paradox’. In this paradox, L-arginine supplementation improves NO impairment and 
endothelial dysfunction despite the fact that NOS should already be fully saturated by basal 
concentrations of extracellular L-arginine. Data from chapter 5 provided some evidence of the 
role of ADMA in the paradox, by revealing that pre-loaded intracellular [3H]ADMA could indeed 
be trans-stimulated by extracellular L-arginine, with the reverse also being demonstrated 
when intracellular ADMA actually increased the accumulation of extracellular [3H]L-arginine 
compared to cells that were not preloaded with ADMA. Although this provides evidence for 
ADMA in the ‘L-arginine paradox’ the experiments were not performed in a physiologically 
relevant system where a variety of factors are likely to have an impact on cellular influx and 
efflux of CAAs and the catabolism of ADMA and L-arginine – the latter important with regards 
to intracellular pools. 
Although plasma concentrations of ADMA have been linked to disease, little is known about 
intracellular concentrations in physiological states let alone in disease. This is not only 
important with regards to the ‘L-arginine paradox’, but will also have implications with ADMA 
and NO physiology as a whole, especially regarding subcellular pools of ADMA and L-arginine. 
Data identifying and understanding these pools is limited due to the complexity of their 
function and cellular location as well as the recent occurrence of the investigations. If L-
arginine and ADMA from these intracellular pools have preferential access to the intracellular 
enzymes that regulate their levels and if extracellular L-arginine and ADMA have access to 
these pools is the next logical course of investigation to properly clear up the role of ADMA 
and the ‘L-arginine paradox’.  
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8.3. Exogenous molecules – eflornithine and nifurtimox 
Human African trypanosomiasis is classified as a neglected tropical disease because it is 
confined to specific areas of sub-Saharan Africa and has been poorly managed at the local 
government level. It is only in the last decade that concerted efforts spearheaded by the WHO 
and determined health programmes have attempted to counteract this disease. The neglected 
status of the disease extends to its research which has only recently revealed new drug 
candidates. These reasons make it important to study what is currently available to treat the 
disease not only to help the people suffering from the disease, but to help and guide research 
for better drugs. Our research group is one of the few researching the drug delivery aspect and 
so we decided to build on our expertise by using a human in vitro model of the BBB to isolate 
specific transport systems. 
8.3.1. Chapter 6 – eflornithine interactions with the BBB and other anti-HAT drugs 
In chapter 6 we sought to investigate evidence of interactions between eflornithine and the 
human BBB in terms of CAA transport. This is because eflornithine is a closely related analogue 
of the CAA ornithine and so it was hypothesised that the molecule could use CAA systems to 
enter the BBB. We revealed that [3H]eflornithine competed with several CAA substrates for 
entry to the cell, which was most likely to be a member of the system y+ transport family as 
implicated by use of the potent system y+ inhibitor, L-homoarginine. These data were in 
contrast to our previous in situ brain perfusion work using mouse models, where it was 
demonstrated that eflornithine had a limited ability to cross the BBB and did not use a 
transport system (Sanderson et al., 2008). However, it is important to point out that 
eflornithine appears more likely to cross the human BBB than the mouse BBB according to our 
data, and this could explain why the drug is efficacious in humans. But an important fact here 
is that a large concentration of the drug is required over a long time-period to be efficacious in 
humans, which points to the fact that the drug is poor at crossing the BBB.  
The second line of investigation in this chapter concerned the impact of combination 
therapy on the delivery of eflornithine as improvements of treatments with anti-HAT drugs 
have been widely reported (Priotto et al., 2006, Priotto et al., 2009). We hypothesised that 
combination of the drugs would actually improve drug delivery to the brain through 
transporter interaction or DDIs between the drugs. Linking the first line of investigation with 
the second in this chapter, our data from the pentamidine co-incubation with [3H]eflornithine 
implicated polyamine transporters may be able to transport eflornithine across the BBB as 
 INTERACTIONS OF ENDOGENOUS AND EXOGENOUS MOLECULES WITH 




they do in the parasites themselves, but their expression has not been investigated at the 
human BBB in vitro or in vivo in any model, and this would be an interesting course of 
investigation to take in the future with regards to CAA transport of eflornithine.  
We found conflicting data when we co-incubated [3H]eflornithine with suramin compared 
to our previous in situ work which showed an improved delivery of eflornithine to all mouse 
brain regions, which was hypothesised to be due to DDIs between the two drugs that 
increased the brain uptake of eflornithine through endocytotic events (Sanderson et al., 2008). 
The other data from the CT studies with the clinically relevant concentrations of nifurtimox, 
eflornithine and melarsoprol were in alignment with our previous work, where no changes 
were seen. These data taken together suggest that the success of NECT is due to countering 
drug resistance in the trypanosomes themselves, rather than an improvement in brain 
delivery. This has not been investigated directly however, and is also an interesting line of 
investigation for future research. 
The latest review regarding S2 HAT treatment at the time of writing this thesis describes 
how NECT has brought about a 12% decrease in melarsoprol usage, is cheaper than 
eflornithine monotherapy and has improved on the adverse affects of monotherapy on 
patients (Simarro et al., 2012). The review also highlights that NECT is still too expensive for 
many local authorities and far from an ideal therapy – due to logistical implications and a less 
than ideal toxicity risks – and calls for more research into better drugs for the disease.  
The Drugs for Neglected Diseases initiative (DNDi) has accelerated efforts to eradicate this 
disease through collaborations between health agencies such as the WHO, pharmaceutical 
giants such as GlaxoSmithKline and academia and aims to bring a HAT-specific portfolio by 
2014, with several exciting new drugs in the pipeline (see: dndi.org/). 
8.3.2. Chapter 7 – nifurtimox interactions with the human BBB 
Chapter 7 investigated the impact of CT on the delivery of nifurtimox and the roles of efflux 
transport systems as with eflornithine in chapter 6 due to their association through NECT. For 
this area of investigation, our data failed to comply with our in situ work as no changes in 
[3H]nifurtimox accumulation were noted with any combination of anti-HAT drug except with 
the addition of pentamidine where we noted an increase in [3H]nifurtimox accumulation. In 
our previous in situ studies, significant decreases in [3H]nifurtimox brain distribution were 
noted with all anti-HAT drugs except pentamidine which caused an increase in [3H]nifurtimox 
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brain distribution (Jeganathan et al., 2011). The finding with pentamidine suggests this drug 
interacts with an efflux system for nifurtimox, not involving P-gp and therefore future studies 
investigating this are necessary to understand the culprit – possibly a MRP member or BCRP. 
The reasoning behind the difference between the other findings of our study in comparison to 
our earlier work could be due to model and/or species differences. It is important to point out 
that comparing data between species and models must be taken with caution due to a variety 
of missing factors in the in vitro system that are likely to have direct impact on drug 
accumulation – such as a lack of flow for instance. It remains unlikely that nifurtimox uses an 
influx transport systems as self-inhibition would likely have induced a decrease in 
[3H]nifurtimox accumulation had there been any, and no evidence has been uncovered to 
suggest otherwise. It may be possible that in situ these drug combinations induced DDIs and 
indeed melarsoprol and nifurtimox have been suggested to have synergism (Bisser et al., 
2007), possibly affecting the diffusion of nifurtimox across the BBB, although this is 
speculation. Detailed studies isolating the precise method of nifurtimox entry would be 
required to provide more compelling answers. 
The second focus of chapter 7 was designed to follow on from previous in situ data 
generated by our group where evidence was uncovered for a nifurtimox efflux system 
separate from P-gp (Jeganathan et al., 2011). In our previous paper, the role of increasing 
nifurtimox concentrations was not assessed, and so this was an important aspect of our in vitro 
investigations. The findings that increasing concentrations of unlabelled nifurtimox induced 
increases in [3H]nifurtimox accumulation, complied with our other data implicating BCRP – 
through use of BCRP interacting drugs and ATP depletion. However, the data produced from 
board-scale inhibitors acting on MRP and OATP transport systems also caused significant 
increases in nifurtimox accumulation, albeit to a lesser extent than the BCRP interacting drugs, 
and therefore we could not rule out the role of OATP or MRP members in the transport of 
nifurtimox. These data highlight the specificity problems of transporter inhibitors and the need 
to be precise when instigating their use in drug transport assays. Our experimental design was 
carefully planned based on the work of published data (discussed below). It is likely that there 
was a certain amount of nonspecific interaction between some of the drugs we used, 
particularly so in our in vitro model that was devoid of flow and so the transporter interacting 
drugs had a greater length of access than they would in vivo. 
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8.4.  Model limitations 
Throughout this thesis, the immortalised hCMEC/D3 cell line has been the in vitro BBB 
model under investigation. The ease of use and the thorough characterisation of the cell line 
make it an attractive model for researchers looking at the human BBB. But as with any in vitro 
model, there were several limitations. 
The first limitation throughout this study regarded transporter inhibitors during the 
accumulation assays as touched on above. The lack of specific inhibitors hinders accurate 
explanation of results and researchers must be careful when designing experiments using 
them. It is likely that siRNA knockdown experiments of candidate transporters are likely to 
provide greater evidence of the transporters involved and help to clear up these issues. A 
siRNA approach is specific, whereas many transporter inhibitors and substrates are non-
specific – a limitation for the transporter experiments in the accumulation studies in this 
thesis. Although efforts were made to use established inhibitors at the correct concentrations, 
there is still a possibility of non-specific interactions. The inhibitors used in chapter 7 for the 
ABC-transporters where used at highly specific concentrations according to the very thorough 
publication by Matsson et al., who demonstrated overlap for many of the inhibitors used today 
in drug transporter experiments (Matsson et al., 2009). 
Regarding the cells themselves, a variety of limitations were apparent. The hCMEC/D3 cells 
were grown alone in monoculture, not in co-culture with pericytes and/or astrocytes 
throughout this thesis. It is well established that these two cell types are crucial for proper BBB 
phenotype formation such as TJ formation and polarisation (Abbott et al., 2006, Abbott et al., 
2010, Armulik et al., 2010). Without proper junctional formation, proper polarisation cannot 
occur, and this leads to doubts of the orientation of transporters. This is a likely reason why 
the hCMEC/D3 monolayer remains leaky to hydrophilic molecules via the paracellular route 
and explains the low TEER values of the hCMEC/D3s in chapter 3 when they were grown on 
transwell filter inserts. Attempts to improve the paracellular tightness of the hCMEC/D3s by 
co-culture with astrocytes and/or pericytes have shown higher electrical resistance that 
monocultures (Hsuchou et al., 2010, Hatherell et al., 2011), but the highest TEER values 
reached were 65 ohm.cm2, which is well below other in vitro models such as bovine co-culture 
models (bovine BMECs and astrocytes) (Weksler et al., 2005) and porcine co-culture models 
(porcine BMECs and astrocytes) (Smith et al., 2007). The in vivo BBB which is well over 1000 
 INTERACTIONS OF ENDOGENOUS AND EXOGENOUS MOLECULES WITH 




ohm.cm2 (Abbott, 2002). There are also other ways to improve in vitro TEER values in BBB in 
vitro models such as culturing BMECs in astrocyte conditioned media and growing cells in 
models with shear stress (see (Wilhelm et al., 2011) for a recent detailed review of these). 
hCMEC/D3s co-cultured with astrocytes have been grown in shear-stress conditions and 
showed an in vivo TEER of 1000 ohm.cm2 , which dropped to 70 when the same cells were 
grown on transwell filter inserts in static situations suggesting the shear-stress has greater 
impact on TEER than astrocytes and pericytes (Cucullo et al., 2008). The reasons for this 
improved TEER due to shear stress are not clear, but it is known that shear stress induces a 
variety of metabolic changes in cells, particularly with regards to aerobic metabolism via the 
improved access to oxygen in the flow model when compared to the static transwell filter 
inserts (Cucullo et al., 2008). This dynamic flow model remains the most accurate in vitro BBB 
system available for researchers, but the logistical and economical constraints of some labs as 
well as limited expertise of this model mean many researchers rely on the transwell filter 
system to generate their data. It is very important to point out however that TEER values are 
not always reflective of molecular/large drug permeability. It has previously been shown that a 
TEER above 120-130 ohm.cm2 does not reduce permeability to 4kDa FITC-Dex (Gaillard and de 
Boer, 2000, Wilhelm et al., 2011), but as many drugs are below this size, they are still likely to 
be susceptible to the leaky hCMEC/D3 paracellular route. 
With regard to the CAA studies, the glycocalyx was not taken into consideration during this 
study. The glycocalyx is the layer of extracellular polymeric material on cells and bacterium 
that has a variety of functions such a protective qualities to acids and immune molecules 
(Erlandsen et al., 2004). It has been shown to form on cultured endothelial cells (Ebong et al., 
2011) and it is known to attract cationic molecules – indeed these are used as dyes to stain it 
for photographic purposes (Erlandsen et al., 2004). Therefore, if the cationic radiolabelled 
ADMA and L-arginine were entering the cell or just sticking to it remains unknown. If the 
hCMEC/D3s have a glycocalyx has not been demonstrated, but it seems plausible as other 
vascular endothelium have been shown in vitro to express it (Ebong et al., 2011). It is 
important that we used [14C]sucrose as a correction factor for non-specific binding however, as 
it carries no charge, we cannot rule out the possibility we were measuring extracellular values 
along with intracellular ones.  
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8.5. Closing comments 
The basic science approach of this thesis was designed to uncover the first evidence of 
novel interactions between clinically relevant endogenous (ADMA) and exogenous molecules 
(eflornithine and nifurtimox) and the human blood-brain barrier. In that respect we have 
provided much novel data that could direct future research in these areas. However, for future 
work in this field it is important that research funding into this area does not stop. This is a 
particularly pertinent issue as the population ages and an increase in neurodegenerative 
diseases are increasingly common. There is still no ‘perfect’ human BBB in vitro model, but 
optimisation of the hCMEC/D3s with shear-stress and co-culture systems remain the best 
method of research available before better models can be generated. The advance of medical 
imaging techniques such as MRI is also allowing researchers to gain non-invasive insight into 
the workings of the BBB in vivo and it seems likely that techniques such as these will only help 
to improve the understanding of the BBB and its role in disease. 
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Normal accumulation buffer stocks: 
BUFFER Conc. Volume (µl) Weight (g) 
NaCl 5M 675 
 Hepes 1M 250 
 KCl 1M 135 
 CaCl₂ (CaCl₂ · 2H₂O) 1M 37.5 













                   
Accumulation buffer consisting of sterile distilled water (dH2O), 135mM NaCl, 10mM HEPES, 
5.4mM KCL, 1.5mM CaCl2, 1.2mM MgCl2, 1.1mM glucose, all sterile filtered with a 0.2µm filter 
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TGN Lysis buffer stock for cell lysates: 
In a 50 ml Falcon; 
 
2.5 ml     1M Tris 
1.5 ml      5M NaCl 
5 ml         Glycerol 
5 ml         0.5M glycerophosphate 
0.5 ml     Tween 20 
0.1 ml     NP-40 (Nonident P 40) 
 
Fill up with dd water (35.4 ml) to get a total of 50mls and mix well. 
Store in 5ml aliquots at -20°C (5mls per bijou) 
TGN lysis buffer (50mM Tris, 150mM NaCl, 10% glycerol, 50mM glycerophosphate B, 1% 
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Polyacrylamide gel stock solutions (adapted from Rachel Brown’s protocol with permission): 
1.5 M Tris-HCl, pH 8.8 – stored at 4°C 
54.4 g Tris base (Sigma Aldrich Company Ltd, Poole, UK) 
150ml dH2O 
Adjust to pH 8.8 with 1M HCl.  Make to 300ml with dH2O and store at 4°C. 
 
0.5 M Tris-HCl, pH 6.8 – stored at 4°C 
6 g Tris Base 
~60ml dH2O 
Adjust to pH 6.8 with 1M HCl.  Make to 100ml with dH2O and store at 4°C. 
 
10% APS (Sigma Aldrich Company Ltd, Poole, UK) made fresh each time – 0.1g in 1ml PBS 
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10% separating gel recipe: 
Materials 10% 
dH2O 4.426 ml 
1.5 M Tris-HCl  2.5 ml 
10% SDS 100l 
Acryl/Bis (40% stock solution from 
Merck Chemical Ltd, Nottingham, UK) 
2.87 ml 
10% APS 100l 
TEMED (Sigma Aldrich Company Ltd, 
Poole, UK) 
4l 
Total Volume 10 ml 
The above amount was enough for two separating gels on Biorad Mini-PROTEAN 3 cells. 
4% stacking gel recipe: 
Materials 4% 
dH2O 3.182 ml 
0.5 M Tris-HCl 1.25 ml 
10% SDS 50l 
Acryl/Bis 488µl 
10% APS 25l 
TEMED 5l 
Total Volume 5 ml 
The above amount was enough for two separate stacking gels on Biorad Mini-PROTEAN 3 cells. 
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10x Running Buffer, pH 8.3 - stored at 4°C 
29.0 g Tris Base 
144.0 g Glycine (Sigma Aldrich Company Ltd, Poole, UK) 
10.0 g SDS (Sigma Aldrich Company Ltd, Poole, UK) 
to 1 L with dH2O 
Dilute to 1x for running gels in dH2O. 
 
Transfer Buffer, pH 8.1-8.5 - stored at 4°C  
3.025 g Tris base 
14.4 g Glycine 
100 ml Methanol (Sigma Aldrich Company Ltd, Poole, UK) 
Add dH2O to final volume of 1 L.  pH to 8.1-8.5 and de-gas prior to first use. 
 
PBS-Tween – 1 tablet (Merck Chemical Ltd, Nottingham, UK) in 1 L of dH2O, automatically pH 
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Na+ and Cl- free accumulation buffer: 
BUFFER Conc. Volume (µl) Weight (g) 
Sucrose 1M 6000 
 Hepes 1M 250 
 C6H11KO7 (Potassium-D 
gluconate) 1M 100 
 CaSO4 1M 70 
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PNGase F protocol. 
1. Combine 1-20µg of glycoprotein, 1µl of 10X Glycoprotein Denaturing Buffer and H2O (if 
necessary) to make a 10µl total reaction volume.  
2. Denature glycoprotein by heating reaction at 100°C for 10 minutes in heat block. 
3. Make a total reaction volume of 20µl by adding 2µl 10X G7 Reaction Buffer, 2µl 10% NP40, 
dH2O and 1-2µl PNGaseF.  
4. Incubate reaction at 37°C for 1 hour.  
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